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ABSTRACT  
 
The C. albicans community is currently laying the foundation of understanding how this 
human pathogen causes infection. C. albicans infections represent a major medical and 
economic burden for today’s society with an estimated 400,000 blood stream infections 
worldwide and direct costs exceeding 1$ billion dollar a year in the U.S. alone. Although 
finding the biological causes of this disease seemed to be beyond our reach in the past, 
various aspects of the infection have been recently unveiled including its pathology, 
immunology, histology, and epidemiology. Here we explored the genetic components of this 
disease by studying the complex host-pathogen dynamics through a series of in vivo, ex vivo 
and in vitro experiments. By using a pathogen unbiased reverse genetic approach and a host 
gene candidate strategy we uncovered some of the genes and pathways that are important for 
pathogenicity and immunity. In particular we explored the complex host-pathogen dynamics 
using a C. albicans - C. elegans model system and identified four novel putative virulence 
factors. We focused on Zcf15, a C. albicans transcription factor that has been poorly 
characterized in the literature and that plays an important role in the pathogen’s ability to 
resist host generated reactive oxygen species (ROS). By leveraging the power of RNASeq 
and ChIP-Seq we identified Zcf15 transcriptional targets and DNA binding sites. These 
studies suggest that Zcf15 plays a critical role in carbon metabolism and that it exerts its 
ability to protect the pathogen from ROS by controlling the expression of thiol- peroxidases 
and other detoxifying enzymes.  
We also showed here that in C. elegans, the host’s ability to counteract the infection relies 
on the MAPK pathway, evidence that mirrors what has been found by others in mammals 
  
 
and that emphasizes the usefulness of studying C. albicans infections in smaller genetically 
traceable organisms like C. elegans.  
The nematode model is also shown here to be a powerful tool not only to study the genetic 
bases that drive infection and immunity but also to identify new compounds that can be used 
for therapeutic intervention. This model was instrumental in identifying filastatin, a small 
molecule that was subsequently found by our collaborators to be capable of reducing 
virulence in mammals. The antifungal properties of filastatin are currently undertaking 
further preclinical testing. 
Overall this thesis shed light on the complex mechanisms of C. albicans pathogenicity and 
host immunity and identified novel virulence determinants that can be used by the larger 
community for further biological studies or even drug development.  
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1 Introduction and background 
   
 
1.1 Human fungal infection: a growing threat  
Human fungal infections have alarming morbidity, mortality, and a heavy 
pharmacoeconomical impact on today’s society. Fungal infections, also known as mycosis, 
are caused by various types of fungi capable of colonizing and invading several human 
tissues. It is estimated that there are approximately 5.1 million different species of fungi on 
earth and about 300 of those are pathogenic to humans (Blackwell, 2011; Garcia-Solache and 
Casadevall, 2010). These infections are very common comorbidities of immunocompromised 
patients and represent a growing threat especially considering that the pool of 
immunocompromised patients has been growing rapidly in the last few decades (Miceli et al., 
2011). In 2008, in the U.S. alone over 23,000 patients were treated with immunosuppressive 
therapy before organ transplantation, a number two times higher compared to the previous 10 
years (Low and Rotstein, 2011). This number coupled with the use of more potent 
chemotherapeutic agents and the high incidence of HIV infections lead to an estimated 10 
million immunocompromised people in the U.S., a remarkable 3.6% of the total population 
(Kahn, 2008). The increased number of immunocompromised patients in the last three 
decades has been mirrored by a rise in fungal incidence. In the U.S. from 1980 through 1997, 
the annual number of deaths caused by fungal infections increased from 1,557 to 6,534, a 
320% increase in 17 years (McNeil et al., 2001) and it is estimated that Candida infections of 
the oral cavity affect 2 million people worldwide (Buchacz et al., 2010) and that 70% of all 
premenopausal women experience at least one episode of vulvovaginal candidiasis in their 
lives (Fidel et al., 1999). 
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In the last two decades a large body of research literature has been accumulated and shed 
some light on some of the common mechanisms causing fungal infections (Casadevall, 
2007). However, many of the cellular pathways and signal transduction cascades responsible 
for the infections remain elusive, and there is a pressing need for more research in order to 
develop better diagnostics and therapeutics. 
 
1.2 Types of fungal infections  
Fungal infections can be divided into two types depending on their sites of infections: 
 Superficial: infections occurring on keratinized tissue like skin, nails or hair. 
 Mucosal/Invasive: infections taking place on moist surfaces like the oral cavity, 
gastrointestinal, urogenital and respiratory tract and that have the potential to reach 
the bloodstream, infecting normally sterile sites like internal organs or the 
cerebrospinal fluid.  
Superficial and mucosal infections, although unpleasant, recurrent and difficult to treat are 
usually not life-threatening. On the other hand, mucosal/invasive infections have a 
significantly lower incidence but their prognosis can be very poor. 
 
1.2.1 Superficial infections  
Superficial infections affect up to 25% (~1.7 billion) of the general population worldwide 
(Havlickova et al., 2009) and most people will experience at least one episode of superficial 
infection during their life time. These infections are primarily caused by dermatophytes like 
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Tinea pedis, Trichophyton rubrum, Microsporum canis and lead to well-known conditions 
like athlete’s foot, ringworm of the scalp and nail infections (Figure 1.1). Prevalence rates 
associated with these infections are exceptionally high, with athlete’s foot occurring in one 
every five adults, infection of the nails affecting up to 10% of the general population and 
ringworm of the scalp estimated to affect more than 200 million individuals worldwide 
(Havlickova et al., 2009; Thomas et al., 2010). These infections are very difficult to diagnose 
and are often mistaken for other conditions like eczema or psoriasis which are immune-
mediated conditions that have a very different etiology, therapeutic approach and outcome.  
Athlete’s foot infections are usually long-lasting, recurring and cause symptoms like burning, 
itching, cracking and scaling and, if left untreated, can lead to severe swelling and even limb 
amputation in diabetic subjects. The infection is usually caused by one of two types of fungi: 
Trichophyton metagrophytes that cause blisterlike infections that appear suddenly but that are 
easily treated and Trichophyton rubrum that cause long-lasting, recurrent and difficult to treat 
infections. In contrast to the large majority of other fungal infections, athlete’s foot is very 
contagious and can spread through direct (human-to-human) or indirect contact (trough 
vectors like flies, mites or fleas).  
These infections are traditionally treated with a combination of systemic and topical 
treatment and recently the FDA granted marketing approval for laser therapies that can reach 
deeper tissues. Although recent gene expression profiling studies have shed some light on the 
genes involved in pathogenesis (Maranhao et al., 2011), very little is known about the cellular 
pathways and mechanisms that lead to adhesion, skin layer penetration, tissue invasion and 
virulence.  
Ringworm of the hair is usually caused by dermatophytes in the Trichophyton and 
Microsporum genera and can cause severe itching of the scalp and bald patches especially in 
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areas where the fungus has rooted itself in the skin. Trichophyton infections occur 
predominantly in the United States, Central America and Western Europe while infections 
from Microsporum are more common in South America, East and Central Europe, Africa and 
the Middle East. Pets are usually the vehicle for the infection, but the infection can also be 
transmitted between humans. Novel nested PCR based strategies have revolutionized 
dermatophytes diagnostics (Verrier et al., 2013; Wisselink et al., 2011) but our understanding 
of how the fungus infects and evades the human immune system remains elusive.   
 
 
Figure 1.1: Examples of fungal superficial infections. 
(A) A severe case of athlete’s foot caused by the fungus Trichophyton rubrum. Adapted from 
(Heilman, 2011) (B) An example of ringworm of the hair (webMed, 2007). (C) A case of 
onychomycosis, commonly known as fungal nail infection. Fungal nail infections are difficult 
to treat because the infection is embedded within the nail and accessing the site of infection is 
problematic. (Medbullets, 2013) 
Nail infections, also known as onychomycosis, are also very common and can be caused by 
dermatophytes like various species of Trichophyton, Candida or nondermatophytic molds 
like Scytalidium, Scopularipsis or Aspergillus. These infections usually cause the nail to 
become thickened and discolored first, brittle and fragile next and eventually inflamed and 
painful if left untreated. These infections are commonly treated with topical antimycotics, 
however these drugs are often ineffective because they can’t reach the site of infection that is 
embedded within the nail. Recent research shows that laser-driven heat killed strategies might 
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represent a great therapeutic alternative to topical antimycotics because of their ability to 
effectively reach the site of infection (Suga et al., 2014). 
Superficial infections are very rarely life threatening but they are associated with high 
morbidity, and their refractory to pharmacological treatments can be the first indication of an 
underlying immunodeficiency. In addition to the pain and chronic discomfort, superficial 
infections can cause psychological, social or employment-related difficulties.     
1.2.2 Mucosal/Invasive infections  
While superficial mycosis are limited to outermost layers of the skin and don’t perfuse to 
deeper tissues, mucosal infections are significantly more serious and can reach moist surfaces 
like lungs, mouth, intestine or urogenital tract. In severely immunocompromised patients, 
these infections can reach the blood stream and cause systemic infections. The four most 
common pathogens that cause mucosal/invasive infections are Crytpococcus, Histoplasma, 
Aspergillus and Candida.  
Cryptococcus species can cause severe fungal infection called cryptococcosis and are usually 
caused by C. gattii and C. neoformans. These two fungi belongs to the phylum of  
Basidiomycota and are responsible for global deaths of more than 600,000 worldwide 
(Kwon-Chung et al., 2014). These pathogens live in the soil, and humans can be infected by 
inhaling airborne, dehydrated yeast cells or spores. These yeasts are weakly encapsulated 
when found in the wild, however, when they reach the lungs they are capable of forming 
thick melanin-rich capsule that protect them from the immune system. These encapsulated 
yeast cells are capable of traveling through the blood stream either on their own or within 
macrophages and can infect other areas of the body, typically the central nervous system. If 
they reach the central nervous system they cause meningoencephalitis, a condition that 
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resembles both meningitis (inflammation of the meninges) and encephalitis (inflammation of 
the brain). Cryptococcosis is usually diagnosed upon detection of cryptococcal antigen either 
in sputum, urine or cerebrospinal fluid (Antinori, 2013). Although recent gene expression 
profile studies have elucidated some of the mechanisms that lead to the infections (Fan et al., 
2005; Goebels et al., 2013), very little is known about its ability to elude the human immune 
system and cross the blood brain barrier.  
Histoplasma is dimorphic fungus usually found in bird and bat droppings that can cause a 
respiratory disease called histoplasmosis. When inhaled, the fungus can lodge deeply in the 
lung tissues, enter a latent stage and remain undetected for many years (Rihana et al., 2014). 
However, if the immune system is compromised (HIV, chemotherapy or organ transplant) the 
pathogen can colonize the lungs and cause pneumonia-like symptoms like non-productive 
cough, chest pain and fever. In rare cases of patients severely immunocompromised the 
infection can disseminate to internal organs like the liver causing severe hepatic 
histoplasmosis. Histoplasmosis is considered a rare disease; however in HIV-infected patients 
the mortality rate is estimated to be as high as 10% (Kauffman, 2007).  
Aspergillus is a member of the deuteromycetes fungi and can cause infections and diseases in 
patients with tuberculosis or with chronic obstructive pulmonary disease. Aspergillus spores 
can be inhaled by susceptible patients and can colonize the lungs. The warmer environment 
of the lungs triggers a morphological change that leads to the formation of oval budding yeast 
cells that can be phagocytized by macrophage and travel to other body parts like lymph nodes 
or other internal organs. Invasive aspergillosis can be a devastating disease with mortality 
rates as high as 90% in certain patient populations (Dagenais and Keller, 2009).  
Although difficult to diagnose and treat, infections caused by Crytpococcus, Histoplasma and 
Aspergillus are rare and observed only in severely immunocompromised patients. In contrast, 
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yeast infections caused by Candida are significantly more common. These infections are 
caused by a large variety of different Candida species. Pfaller and Diekema 2007, recently 
published the results of a global antifungal surveillance program that give us a sense of the 
most common Candida species causing infections.  
 
Figure 1.2: Candida species most commonly isolated from fungal infected patients and 
their characteristics.  
(A) Candida species distribution obtained from the Artemis Disk Global Antifungal 
Surveillance Study (Pfaller and Diekema, 2007).  (B) Among all Candida species causing 
infections, C. albicans is considered the most frequent and the most virulent of all. Adapted 
from (Marr, 2004).  
Samples collected from blood, mouth, urine and genitals of patients suffering from fungal 
infections were collected across 127 medical centers and 39 countries. The study lasted 6.5 
years and a total of 134,715 samples were collected. As shown in Figure 1.2, C. albicans was 
by far the most common Candida specie isolated (66.8%) followed by C. glabrata (11.0%), 
C. tropicalis (6.7%), C. parapsilosis (6.1%) and C. krusei (2.5%).   
This global study highlight that C. albicans is and remains the most frequent species 
responsible for fungal infections. C. albicans is considered the fourth most common cause of 
hospital-acquired infections and the third most common cause of bloodstream infections in 
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intensive care units (Lewis, 2009). In addition to being the most prevalent, C. albicans has 
been shown to be the most virulent species and the one associated with the most concerning 
prognosis (Papon et al., 2013). The high prevalence, morbidity and mortality of C. albicans 
infections are some of the reasons why in this dissertation we focused on this organism.   
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1.3 C. albicans infections: mortality, morbidity and costs  
In December 2013, the Centers for Disease Control and Prevention (CDC) released the 2013 
infectious disease threat report, a document that gave the general public a snapshot of the 
burden and threats posed by drug-resistant pathogens in the United States. Drug-resistant 
fungal infections caused by Candida albicans were classified as the fourth most serious 
threat, behind bacterial infections caused by Clostridium difficile, Neisseria gonorrhoeae and 
Enterobacteriaceae (Hampton, 2013). The report estimated 46,000 Candida systemic 
infections a year, 3,400 of which were drug-resistant and that lead to 220 deaths. One major 
reason that explains these alarming numbers is the remarkable genomic plasticity of C. 
albicans. C. albicans generates diversity through a variety of different mechanisms, including 
parasexual alteration in chromosome number, mating, loss of heterozygosity and 
recombination between homologous chromosomes (Robinson, 2008; Selmecki et al., 2010a). 
Its genomic plasticity makes C. albicans remarkably capable of coping with various 
environmental stresses, including host immunity and antifungal drug exposure. A large body 
of literature has been accumulated over the past two decades (Mayer et al., 2013), however 
there is still a pressing need for more research in order to facilitate the development of better 
therapies and diagnostics.  
C. albicans is a ubiquitous member of the human microbiome that, under certain 
circumstances, can colonize mucosal and non-mucosal surfaces like the mouth, lining of the 
gut, nasal passages, airways, urinary tract and genitals. C. albicans infections incidence rates 
are remarkably high as it is estimated that 50 to 75% of women in their childbearing years 
will suffer from at least one episode of vulvovaginitis caused by Candida and up to 8% of 
them will have at least four episodes annually (Sobel, 2007). The large majority of C. 
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albicans infections are either superficial or mucosal (also known as Candidiasis), however, in 
conditions of severe immunosuppression, C. albicans can reach the bloodstream, leading to 
systemic infection (Candidemia). Once C. albicans reaches the blood stream, it can evade 
many host immunological barrier and colonize several internal organs like liver, spleen and 
kidney. Interestingly, it has been shown that C. albicans has the ability to traverse the blood 
brain barrier and cause severe and frequently lethal meningitis (Aleixo et al., 2000; Jong et 
al., 2001; Liu et al., 2011). Estimated mortality rates for Candidemia are as high as 40%, and 
the associated health care costs are between 1$ and 2$ billion per year in the U.S alone 
(Gudlaugsson et al., 2003a; Rentz et al., 1998).  As shown in Figure 1.3 C. albicans can cause 
oropharyngeal thrush even in immunocompetent infants (Figure 1.3 A), skin infection in 
immunocompromised patients (Figure 1.3 B) or systemic infection that reaches the blood 
stream usually through the intestinal microvilli (Figure 1.3 C).   
 
Figure 1.3: Examples of C. albicans superficial infection.  
(A) Oral thrush, an infection of the oral cavity very common in low birth weight babies and 
adult patients affected by HIV. Adapted from (Heilman, 2008) (B) C. albicans skin infection. 
Adapted from (Candidaeffects, 2013) (C) Cartoon depicting an epithelial infection that 
reaches the blood stream by penetrating the intestinal microvilli. C. albicans in yeast form 
adhere to the intestinal microvilli, penetrate the epithelial tissue (b and c) and reaches the 
blood stream (d). Once in the blood stream C. albicans can infect any internal organs with 
kidney as one of the preferential targets (e). Adapted from Chauhan et al. 2006 
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Therapeutic options for patients affected by C. albicans infections are limited. The drugs 
most commonly prescribed were all FDA approved in the 1980-90s and their efficacies are 
progressively decreasing as the number of drug resistant strains has been exponentially 
increasingly (Cannon et al., 2007; Mukherjee et al., 2003). In order to develop new 
diagnostics and therapies some of the fundamental biological and molecular questions 
regarding the pathogen’s ability to adhere, infect, penetrate and thrive in the human body 
need to be answered. In addition, despite a growing list of risks factor that have been 
recognized, the fundamental mechanisms that allow this pathogen to attack the mucosal 
tissue and evade the immune system remain elusive. One of the goals of this thesis is to 
explore new genes and virulence mechanisms that lead to C. albicans infections.  
 
1.4 C. albicans virulence mechanisms  
 
 
The most important etiological factor that controls C. albicans infection is the physiological 
status of the host as C. albicans infections are commonly found in immunocompromised 
patients. However, C. albicans is also found in approximately 50% of the population as part 
of the harmless individual’s microflora and it has been shown that slight alterations in the 
host can turn this normally harmless commensal into a life-threatening pathogen (Naglik et 
al., 2003). The transition from harmless commensal to pathogen is a fine line in C. albicans 
and it is attributable to its extensive arsenal of virulence factors that are selectively expressed 
under suitable predisposing conditions. These mechanisms are summarized in Figure 1.4 and 
include: 
 Ability to adhere and penetrate host tissues (Figure 1.4 A and B). 
 Ability to form biofilm (Figure 1.4 C). 
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 Ability to switch from yeast-to-hypha (Figure 1.4 D). 
 Ability to switch from white to opaque state (Figure 1.4 E). 
 Ability to resist stress, uptake amino acids, adapt to pH fluctuations and utilize 
extracellular carbon, nitrogen and essential trace metals (Figure 1.4 F). 
C. albicans infections begin with the adhesion of yeast cells to host tissues (Figure 1.4 A). 
This process is mediated by adhesins proteins like Als (Agglutinin-Like Sequence) (Hoyer, 
2001). Als are a family of eight glycosylphosphatidylinositol (GPI)-anchored cell surface 
proteins that protrude from the C. albicans cell wall and that are capable of binding host 
surface proteins and extracellular matrix.  
Once C. albicans attaches to host cells, thigmotropism (contact sensing) triggers C. albicans 
filamentation and allow the pathogen to penetrate deeper host tissues (Figure 1.4 B) via the 
secretion of hydrolytic enzymes like Saps (Secreted Aspartyl Proteases) and phospholipases 
(Aoki et al., 2011; Schaller et al., 2005).  
This remarkable ability to switch from yeast to hyphae has been shown to be critical for 
virulence. During yeast growth C. albicans has the traditional oval shape while during hyphal 
growth C. albicans has an elongated ellipsoid form and can form long filaments that 
penetrate deeper tissues (Figure 1.4 D). The hyphal form is considered more invasive that the 
yeast form (Jacobsen et al., 2012) but the ability to switch from one form to the other is 
critical for virulence. In particular, strains locked in one form or the other have a significantly 
reduced virulence compared to strains that can freely switch from one form to the other (Lo et 
al., 1997). The working hypothesis is that hyphal forms are important for tissue invasion in 
epithelial infections while yeast form, which are smaller in size and can travel more 
effectively in the blood stream are required for systemic infections (Saville et al., 2003). 
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Figure 1.4: C. albicans common virulence mechanisms. Adapted from (Mayer et al., 
2013) 
 
C. albicans has also a remarkable ability to form biofilms in abiotic surfaces like catheters, 
dentures and other implants (Figure 1.4 C). Upon adhesion C. albicans proliferates, forms   
hyphal cells in the upper part of the biofilms and finally produce a complex extracellular 
matrix that renders the biofilm more resistant to antimycotic agents (Finkel and Mitchell, 
2010). Recent gene expression profiling and ChIP-ChIP experiments  suggest that the cellular 
circuit controlling biofilm formation is regulated by six transcriptional regulators (TEC1, 
EFG1, BCR1, NDT80, ROB1 and BRG1) that tightly controlled the expression of ~1,000 
target genes (Nobile et al., 2012).   
C. albicans is also capable to switch from the normal yeast morphology (white) to the 
mating-competent elongated form (opaque) and this influences its ability to colonize the host 
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(Sasse et al., 2013). In particular white and opaque cells are differentially adapted to specific 
host niches with opaque cells more virulent in the hypoxic environment of the mammalian 
intestine (Ramirez-Zavala et al., 2008).  
In addition to these direct virulence factors, C. albicans has various “fitness traits” that allow 
it to grow and resist host immunity. These mechanisms include a robust stress response 
mediated by heat shock proteins (Hsps) as well as an arsenal of detoxifying enzymes and 
efflux pumps. Moreover, C. albicans has a remarkable ability to adapt to the different 
nutritional environments of the host. Modulating glycolysis, gluconeogenesis, amino acids 
uptake and starvation responses are all believed to be important for virulence. For example, in 
the gastrointestinal tract the concentration of nutrients is relatively high but C. albicans 
competes for nutrients with other members of the microbiome. If the gastrointestinal flora is 
imbalanced (for example in patients undergoing systemic antibiotics therapies), C. albicans 
has access to additional nutrients and can outgrow the other organisms (Brock, 2009). On the 
other hand, when C. albicans is in the blood stream glucose is highly abundant (6-8 mM) but 
as soon as it is phagocytized the nutritional environment changes completely and C. albicans 
faces nutrient starved conditions. Inside the macrophage C. albicans promptly switches from 
glycolysis to gluconeogenesis and downregulated energetically demanding processes like 
ribosome biogenesis (Lorenz et al., 2004). Since the environments that C. albicans faces 
during infection are various, a prompt and efficient metabolic plasticity is required for 
adapting to such different conditions.  
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1.5 C. albicans therapeutics  
 
1.5.1 Antifungal drugs 
 
As previously discussed in chapter 1.1 the increased use of immunosuppressive therapies, 
potent chemotherapeutic agents and the surge of AIDS patients caused a dramatic increase in 
the number of immunocompromised patients, which lead to a dramatic rise in the number of 
patients suffering from C. albicans infections (Wang and Xu, 2008). In addition to the 
increased number of C. albicans infected patients, the clinical outcome of these infections is 
complicated by the ability of the strain to develop drug resistance and by the limited number 
of antimycotics currently available (Ferreira et al., 2010). In the last two decades, C. albicans 
developed various clever mechanisms for drug resistance, including genetic alteration of the 
targeted proteins and overexpression of efflux pumps (White et al., 2002). Patients infected 
with drug resistant strains don’t respond to the pharmacological therapy and, because the 
number of antimycotic alternatives is limited, the prognosis can be poor. The large majority 
of antimycotics currently prescribed have been FDA approved in the 1960s and 1990s and 
there are not very many drugs in company pipelines that have promising safety and efficacy 
profiles (Ostrosky-Zeichner et al., 2010).  
In these paragraphs the antifungal drugs available and their mechanisms of actions will be 
described in the chronological order by which they were discovered (Figure 1.5). 
Historically, the antifungal drug discovery process has always faced a big challenge: the 
eukaryotic nature of the infecting organism. This factor dramatically limits the number of 
targets available and significantly increases human toxicities (Roemer and Krysan, 2014). 
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Treatments of fungal infections are further hampered by solubility problems, short half-life 
and poor pharmacokinetics.  
In the pre HIV-era, the incidence of fungal infections was considered low and the 
pharmaceutical industry invested very little money and time in research and drug discovery. 
For many years the only antimycotic available was amphotericin B, a polyene delivered 
intravenously with an atypical mode of action. Instead of inhibiting an enzyme in a metabolic 
pathway it directly binds ergosterol, the principal sterol in the fungal cell membrane 
(Baginski and Czub, 2009). Upon binding, amphotericin B interferes with membrane 
polarity, structure and fluidity causing the leakage of cellular monovalent and divalent 
cations like Ca
++
 and K
+ 
(Ellis, 2002), Figure 1.6 A. Amphotericin B is a fungicidal because it 
causes cell death and it is believed that, on top of the ergosterol binding ability its toxicity 
may include oxidative damage and host immune stimulation (Hawser and Islam, 1999). 
Although amphotericin B is still commonly used to treat serious infections, its use is limited 
by infusion-related side effects like chills, fever, anaphylactoid-like reactions (Eriksson et al., 
2001) and dose-limiting nephrotoxicity like renal vasoconstriction or tubular acidosis 
(Sawaya et al., 1991). After the introduction of amphotericin B in 1957, the discovery of a 
new safer and more efficacious drug proved to be difficult. In 1964 5-fluorocytosine (5-FC), 
also known as flucytosine, was discovered, but the development of drug resistance soon 
limited its use. The drug was originally developed as a potential anticancer but, although 
ineffective against tumors, it was proven efficacious against fungal infections. 
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Figure 1.5: History of fungal infections and antifungal drug development. 
Figure adapted from (Anaissie et al., 2009). In the 1830s and 1840s the first reports 
documenting fungal etiology for many human and non-human infections were proposed 
(black circles). Between the end of the 19
th
 century and the beginning of the 20
th
 century, 
human diseases like blastomycosis, histoplasmosis and cryptococcosis were discovered (red 
circles). Four major breakthroughs were made in the history of medical mycology: in 1955, 
1964, 1990 and 2002 amphotericin B, 5-flucytosine (5-FC), fluconazole and caspofungin 
were discovered respectively (green circles). These four drugs belong to four different 
chemical classes: polyenes, pyrimidine analogs, azoles and echinocandins. Although many 
chemical analogs have been developed, these 4 drugs are still the most commonly prescribed 
antimycotics against fungal infections.  
As shown in Figure 1.6B, 5-FC is transported by a fungal specific cytosine permease into the 
cytoplasm and converted to 5-fluoruracil (5-FU). 5-FU is a pyrimidine analog that is 
incorporated into RNA during transcription and that interferes with mRNA translation, 
causing the synthesis of miscoded proteins and ultimately translational arrest. 5-FU not only 
interferes with transcription and translation but also with DNA replication: 5-FU is converted 
to its deoxynucleoside (a nucleotide without a phosphate group) which interferes with proper 
DNA synthesis. Although initially efficacious, resistance to 5-FC is quite commonly seen 
even in treatment-naïve patients and this drug is no longer prescribed as a monotherapy and 
only used in combination with amphotericin B. 
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Figure 1.6: amphotericin B and 5-fluorocytosine mechanisms of action.  
Figure adapted from (Russell, 2010). Amphotericin B binds ergosterol, compromising cell 
membrane fluidity and polarity. Leakage of important cations like Ca
++
, Na
+
 and K
+
 are the 
ultimate cause of the fungicidal effect. 5-fluorocytosine is imported in the cytoplasm by 
cytosine permease and ultimately converted into 5 fluorouracil, a pyrimidine analog that 
interferes with gene transcription and mRNA translation. 
The 1970s and 1980s represent the nadir in the search for new safer and more effective 
antimycotics, and for these two decades amphotericin B and 5-FC were essentially the only 
two therapeutic alternatives. The only drug approved in these two decades was ketoconazole, 
an imidazole with poor solubility and lack of intravenous formulations.  
In 1990, the introduction of fluconazole revolutionized antifungal pharmacological therapy; 
fluconazole displayed a broader spectrum of antifungal activity, a significantly higher 
efficacy and a markedly improved safety profile compared to amphotericin B and 
ketoconazole. In addition, fluconazole was the first antifungal drug to be developed that 
could be used both orally for minor superficial infections and intravenously for more serious 
systemic infections. As shown in Figure 1.7, Fluconazole is a triazole that inhibits the 
synthesis of ergosterol, a fungal specific cell membrane sterol that regulates membrane 
fluidity and cell signaling. Fluconazole interacts with 14--demethylase, a cytochrome P-450 
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enzyme necessary to convert lanosterol to ergosterol. By inhibiting ergosterol biosynthesis, 
fluconazole increases cellular permeability and cause leakage of cellular content. In addition 
to ergosterol biosynthesis inhibition, fluconazole is believed to interfere with endogenous 
respiration, phospholipid biosynthesis and purine uptake (Pasko et al., 1990). Twenty-five 
years after its discovery, fluconazole is still the drug of choice to treat fungal infection.  
 
Figure 1.7: cellular antifungal targets. 
Cell wall, endoplasmic reticulum and nuclear DNA are the three most common antifungal 
targets. Echinocandins interferes with cell wall architecture by inhibiting the enzyme (1-3)-
D-glucan synthase and preventing -glucans synthesis. Triazoles and allylamines target the 
endoplasmic reticulum by inhibiting the synthesis of ergosterol, a sterol essential for cell 
membrane fluidity. Flucytosine is a pyrimidine analog that inhibits gene transcription and 
DNA replication as described more in details in Figure 1.6. Figure adapted from (Cowen, 
2008) 
 
In 2001 the FDA approved caspofungin, a lipopeptide member of a new family of antifungals 
called echinocandins. Caspofungin inhibits cell wall synthesis by inhibiting the enzyme 1,3-
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beta glucan synthase, a glucosyltransferase involved in the generation of beta-glucans in 
fungi. Although proven to be efficacious against C. albicans infections, caspofungin can only 
be administrated intravenously. Moreover, animal studies have shown that it has embryotoxic 
effects and it can be administrated to pregnant women only if the benefits to the mother 
clearly outweigh the potential risk for the fetus.  
As evident from this chapter, the number of antifungal drugs available is limited and C. 
albicans is rapidly developing drug resistance against them. There is therefore a pressing 
need to foster our understanding of the mechanisms that lead to C. albicans virulence in order 
to identify new targets and better therapeutics.  
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1.5.2 C. albicans vaccine, promises and challenges      
On top of the traditional pharmacological therapy, the research community is exploring new 
therapeutical avenues. Among them, the possibility of generating a C. albicans vaccine has 
recently gained some traction. Vaccines are arguably one of the greatest inventions of modern 
medicine and the World Health Organization estimated that immunization currently saves 
two-to three million lives per year worldwide. Many Candida antigens have been proposed as 
vaccine candidates (Raska et al., 2005; Vecchiarelli et al., 2012), including heat shock 
proteins (Hsp90), proteins involved in energy production and glycolysis like Eno1 and Pgk1 
(Li et al., 2011) and enzymes involved in tissue penetration and nutrient utilization like Sap2 
(De Bernardis et al., 2012). All of these proteins have two qualities in common; they are 
required for wild-type virulence and don’t have human homologs. In addition to proteins, 
many fungal polysaccharides and glycoproteins have been prophylactically injected in 
smaller mammals and proved to induce a strong immunological response and fungal 
protection (Huang et al., 2010; Xin et al., 2012). Figure 1.8provides a snapshot of all the 
fungal antigens that have been studied for their immunological and protective properties 
against C. albicans.   
Among all of these approaches, two (NDV-3 and PEV-7) have successfully completed Phase 
I clinical trials and are planned to enter further clinical investigation in larger patient 
populations. One of them, NDV-3, developed by NovaDigm Therapeutics, is a formulation 
containing the N-terminal portion of the C. albicans agglutinin-like sequence protein 3 (Als3) 
and the immunologic adjuvant aluminum hydroxide. This formulation has been shown to 
have protective efficacy in animal models of oral, vaginal and disseminated candidiasis 
(Ibrahim et al., 2006; Spellberg et al., 2008). Als3 has sequence and structural homology with 
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various S. aureus cell surface proteins, and preclinical data showed that NDV-3 is safe and 
efficacious against both candidemia and staphylococcemia (Spellberg et al., 2008). In 
addition, clinical data has shown that NDV-3 is safe and well tolerated in 40 healthy humans 
(Schmidt et al., 2012). Adverse effects were mild, not statistically significantly compared to 
placebo, and treatment elicited a robust B- and T-cell immune response. Encouraged by these 
results, NovaDigm is now recruiting patients for a phase II study, the first ever phase II study 
for a human fungal vaccine. The double-blind, placebo-controlled interventional 2-year study 
will recruit a total of 45 women suffering from recurrent vulvovaginal candidiasis, and 
vaccine efficacy will be evaluated using vulvovaginal recurrence rate as the primary 
endpoint.  
 
Figure 1.8: C. albicans antigens suggested as potential candidates for epitope-based 
vaccine approaches. Figure adapted from Vecchiarelli et al., 2012.  
 
Another interesting vaccine approach under development is PEV-7, a virosomal formulation 
containing C. albicans Sap2 that has been recently developed by Pevion Biotech. Sap2 is a C. 
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albicans secreted aspartyl protease that is able to hydrolyze epithelial proteins that are 
subsequently used by the pathogen as nutritional nitrogen sources. The recombinant Sap2 is 
encapsulated in virosomes, influenza-virus envelopes that potentiate immunological response. 
In mice and rats, PEV-7 delivered intramuscularly triggered a potent immunological response 
that lead to the production of vaginal anti-Sap2 IgG and IgA that conferred protection against 
post-immunization C. albicans challenge (De Bernardis et al., 2012). The protection was Sap-
2 antibody-mediated and it was further confirmed by the fact that murine anti-Sap2 
monoclonal antibodies conferred vaginal passive protection in the same animal model. 
Pevion Biotech recently completed a phase I clinical study to evaluate the safety and 
tolerability of the vaccine administrated either intramuscularly or intravaginally. Although a 
paper detailing the results hasn’t been published yet, the company claims that the study met 
both primary and secondary end points and that no serious adverse events were reported.  
Although expectations for these vaccines are high, they will enter further clinical evaluations 
only if industrial interest and sufficient financial support will be raised. In addition, 
development of a vaccine for C. albicans is hampered by its remarkable ability to evade the 
host immune systems. Many researchers argue that a monovalent vaccine like the ones under 
development won’t be effective against recurrent infections and only a vaccine that triggers 
against multiple, unrelated virulence factors has the potential of being successful (Cassone, 
2013).   
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1.6 Model organisms to study C. albicans infections   
 
Many in vitro approaches have been developed to study various aspects of C. albicans 
biology including filamentation, adhesion and phenotype switching. However these in vitro 
approaches can mimic only some aspects of the infection and it is imperative to use in vivo 
whole animal models to fully understand pathogenicicty. Several model organisms have been 
used to study C. albicans infections and allowed researcher to explore various virulence 
aspects in simpler organisms. Because of the common descent of all living organims and the 
conservation of metabolic pathways across species, many of the lessons learned in these 
simpler organisms were proven valid in humans. Model organisms also allow researchers to 
study both sides of the pathogenesis equation, the pathogen and the host. This approach 
provides insights on the conditions that the pathogen faces during infection and, at the same 
time, elucidate the mechanisms the host utlizes to counteract the infection.  Model organisms 
commonly used to study fungal infection include vertebrate mammals like mouse, rats and 
Danio rerio (zebrafish) as well as invertebrate organims like Caenorhabditis elegans, 
Drosophila melanogaster, Galleria mellonella (moth). Compared to studying the infection in 
clinical settings, using simpler organisms has many advantages, including the availiblity of 
genetic and molecular resources (knockout mutants, RNAi libraries etc) as well as costs and 
ethical considerations.  In the next few paragraphs we summarized the most commonly used 
model organisms used to study C. albicans and their advantages and disadvantages.   
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1.6.1 Mammals 
Mice and rats have been used to model various aspect of fungal infection for at least the last 
four decades. In 1976 Rogers and Balish were the first to demonstrate that mice challenged 
intravenously with C. albicans accumulate actively dividing yeast cells in the spleen, liver, 
lungs and kidneys up to 24 days post infection.  The same paper also showed that: 
 Kidneys are the preferential internal organs targeted by C. albicans followed by liver, 
spleen and lungs (Figure 1.9 A) 
 There is no difference in susceptibility between male and female mice (Figure 1.9 B). 
 
Figure 1.9: C. albicans multiplies in mice and rats challenged intravenously. 
(A) Tissue specific time points of mouse challenged intravenously with 4x10
4
 C. albicans 
cells. Yeast cells are preferentially infecting the kidneys (Δ) followed by liver (□) spleen (○) 
and lungs (●). (B) Course of infection in male (●) and female (○) mice kidneys. (Figures 
adapted from (Rogers and Balish, 1976) 
 
Rogers and Balish pioneering work opened up an entire new field of studies, and scientists 
have developed over the years many innovative models to mimic both systemic and epithelial 
C. albicans infections. Systemic models of infection are usually carried out in 
immunocompetent mice by lateral tail vein injections (Clancy et al., 2009). Epithelial 
infections are usually carried out in immunosuppressed mice using a variety of different 
strategies. These strategies include sublingual inoculation of the oral cavities with saturated 
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swabs to mimic oropharyngeal candidiasis (Solis and Filler, 2012), intravaginal injections to 
study C. albicans vaginitis (Chen and Kong, 2007) and force feeding (gavage) to study 
gastrointestinal colonization (Flattery et al., 1996). This repertoire of mammalian models has 
been instrumental to validate many of the hypotheses that have been formulated clinically. 
For example, many of the genes that have been shown to be upregulated in clinical samples 
have also been shown to be required for virulence in mouse models. For example Saps, a 
family of secreted aspartyl proteases, are upregulated during the infection, and their loss of 
function leads to a reduced pathogenicity in murine models of epithelial and systemic 
infection (Naglik et al., 2003a).  
In addition to studying the pathogen’s strategies used to infect, murine models are powerful 
tools to study mechanisms exploited by the host to cope with the infection. This is 
particularly true for mice, which have a genome remarkably similar to humans. The mouse 
genome was sequenced in 2002 (Waterston et al., 2002) and the study highlighted that: 
 the mouse genome is comparable in size to the human one (2.5 Gb vs 2.9 Gb) 
 75% of the mouse ORFs are conserved in humans 
 over 90% of the mouse and human genomes can be partitioned into corresponding 
regions of synteny.   
The remarkable conservation of genes and metabolic pathways between these two species 
allows researchers to validate many clinical observations in this simpler model organism. For 
example, clinical observations suggested that epithelial infections occur more frequently in 
patients with defects in cell-mediated immunity, while systemic infections are more frequent 
in patients with deficiencies in neutrophil number or function. These observations were 
mirrored in mouse models of infections. The ability of mice to resist epithelial infections is T 
lymphocyte-dependent, and T lymphocytes play a central role in cell-mediated immunity 
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(Ashman et al., 2004). On the other hand, IL-17AR
-/-
 mice that have an impaired ability to 
drive neutrophils to infected internal organs were significantly more susceptible to systemic 
but not epithelial infections (Huang et al., 2004). Taken together, these studies show the 
usefulness of using mice as model organisms to study C. albicans infection and validate 
hypotheses formulated either clinically or in other model organisms. 
 
1.6.2 Drosphophila melanogaster 
D. melanogaster is a species of fly generally known as the common fruit fly. This fly has 
been widely used as a model organism to study various aspects of microbial pathogenesis. D. 
melanogaster has many advantages over vertebrate models: the fly life cycle is only 8-9 days, 
they produce a large number of externally laid embryos and they can be genetically modified 
in numerous ways. Interestingly, not only many individual genes have been conserved 
between humans and flies (Adams et al., 2000) but also entire cellular signal transduction 
pathways have been shown to be conserved between the two organisms (Rubin et al., 2000). 
In addition, D. melanogaster, although lacking an adaptive immunity, has an innate immune 
system with striking similarities with mammalian defense mechanisms (Hoffmann et al., 
1999). Immune-deficient D. melanogaster has been shown to be susceptible to C. albicans 
infection but not to non-pathogenic baker’s yeast S. cerevisiae (Alarco et al., 2004). Flies 
injected in the thorax with C. albicans have been shown to accumulate an overwhelming 
amount of C. albicans within hours post injection, suggesting that C. albicans can thrive 
inside the flies’ body cavity (Figure 1.10 A). Interestingly, the ability of C. albicans to kill 
D. melanogaster requires the presence of CDC35, CLA4, SAP4 and SAP6, four genes that 
have also been shown to be important in infections in murine models (Leberer et al., 1997; 
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Naglik et al., 2003a). This work shows that C. albicans genes essential for virulence in 
mammalian rodents are also critical for virulence in flies, validating the use of this insect 
model to study C. albicans infections.  
 
Figure 1.10: D. melanogaster is susceptible to C. albicans. 
A) Flies injected with GFP-tagged C. albicans 1 and 48 hours post injection. B) Toll mutant 
D. melanogaster are sensitive to wildtype C. albicans (SC5314), less sensitive to C. albicans  
mutants deleted in key virulence factors (SAP4-6, CLA4 and CDC35) and insensitive to S. 
cerevisiae. Figures adapted from (Alarco et al., 2004) 
Alarco et al. (2004) pioneering work showed that D. melanogaster can be used as a powerful 
model to dissect host-pathogen interaction in a model of innate immunity that doesn’t rely on 
the complexities of complement and antibody responses.  
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1.6.3 Galleria mellonella 
In the last decade Galleria mellonella has been proposed as a model organism to study fungal 
infection. Although its genome has not been sequenced and there is not a well-established 
method to generate mutants, this model organism offers a couple of chief advantages. First, 
the greater wax moth is capable of supporting interactions with human pathogens at human 
physiological temperature (37°C). Second, Galleria mellonella can mount both cellular and 
humoral immune responses when the pathogen is injected in the hemocoel, the body cavity 
that contains hemolymph. Cells in the hemolymph are capable of phagocytosing microbial 
invaders and their kinetic and mechanism of killing are strikingly similar to human 
neutrophils (Bergin et al., 2005). For example, human proteins responsible for the production 
of superoxide via NADPH oxidase are conserved in moth and they play key roles in their 
immune systems (Bergin et al., 2005). Humoral responses to pathogen relies on the 
production of lysozyme and small antimicrobial proteins like cecropins (Ibrahim et al., 2006).  
When larvae were injected with 2x10
6
 C. albicans cells in the hemocoel only 15% and 0% of 
them survived 24 hours and 48 hours post challenge (Cotter et al., 2000). In contrast, when 
injected with non-pathogenic S. cerevisiae, 75% and 48% of them survived 24 and 72 hours 
post challenge (Figure 1.11). Interestingly, the authors of the paper also showed that C. 
albicans clinical isolates were more pathogenic than laboratory strains.  
The pioneering work of (Cotter et al., 2000) opened up the possibility of using G. mellonella 
as a model organism to study C. albicans infection and many other papers substantiate and 
expanded their initial discoveries. For example (Brennan et al., 2002) showed that C. 
albicans mutants with reduced virulence in mice were also less virulent in G. mellonella.   
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Figure 1.11: Galleria mellonella is susceptible to C. albicans. 
A) G. mellonella larvae before inoculation with C. albicans B) G. mellonella larvae 48 hours 
post injection with 2x10
6
 C. albicans cells in the hemocoel. Typical discoloration of the 
cadavers due to melanization is visible. Melanization is believed to be a key component of 
the defense against pathogens and accumulates around microbes in the hemolymph 
(Kavanagh and Reeves, 2004) C) G. mellonella were injected with increasing concentration 
of wild type S. cerevisiae JJ1A or C. albicans MEN (clinical isolate from a patient with an 
eye infection) and survival rates at 24, 48 and 72 hours calculated. Figures adapted from 
(Cotter et al., 2000) 
 
Taken together, the results demonstrate that G. mellonella can be a useful host model to study 
many aspects of C. albicans pathogenesis.  
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1.6.4 Danio reiro  
Zebrafish (D. reiro), is a small tropical fish originally isolated from Southeast Asia.  
Zebrafish has a unique combination of genetic and experimental advantages that make it an 
ideal organism to study many biological mechanisms. Zebrafish has a small generation time, 
it can lay hundreds of eggs from a single adult, it is optically transparent and its genome has 
been recently sequenced (Howe et al., 2013). Transient disruption of gene function can be 
easily achieved by microinjecting mRNA, DNA or short anti-sense oligomers called 
morpholinos. The availability of these technologies makes transient reverse genetic strategies 
very rapid, affordable and easy to achieve. A key factor that separates this model organism 
from others is the presence of both an innate and adaptive immune systems. Zebrafish have 
cytokines, macrophages, neutrophils, dendritic cells, mast cells, T cells, B cells and 
eosinophil that have remarkable similarities with humans (Sullivan and Kim, 2008).  In 
recent years zebrafish has been used as a mini-vertebrate host model to study C. albicans 
infections. Brothers et al., 2011 showed that zebrafish embryos can be injected with C. 
albicans through the otic vesicle into the hindbrain. When injected in the hindbrain, C. 
albicans cause lethal disseminated infections. Remarkably, the mortality rates of these 
infections can be further exacerbated by knocking down zebrafish NADPH oxidase 
expression (Figure 1.12), suggesting that ROS play a major role in protecting zebrafish from 
C. albicans infections. The macrophage human respiratory burst is one of the first line of 
defense against C. albicans; the fact that the same mechanism is required for zebrafish 
resistance to C. albicans uncovers the promise of using this model to study C. albicans 
infections. 
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Figure 1.12: Zebrafish is susceptible to C. albicans.  
A) Confocal microscopy of zebrafish injected with GFP-expressing wildtype C. albicans 24 
hours post injection. B) Within 5 days post infection, more than 50% of the zebrafish injected 
with C. albicans succumbed the infection. C) The zebrafish sensitivity was significantly 
enhanced when the p47
phox
 subunit of the NADPH oxidase was knockeddown with p47
phox
 
morpholino (Control Inf. vs p47
phox
 Inf.).  Figures adapted from (Brothers et al., 2011) 
 
Every model organisms proposed to study C. albicans infection has its own advantages and 
disadvantages. However C. elegans is the only one that doesn’t rely on injections but just on 
the addition of the pathogen to its regular source of food. This makes C. elegans the desirable 
model organism to study C. albicans and is briefly described in the next paragraph and its has 
been extensively used through this thesis.    
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1.6.5 Caenorhabditis elegans  
 
C. elegans is a transparent nematodes that can be easily grown on E. coli lawns as the sole 
source of food. These nematodes are either self-fertilizing hermaphrodites or males, have a 
generation time of 3-4 days, a life span of 2-3 weeks and can be stored frozen almost 
indefinitely in liquid nitrogen. In addition, the developmental pattern of its 959 somatic cells 
has been traced through its transparent cuticle and its genome has been sequenced at high 
coverage.  All of the above qualities, in addition with the availability of functional mutants, 
fluorescently labeled transgenic strains and RNAi knockdown libraries make C. elegans an 
extraordinarily powerful model organism. C. elegans has been used to study a variety of 
biological processes including neuronal development, cell division, apoptosis and host-
pathogen interactions. Historically nematodes have been used to study bacterial infections 
like the one caused by Pseudomonans aeruginosa (Tan et al., 1999), Staphylococcus aureus 
(Sifri et al., 2003) or Salmonella typhimurium (Aballay et al., 2000) but it has also been used 
to study fungal pathogens like Cryptococcus neoformans or Drechmeria coniospora 
(Mylonakis et al., 2002). These studies have highlighted that many of the mechanisms used 
by the pathogen for virulence and by the host for immunity are analogous to the ones 
observed in human.   
Recently our lab and others have shown that C. elegans is susceptible to C. albicans 
infections. When C. albicans is added to E.coli lawns it is ingested by the worms and 
colonizes the intestine. C. albicans infections cause in worms a distinct swelling of the anal 
region (Figure 1.13 A-B), a significantly shorter survival and, in certain conditions, C. 
albicans is capable of killing worms by piercing their cuticle (Jain et al., 2013b; Jain et al., 
2009a; Pukkila-Worley et al., 2011; Pukkila-Worley et al., 2009). 
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Figure 1.13: C .elegans is susceptible to C. albicans.   
A-B) Worms infected with C. albicans in solid media show a distinct swelling of the anal 
region (Jain et al., 2013) C-D-E) Worms infected with C. albicans and various other yeasts in 
liquid media. C. albicans is capable of infecting the nematode and piercing their cuticle (C) 
while other yeasts not capable of hyphal growth like D. hansenii (D) and C. lusitaniae (E) are 
not (Pukkila-Worley et al., 2009).  
In addition, these studies have shown that many of the genes required for virulence in murine 
models of infection are also required for virulence in nematodes. For example RIM101, a C. 
albicans  transcription factor required for alkaline-induced hyphal growth is required for both 
virulence in murine oropharyngeal candidiasis (Nobile et al., 2008) and virulence in C. 
elegans (Pukkila-Worley et al., 2009). Other genes like NRG1, CAS5, ADA2, CPH1 and 
EFG1 have also shown to be required for virulence in both mice and nematodes. These 
studies clearly showed that many of the conclusions drawn using this simpler organism 
remain valid in higher mammals, reiterating the amenability of using C. elegans for forward 
or reverse genetic screening. In addition, this model can be used for small molecule drug 
screening. (Okoli et al., 2009) developed a high-throughput semi-automated version of the C. 
  
35 
 
 
elegans-C. albicans model system and screened a library of 3,228 compounds. 7 of the 19 
compounds capable of extending nematodes survival were known antimycotic validating 
their approach.  
Taken together these studies show that C. elegans can be used as a powerful tool to study not 
only the complex host-pathogen dynamics but also for initial large scale drug screening.  
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2 A versatile in vivo model to study C. albicans virulence  
 
2.1 Introduction 
 
C. elegans has been used as a powerful model organism for now more than 50 years. In 
1960s South African biologist Sydney Brenner pioneered the use of C. elegans to study 
neuronal development and paved the way for a long lineage of “C. elegans scientists” that 
studied various aspects of cell and animal biology in nematodes. This lineage includes Nobel 
Price Laureates Craig Mello and Andrew Fire for their RNAi work (Fire et al., 1998), Robert 
Horvitz and John Sulston for their work on organ development and apoptosis (Ellis and 
Horvitz, 1986; Hengartner et al., 1992; Sulston and Horvitz, 1977) and Martin Chalfie for his 
work on green fluorescent protein (Chalfie et al., 1994). Although this model organism has 
been traditionally used to study molecular and developmental biology, over the past 15 years, 
researchers have begun to use C. elegans to investigate the biology of various human 
pathogens including Pseudomonas aeruginosa, Staphylococcus aureus, Salmonella enterica 
and Serratia marcescens (Irazoqui et al., 2010; Kaletta and Hengartner, 2006; Kong et al., 
2014; Marsh and May, 2012; Sem and Rhen, 2012). These papers revealed that many of the 
mechanisms involved in the human-pathogen interaction are conserved in nematodes, but 
also that there are some immunity mechanisms that are unique to this model organism (Bae et 
al., 2004; Kim et al., 2002). In nature, C. elegans encounters a variety of threats from 
ingested pathogens present in the soil and this has provided a strong selective pressure to 
evolve and maintain a sophisticated innate immune system in its intestinal lumen. Many of 
the genes and mechanisms involved in the protection of intestinal lumen are orchestrated by 
highly-conserved elements that exist also in higher mammals (Couillault et al., 2004; Kim et 
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al., 2002). C. elegans therefore represents a great model to study gastrointestinal pathogens 
like Salmonella enterica (Aballay et al., 2003), Shigella boydii (Kesika and Balamurugan, 
2012) or Vibrio cholera (Cinar et al., 2010). 
A pathogenesis assay using C. albicans and C. elegans has previously been described by our 
lab (Jain et al., 2013; Jain et al., 2009) and others (Okoli et al., 2009; Pukkila-Worley et al., 
2011). Experiments described in these papers show that C. albicans cells are quickly ingested 
by the worms and accumulate in the intestinal lumen causing slower locomotion, distention 
of the intestine, swelling of the vulva, deformed anal region (Dar) and lethality. C. albicans 
infected worms live 10-12 days compared to 20-22 for uninfected controls.    
Here, we expanded the use of the C. albicans - C. elegans assay and highlight its remarkable 
versatility. We show here that this assay can be reliably used for studying (a) host effectors 
important to counteract the infection, (b) pathogen determinants that drive pathogenicity (c) 
pharmacological compounds that can intervene in pathogenesis.   
In order to elucidate the hosts factors that drive C. elegans ability to counteract C. albicans 
infections, we used a candidate-gene reverse genetic approach. Our analysis suggests that the 
MAPK (Mitogen-Activated Protein Kinase) pathway is required for C. elegans resistance to 
C. albicans. Functional knockouts in any of the main players in this pathway (tir-1, pmk-1 
and sek-1) are statistically significantly more susceptible to C. albicans infections compared 
to wild type controls. The MAPK pathway is a highly conserved signaling cascade that has 
been previously shown to be important in C. elegans for heavy metal, starvation resistance 
and neuronal development (Li et al., 2012; Mizuno et al., 2004). To the best of our 
knowledge, this is the first time that this pathway has been associated with the nematode’s 
ability to counteract C. albicans infections. Interestingly, this pathway is conserved in 
humans and it has been shown to play a crucial role in protecting the human epithelium 
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against C. albicans (Moyes et al., 2010; Moyes et al., 2014). In humans this pathway plays a 
critical role in controlling the expression of proinflammatory cytokines like interleukins and 
tumor necrosis factors (TNF) upon C. albicans infection. Our experiments reiterate the 
usefulness of studying C. albicans infection in a simpler genetically tractable organism like 
C. elegans.  
In addition to studying host effectors, we show in this chapter proof of principle experiments 
that demonstrate the amenability of using C. elegans to study C. albicans virulence. When we 
infected C. elegans with C. albicans double knock out mutants in CPH1 and EFG1, two key 
virulence factors required for infection in mouse, rats and human epithelial models (Chen et 
al., 2006; Dieterich et al., 2002; Ricicova et al., 2010), nematodes survived significantly 
longer than controls. These experiments suggest that some of the lessons we learn in this 
simpler model about C. albicans virulence may remain valid in higher mammals and vice 
versa. These proofs of principle experiments encouraged us to use this model for a large scale 
C. albicans reverse genetic screen that is described in detail in chapter 3.   
Finally in this chapter we show that our nematode model system can be pharmacologically 
modulated.  In the presence of fluconazole, the most commonly prescribed antifungal drug, 
worms challenged with C. albicans survived significantly longer than control. This proof of 
principle experiment suggests that the nematode model can be used for small molecule 
screening. Indeed, as further discussed in chapter 6, our C. elegans model was instrumental in 
identifying filastatin, a small molecule inhibiting various aspects of fungal virulence (Fazly et 
al., 2013). 
In summary we show here that our C. elegans - C. albicans model is a versatile and powerful 
tool that can be used not only to study the genetic bases that drive infection and immunity but 
also to identify new compounds for therapeutic intervention.     
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2.2 Materials and methods 
 
2.2.1 Strains and media  
Nematodes were maintained and propagated on E. coli OP50 as described here (Brenner, 
1974). N2 worms were used as wildtype nematodes and we obtained loss of function mutants 
strains (summarized in Table 2.1) from the C. elegans genetic stock center (University of 
Minesota). 
 
Strains  Genotype Mutagen  Reference  
CB502 sma-2(e502) III EMS (Brenner, 1974) 
NU3 dbl-1(nk3) V Tc1 transposon  (Morita et al., 1999) 
CB1370 daf-2(e1370) III EMS Deposited by Riddle D.L. 
CF1038 daf-16(mu86) I TMP + UV (Lin et al., 1997) 
KU25 pmk-1(km25) IV TMP + UV 
Deposited by Kunihiro Matsumoto 
(3/10/06) 
AU1 sek-1(ag1) X EMS (Kim et al., 2002) 
AU3 nsy-1(ag3) II EMS (Kim et al., 2002) 
IG685 tir-1(tm3036) III TMP + UV Deposited by Shohei Mitani (5/25/08) 
IG10 tol-1(nr2033) I TMP + UV (Pujol et al., 2001) 
CB1482 sma-6(e1482) II EMS Deposited by H.R. Horvitz (8/11/87) 
Table 2.1: C. elegans mutant strains used in this study 
 
The C. albicans strains used in this study are wild-type SC5314 (Gillum et al., 1984) and 
CAN34 an efg1/efg1 cph1/cph1 double mutant strain with the following genotype 
ura3Δ::λimm434/ura3Δ::λimm434;cph1Δ::hisG/cph1Δ::hisG;efg1Δ::hisG/efg1Δ::hisG-
URA3-hisG (Lo et al., 1997).  
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2.2.2 C. albicans - C. elegans survival assay  
 
5 mL E. coli and C. albicans liquid cultures were grown overnight respectively in LB at 37°C 
and YPD at 30°C. The E.coli culture was centrifuged at max speed for 1 minute in a 
microcentrifuge tube, washed twice in sterile PBS and resuspended to a final concentration of 
200 mg/mL.  The OD600 of the C. albicans culture was measured and the culture diluted in 
PBS to a final OD600=3. 10  of a streptomycin solution 50 mg/mL was mixed with 2.5 l of 
the E.coli culture obtained in the previous step to 0.5l of the C. albicans OD600=3 solution 
and to 7 l of sterile water. The mixture was plated in the center of a small petri dishes (3.5 
cm in diameter) containing NGM agar and incubated overnight at room temperature. The 
following day, 20 young synchronized adult worms were transferred to the spotted plate (day 
0). Synchronous worm’s populations were obtained 2-3 days after the addition of C. elegans 
eggs to NGM plates seeded with E.coli OP50. In this time frame, the eggs hatched and the 
larvae reached young adulthood. The worms are maintained at 20°C and scored daily by 
gentle prodding with a platinum wire. Dead worms were discarded, while live ones were 
transferred to new seeded plates grown overnight at room temperature. Live worms, dead 
worms and worms to be censored (worms accidentally killed while transferring or found dead 
on the edges of the plates) were scored daily. C. elegans survivals were examined using 
Kaplan-Meir method and statistical significance evaluated using the log-rank test (SPSS 
software). For the drug experiments we added fluconazole to a final concentration of 50 M 
and reduced the amount of water added to the mixture. 
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2.3 Results 
2.3.1 The C. elegans MAPK pathway is required for resistance to C. albicans  
In this study we used a simple reverse genetic approach to pinpoint nematode host effectors 
that play central roles in mounting an immune response to C. albicans infections.  
C. elegans lacks an adaptive immunity and relies on innate immunity to fight pathogens. 
Unlike other invertebrates, C. elegans not only lacks an adaptive immune systems but also 
doesn’t appear to have specialized immune cells. For example, in contrast with Drosophila 
that has macrophage-like haemocytes that engulf invading pathogens, the only haemocytes 
present in C. elegans are six coelomocytes that don’t seems capable of phagocytosis 
(Ewbank, 2002; Fares and Greenwald, 2001). 
In C. elegans, four pathways have been previously implicated in immune response to human 
pathogens (Engelmann and Pujol, 2010):  
 DBL-1 pathway, also known as  TGF- regulates the expression of key antimicrobial 
effectors like lysozymes and lectins (Mallo et al., 2002).   
 DAF2/DAF16 pathway, also known as the insulin signaling pathway, is a general stress 
response pathway that is linked to the expression of multiple antimicrobial proteins like 
saponins, thaumatin-like proteins and lysozymes (Alper et al., 2007; Murphy et al., 2003).    
 MAPK pathway, one of the most ancient signal transduction cascade in immunity shown 
to be involved in nematode resistance to Gram positive and Gram negative bacterial 
infections (Aballay et al., 2003; Huffman et al., 2004) 
 TLR pathway, a signaling pathway required for the expression of heat-shock proteins and 
other defense-like molecules (Tenor and Aballay, 2008). 
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A schematic representation of these pathways and the main players involved in the signaling 
cascades is summarized in Figure 2.1. In order to test the individual contributions of these 
pathways in nematode resistance to C. albicans, we obtained multiple nematode mutants in 
these pathways and challenged them with wild-type C. albicans. 
 
Figure 2.1: Molecular pathways involved in C. elegans immunity and tested in this 
study. 
Mutants tested in this study for their roles in nematode resistance to C. albicans infections are 
circled in blue. dbl-1, sma-6 and sma-2 mutants were chosen to test the DBL-1 pathway; 
mutants in daf-2 and daf-16 to test the DAF-2/DAF-16; mutsnts in tir-1, nsy-1, sek-1 and 
pmk-1 to test the MAPK pathway and tol-1 mutant to test the TLR pathway.     
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In the DBL-1 pathway, DBL-1 functions as a dose-dependent ligand that binds heterodimeric 
receptor DAF-4/SMA-6 triggering a phosphorylation cascade that involves SMAD proteins 
(SMA-2, SMA-3 and SMA-4) and that eventually leads to the activation of transcription 
factor SMA-9 (Figure 2.1). SMA-9 controls the expression of lys-1 and lys-8, two genes 
coding for lysozyme, a hydrolytic enzyme that has long been recognized as key innate 
immune effector (Alper et al., 2007). In order to test the role of this pathway in C. albicans 
resistance, we obtained mutants in the three main components of the pathway, the 
extracellular ligand (dbl-1), the membrane receptor (sma-6) and their cytoplasmic target 
(sma-2).  
The DAF-2/DAF-16 pathway is the C. elegans insulin/IGF-I signaling pathway, an 
evolutionarily conserved pathway that controls embryonic development, reproduction, fat 
storage and resistance to high temperature, osmotic and oxidative stress (Lamitina and 
Strange, 2005; Murphy and Hu, 2013). This pathway plays a critical role in C. elegans 
immunity by regulating the expression of hydrolytic enzymes like Lys-7 (lysozyme), Spp-1 
(saposin) and Thn-2 (thaumatin) (Evans et al., 2008). In the absence of microbial threats, the 
insulin-like peptide DAF-28 binds DAF-2 and triggers a phosphorylation cascade that leads 
to the cytoplasmic retention of the transcription factor DAF-16. In the presence of a microbial 
threat, the pathway is repressed and DAF-16 phosphorylation prevented. In these conditions 
DAF-16 translocates to the nucleus, triggering the expression of antimicrobial peptides. To 
explore the role of this pathway we obtained mutants in daf-2, the receptor tyrosine kinase, 
and daf-16, the forkhead box O (FOXO) homolog that serves as the major transcription factor 
in the pathway.  
The MAPK pathway is probably the most well characterized nematode immune pathway and 
it has been shown to have various biological functions ranging from coordinated locomotion 
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and asymmetric neuronal cell fate to resistance to P. aeruginosa and D. consispora (Kim et 
al., 2002; Pujol et al., 2008). The details of the first few steps of the cytoplasmic cascade are 
still under active debate, but they presumably involve the coordinated action of 
diacylglycerol (DAG) and the protein kinases TPA-1 and DKF-2 (Figure 2.1). Upon 
activation, DKF-2 activates TIR-1, NSY-1, SEK-1 and PMK-1 in a linear phosphotransfer 
cascade that leads to the activation of antimicrobial peptides like nlp-29 and nlp-31. The 
MAPK pathway is a highly conserved pathway and NSY-1, SEK-1 and PMK-1 are the C. 
elegans homologs of human ASK-1, MKK3 and p38 which play major roles in mammalian 
cellular immune response by controlling the expression of pro-inflammatory cytokines like 
IL-1 and TNF alpha. In order to evaluate the role of the MAPK pathway in resistance to C. 
albicans we obtained nematode mutants in each of the players involved in the cytoplasmic 
phosphorylation cascade: pmk-1, nsy-1, sek-1 and pmk-1.   
The TLR pathway in C. elegans, in contrast with Drosophila and mammals, doesn’t act 
downstream of the MAPK pathway and its exact role in immunity is still under active debate.  
This pathway has a role in a specific avoidance-like behavior in the presence of Serratia 
mercenses and is essential to mount an appropriate immune response against Salmonella 
enterica (Tenor and Aballay, 2008). However, this pathway has also been shown not to be 
important for resistance to Pseudomonas aeruginosa, Microbacterium nematophilum and 
Drechmeria coniospora (Pujol et al., 2001). In addition, the TLR pathway hasn’t been fully 
dissected and TOL-1 is the sole C. elegans Toll-like receptor (TLR). TRF-1, PIK-1 and IKB-
1 are the homologues of the mammalian downstream signal transduction components but 
they have been shown not to act downstream of the TOL-1 in C. elegans (Tenor and Aballay, 
2008). In order to evaluate the role of this pathway in resistance to C. albicans, we obtained 
the available mutant in tol-1.   
  
45 
 
 
Before performing our survival assay in the presence of C. albicans we evaluated the life 
span of each of the mutants. Mutations in key immune system modulators have the potential 
not only to severely compromise the nematode’s immunity but also to shorten its life span. 
This would add an extra layer of complexity to the interpretation of our C. albicans survival 
results, creating a confounding element difficult to control experimentally. We therefore 
decided to performed our life span assay first and exclude from our analysis mutants with 
altered life spans. Life span assays were performed using heat killed E. coli as the nematode 
source of food (Tenor and Aballay, 2008). As shown in Figure 2.2, mutants in sma-2, sma-6, 
pmk-1, sek-1, tir-1 and tol-1 (mean time to death 13.4 ± 0.5, 12.1 ± 0.5, 13.5 ± 0.6, 15.9 ± 
0.7, 14.3 ± 0.6, 12.7 ± 0.6 days) didn’t show a statistically significant difference in longevity 
compared to wild-type (mean time to death 14.6 ± 0.5 days). On the other hand, mutations in 
dbl-1, daf-16 and nsy-1 caused a significant shortening of nematode life span (mean time to 
death 7.7 ± 0.4, 9.1 ± 0.6, 8.5 ± 0.6 days) and mutations in daf-2 caused life span extension 
(19.1 ± 0.6 days).  
Loss-of-function mutations in dbl-1 were known to cause markedly reduced body size 
mutants (Suzuki et al., 1999) but, to the best of our knowledge, this is the first time that this 
gene has been implicated in nematode longevity. On the other hand the DAF-2/DAF-16 
pathway has been known for its role in controlling life span and the increased and reduced 
life span of daf-2 and daf-16 mutants have been previously reported (Huang and Zhang, 
2011; Kenyon et al., 1993). 
The working hypothesis is that daf-2 loss of function leads to the hyperactivation of the 
transcription factor DAF-16 which controls the expression of antimicrobial peptides spp-1, 
spp-12 and lys-7. The overexpression of these genes leads to an extended life span as well as 
an increases resistance to pathogens. This hypothesis is corroborated by the fact that daf-16 
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loss of function leads to abrogation of the expression of these genes causing a reduced fitness 
and shorter life span. 
 
Figure 2.2 C. elegans mutants’ life span assay with heat killed E. coli  
A) DBL-1 pathway: mutants in this pathway live just as long as wild-type except for dbl-1 
which is short-lived B) DAF-2/DAF-16 pathway: mutants in this pathway showed 
statistically significant different life spans compared to wild-type C) MAPK pathway: only 
mutants in nsy-1 show a reduced life span compared to wild-type D) tol-1 mutants have life 
spans comparable to wild-type. Survival curves represents average of three biological 
replicates (n = 60).   
Finally, nsy-1 loss of function leads to a reduced life span, indicating that this gene is not 
only required for chemotaxis, egg laying, pathogen response and anoxia resistance (Kim et 
al., 2002; Troemel et al., 1999) but also for longevity. All of the mutants that showed a 
statistically significant difference life span compared to wild-type were excluded from our 
subsequent analysis.  
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Mutants with life spans comparable to wild type were challenged with live C. albicans. As 
shown in Figure 2.3, mutants in either the DBL-1 or TLR pathway lived just as long as 
controls (mean time to death for sma-2, sma-6, tol-1 and wildtype 6.7 ± 0.2, 7.0 ± 0.3, 8.6 ± 
0.5 and 7.2 ± 0.3 days respectively). However, when we tested the MAPK pathway we 
observed that, remarkably, mutants in any of the major players in this pathway (tir-1, pmk-1 
and sek-1) were significantly more susceptible to C. albicans infection compared to controls 
(p < 0.01 at both the Log Rank and Breslow statistical test). This evidence suggests that the 
MAPK pathway plays a crucial role in resistance to C. albicans infections. Interestingly, 
when mutants in the MAPK pathway were infected, we didn’t observed a faster or more 
severe accumulation of C. albicans in their intestinal lumen, indicating that these mutations 
don’t impair the nematode’s pharynx grinding ability or cause any gross structural changes to 
the sites of infection. In addition, infected mutants in this pathway didn’t show any 
substantial difference in the tail region swelling (Dar phenotype), suggesting that MAPK 
mutants’ shorter survival depends on immune mechanisms independent from the Dar 
response.   
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Figure 2.3: MAPK pathway is required for C. elegans resistance to C. albicans  
A) DBL-1 pathway: mutants in this pathway don’t show increased sensitivity to C. albicans 
infection B) Mutations in any of the major players in the MAP kinase pathway resulted in 
increased sensitivity to C. albicans infections C) tol-1 mutants don’t show increased 
sensitivity to C. albicans infections. Survival curves represents average of three biological 
replicates (n = 60).  
These results suggest that the MAPK pathway has a direct role in nematode defense response 
to C. albicans. These findings were recapitulated by others in mammalian models of infection 
(Moyes and Naglik, 2011) and reiterate the usefulness of modeling C. albicans infections in a 
simpler genetically tractable model like C. elegans.  
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2.3.2 Genetic and pharmacological modulation of the C. elegans – C. albicans survival 
assay  
 
In this study we tested the ability of the C. albicans - C. elegans model system to respond to 
either genetic or pharmacologic modulation of the yeast.  
We first tested the ability of the worms to survive infection caused by C. albicans efg1/efg1 
cph1/cph1 double mutant. Efg1 is a highly-conserved transcription factor and an essential 
component of the cyclic AMP/protein kinase A (PKA) metabolic pathway. In C. albicans this 
pathway regulates hyphal morphogenesis (McDonough and Rodriguez, 2012), white-opaque 
switching (Sonneborn et al., 1999) and an arsenal of key virulence factors. These virulence 
factors include Hwp1 and Hwp2, two yeast-specific cell wall proteins involved in adhesion 
and biofilm formation, Eap1 a cell-wall adhesin involved in binding to human epithelial cells 
(Li and Palecek, 2003) and Sap5, an hydrolytic enzyme involved in epithelial tissue invasion 
(Staib et al., 2002). On the other hand Cph1 is a transcription factor that regulates many 
metabolic processes including mating, filamentation and biofilm formation and it has been 
shown to play a critical role in damaging epithelial cells (Korting et al., 2003) and human 
reconstructed epithelium (Dieterich et al., 2002). Disruption of either of these genes has a 
significant impact on virulence and simultaneous disruption of both in cph1/cph1 efg1/efg1 
results in dramatic virulence reduction in various animal models including mice (Lo et al., 
1997), Drosophila (Chamilos et al., 2006), zebrafish (Brennan et al., 2002; Brothers et al., 
2011) and moth (Brennan et al., 2002). cph1/cph1 efg1/efg1 double mutants is considered by 
the C. albicans community as the a-virulent strain by definition and the gold standard for 
validation of novel model systems. As shown in Figure 2.4, worms infected with cph1/cph1 
efg1/efg1 C. albicans double mutant lived statistically significantly longer that controls (p < 
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0.01 at both Log Rank and Breslow statistical test, n = 60) suggesting that these two genes 
are required for C. albicans virulence against C. elegans. These proofs of principle 
experiments suggest that our nematode model can be used to study C. albicans virulence and 
encouraged us to undertake a large scale C. albicans reverse genetic screen that is described 
in chapter 3.   
 
Figure 2.4: C. albicans - C. elegans model can be pharmacologically or genetically 
modulated.   
A) C. albicans accumulation in the nematode intestinal lumen day 3 post infection. Yeast 
cells are quickly ingested by the worms and accumulate in the intestinal lumen completely 
intact indicating that they are able to survive the mechanical crushing of the pharynx. B) 
survival curves of nematodes challenged with C. albicans versus uninfected controls C) 
survival curves of nematodes challenged with either wild-type C. albicans, cph1/cph1 
efg1/efg1 double mutant or wild-type C. albicans + 50 M of fluconazole  
In order to explore the possibility of using our C. elegans model for potential drug screening, 
we tested the effect of the addition of fluconazole to the ultimate outcome of the infection. 
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We used a variety of different concentrations of fluconazole and found that 50 M gave us 
the most significant results. As shown in Figure 2.4, worms infected with C. albicans and 50 
M of fluconazole lived statistically significantly longer that controls (p < 0.01 at both Log 
Rank and Breslow statistical test, n = 60). Interestingly we also found that lower fluconazole 
concentrations (below 25 M) didn’t prolong survivals in a statistically significant fashion 
and that higher concentrations (above 100 M) led to reduced survival suggesting that 
fluconazole might be toxic for the nematodes over a certain concentration. These proof of 
principle experiments showed that our nematode model can be used for small molecule 
antifungal screening. The model was in fact instrumental in the discovery of filastatin, a small 
molecule inhibiting various aspect of fungal virulence that is currently undergoing further 
preclinical studies and that is described in chapter 6 (Fazly et al., 2013).   
   
2.4 Discussion 
 
We used here a gene candidate reverse genetic approach to identify C. elegans immune 
determinants important for nematode resistance to C. albicans. We have shown that 
mutations in any of the genes involved in the MAPK pathway lead to increased sensitivity to 
C. albicans infections. In mammals, this pathway has been implicated in a variety of different 
cellular immune responses against C. albicans infections. This pathway is critical for C. 
albicans phagocytosis by murine macrophages (Ibata-Ombetta et al., 2001), for the 
macrophage ability to discriminate between live and heat inactivated C. albicans (Martinez-
Solano et al., 2009) and for the human epithelia’s ability to remain quiescent under low 
fungal burden while responding strongly upon damage-induced C. albicans penetration 
(Moyes et al., 2010; Moyes et al., 2014). Taken together, these results suggest that the MAPK 
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pathway plays a critical role in immunity against C. albicans in both mammals and 
nematodes suggesting that some of the lessons we learn in this simpler, genetically-tractable 
model may hold true in humans. We have also shown here proof of principle experiments that 
demonstrate that our nematode model can be genetically and pharmacologically modulated 
and can be used to study pathogen’s determinants and for small molecule drug screening.  
In conclusion, our model is a very versatile tool that can be used not only to study the 
contributions of individual host-pathogen genes using forward and reverse genetic but also 
for exploring new molecules for therapeutic intervention.      
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3 Reverse genetic screen identifies ZCF15 a novel virulence 
factor 
 
3.1 Introduction 
 
Candida infections represent a serious public health threat. With an estimated 46,000 
infections per year and direct costs between 1$ and 2$ billion, they represent the fourth most 
common cause of healthcare-associated bloodstream infections in the United States (Rentz et 
al., 1998; Wilson et al., 2002; Wisplinghoff et al., 2004). These infections can be caused by 
many Candida yeasts species, the most common of which is Candida albicans. This 
polymorphic fungus is part of the human microbiome and it usually lives as a harmless 
commensal on the skin and mucosa of healthy individuals. However, under certain 
circumstances, it can cause infections ranging from mild superficial infections to life-
threatening systemic infections. Although in the last two decades a large body of literature 
shed some light on C. albicans pathogenicity (Mayer et al., 2013), our understanding of the 
basic mechanisms that lead this harmless commensal to become pathogenic remain elusive. 
In addition, because drug resistant has dramatically increased the last two decades (Cowen, 
2008), there is an urgent need to identify new targets to develop better diagnostics and 
therapeutics.  
In order to find novel genes involved in virulence, a team of four undergraduate students in 
our lab screened a large library of C. albicans mutants for their abilities to elicit the Dar 
response in C. elegans. This reverse genetic approach identified four novel virulence factors, 
and in this chapter we will focus on ZCF15, a previously uncharacterized Zn(II)2Cys6 DNA 
binding protein that, unlike the other three, doesn’t have a human homolog. This feature is 
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critical because in order to develop effective antimycotics with high selective toxicity it is 
imperative to target fungal specific genes or metabolic processes not conserved in humans.   
Here we show that zcf15/zcf15 homozygous knockout not only is significantly less capable of 
inducing Dar as shown by the team of undergrads, but it is less capable of killing worms, 
survive mouse macrophages ex vivo, and withstanding reactive oxygen species (ROS) in 
vitro.  
We used various experimental approaches to demonstrate that the decreased virulence of the 
zcf15/zcf15 knockout is likely due to its inability to withstand ROS, a common host defense 
mechanism. The C. albicans zcf15/zcf15 knockout is hypo virulent in the nematode model 
except in worms whose ability to produce ROS has been compromised. Results in the worm 
model were recapitulated in mouse macrophage cocultures, further supporting our initial 
findings. In particular, the C. albicans zcf15/zcf15 knockout is hypersusceptible to 
macrophage killing except in macrophage in which the ability to produce ROS has been 
pharmacologically inhibited. Overall, this evidence indicates that ZCF15 plays a key role in 
C. albicans virulence by contributing to the pathogen’s ability to withstand the host’s 
generated ROS. Deletion of ZCF15 has a limited impact in a disseminated murine 
bloodstream model of infection, suggesting that additional layers of regulation exist in the 
context of the murine bloodstream.  
Taken together, these results suggest that ZCF15 is an important virulence determinant and 
plays a critical role in resistance to host generated ROS. Insights on its precise mechanism of 
action is elucidated in chapter 4.    
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3.2 Materials and methods 
 
3.2.1 Strains and media 
 
C. albicans mutants screened in this study and relative references are summarized in Table 
3.1. A total of 724 transposon insertion mutants were screened: 84 protein kinase mutants, 98 
cell wall mutants, 234 transcription factors mutants and 308 mutants in various other genes 
(random mutagenesis approach used).        
Genes targeted 
Fungal genetic stock center 
name 
Number of 
mutants screened 
Reference 
Kinases Kinase set from A. Mitchell 84 (Blankenship et al., 2010) 
Cell Wall CWP plates 1-2 98 (Norice et al., 2007) 
Transcription 
factors 
CJNF TF 84 
(Nobile and Mitchell, 
2005a) 
Transcription 
factors 
2nd Set TF 79 (Rauceo et al., 2008) 
Transcription 
factors 
Dominique Sanglard TF 71 (Sanglard lab, unpublished) 
Random VB GKO plates 1-5 215 (Davis et al., 2002) 
Random Misc 58 (Sanglard lab, unpublished) 
Random SFY 35 (Sanglard lab, unpulished) 
Table 3.1: C. albicans transposon mutant library description and relative references.  
 
Strains were obtained from the Fungal Genetic Stock Center and routinely grown on YPD 
(Yeast-Peptone-Dextrose) liquid or agar plates.  
To validate the results we obtained from the transposon insertion mutant library screen we 
obtained a series of homozygous deletions and complemented strains that are described in 
Table 3.2. 
  
  
56 
 
 
Strain  Phenotype  Genotype Reference  
SN250 Arg- 
his1Δ/his1Δ, leu2Δ::C.dubliniensis HIS1 
/leu2Δ::C.maltosa LEU2,arg4Δ /arg4Δ, 
URA3/ura3Δ::imm434, IRO1/iro1Δ::imm434 
Noble et 
al., 2010 
zcf15/zcf15  Arg- 
his1Δ/his1Δ, leu2Δ /leu2Δ, arg4Δ /arg4Δ, 
URA3/ura3Δ::imm434,IRO1/iro1Δ::imm434,orf19.2753Δ::
C.dubliniensisHIS1/orf19.2753Δ::C.maltosaLEU2 
Noble et 
al., 2010 
dot4/dot4 Arg- 
his1Δ/his1Δ, leu2Δ /leu2Δ, arg4Δ /arg4Δ, 
URA3/ura3Δ::imm434,IRO1/iro1Δ::imm434,orf19.3370Δ::
C.dubliniensisHIS1/orf19.3370Δ::C.maltosaLEU2 
Noble et 
al., 2011 
orf19.1219/o
rf19.1219 
Arg- 
his1Δ/his1Δ, leu2Δ /leu2Δ, arg4Δ /arg4Δ, 
URA3/ura3Δ::imm434,IRO1/iro1Δ::imm434,orf19.3370Δ::
C.dubliniensisHIS1/orf19.3370Δ::C.maltosaLEU3 
Noble et 
al., 2012 
zcf15/ZCF15c 
(LEU2)  
Prototrophic 
his1Δ/his1Δ, leu2Δ /leu2Δ::ORF19.2753-
C.dubliniensisARG4, arg4Δ /arg4Δ, 
URA3/ura3Δ::imm434,IRO1/iro1Δ::imm434,orf19.2753Δ::
C.dubliniensisHIS1/orf19.2753Δ::C.maltosaLEU2 
This work 
zcf15/ZCF15c 
(End)   
His- 
his1Δ/his1Δ, leu2Δ /leu2Δ, arg4Δ /arg4Δ, 
URA3/ura3Δ::imm434,IRO1/iro1Δ::imm434,orf19.2753Δ::
C.dubliniensisHIS1::ORF19.2753-
C.dubliniensisARG4/orf19.2753Δ::C.maltosaLEU2 
This work 
Table 3.2: C. albicans homozygous knockout mutants and complemented strains used in this 
study.  
To complement the zcf15/zcf15 knockout we reintegrated ZCF15 either at the endogenous 
locus (End) or at an ectopic locus (LEU2) (Table 3.2). In the former case the expression is 
controlled by the endogenous regulatory sequences, in the latter by the LEU2 promoter. For 
endogenous reintegration, we first PCR amplified a fragment containing the ZCF15 coding 
sequence plus ~700 bp upstream using primer 548 and 555 (Table 3.3). As a template for 
PCR we used genomic DNA extracted from wildtype strain using standard 
phenol:chloroform extraction (Hoffman and Winston, 1987). The PCR product was BamHI-
AflII digested and cloned into a BamHI-AflII digested pSN69 (Noble and Johnson, 2005) in 
order to obtained plasmid pLI101. We subsequently amplified a ~700 bp fragment 
downstream of the ZCF15 open reading frame using primers 554 and 556. The PCR product 
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was XhoI-XbaI digested and cloned it into a XhoI-XbaI digested pLI101 to obtain plasmid 
pLI102. Finally we digested pLI102 with BamHI and XbaI to liberate an integrating fragment 
made of ZCF15 - C. dubliniensisARG4 flanked by ~700bp upstream and downstream of 
ZCF15. The integrating fragment was transformed into zcf15/zcf15- following the LiAc 
protocol (Wilson et al., 1999) and plated in media lacking arginine. Arg
+
 colonies were 
restreaked on SC-ARG plates to confirm their true Arg
+
 nature and then grown overnight in 
SC-ARG liquid medium. Genomic DNA was extracted from these cultures using standard 
phenol:chloroform procedures and integration of ZCF15 was confirmed by PCR using 
primers designed to the check the presence of the new 5’ and 3’ junctions (Table 3.3, 583-584 
for the 5’ junction and 585-586 for the 3’ junction). 
Primer number Primer sequence 
548 TTGCAAGGATCCTCTGGTCCCTCGGATCAACAAGAT 
555 
GCTCGACTTAAGTATTTATTTAATCAATATATGTAAAAAAAGA
GTCT 
554 
GTCGATCTCGAGAGACTCTTTTTTTACATATATTGATTAAATAA
ATA 
556 GATCATTCTAGAACAAGCACAAATGTTATTCCATGC 
583 CCAAAGAGTTAGCTTACTAATTACC 
584 GGATTGTGCGTCGATCAATAA 
585 ACGAAGGTCACACTGACTTATG 
586 ACTGATGATGAGTTGCGATATGA 
587 
GTAAAATTACAATTGGTATTTTCAACCAATATTACCACACAGG
AGGAGGAGGACAAGAAA 
589 
CTATCTCTCTTTTTTTTGCCCATTTGAGTTAGTGCATGACATCA
AACATCAGCAGGAGGA 
600 GTAACGACGCCAAATCTCAATAC 
568 TGGGTTTCCTTCAGCATCAA 
601 GTATCGCCTTTGGGATGTCTAT 
602 CAATAACTACCTCGGCACCTT 
Table 3.3: primers used in this study. 
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To complement ZCF15 in the LEU2 locus we leveraged the power of gap repair cloning in S. 
cerevisiae (Bessa et al., 2012). We first amplified ZCF15 and its ~600 bp upstream and ~600 
bp downstream with primers 587 and 589 from genomic SN250. This fragment was digested 
with BmgBI and co transformed with BmgBI digested pSN105 (Noble et al., 2010) into S. 
cerevisiae BY4741 (Brachmann et al., 1998) using standard LiAc protocol. The primers have 
been designed so that the PCR product is flanked by 40 bp that are homologous to the 
extremities of the digested plasmid. The yeast homologous recombination machinery 
recognized the homologous sequences and ligated them giving the strains the ability to grow 
in media lacking uracil. Colonies growing in media lacking uracil were restreaked in SC-
URA plates and subsequently grown overnight in liquid culture lacking uracil. The “gap 
repaired” plasmid (pLI103) was extracted using the QIAprep mini kit (Qiagen) and the 
presence of ZCF15 was confirmed by both PCR and diagnostic restriction double digestion. 
pLI103 was electroporated into E. coli  DH5and plated in LB media + 100g/mL 
ampicillin. After plasmid mini prep, pLI103 wasdigested with PmeI to liberate the ZCF15-
ARG4 inserting cassette flanked by the ~500 bp fragments upstream and downstream of the 
LEU2 open reading frame. The digested plasmid was transformed into zcf15/zcf15 following 
the LiAc protocol and plated in media lacking arginine. Arg
+
 colonies were restreaked on SC-
ARG plates, grown overnight in SC-ARG liquid and genomic DNA was extracted using 
standard phenol:chloroform procedures. Proper integration of ZCF15 in the LEU2 locus was 
confirmed by checking the presence of the novel 5’ and 3’ junction using primers 600-568 
and 601-602 respectively (Table 3.3). 
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3.2.2 C. albicans - C. elegans deformed anal region (Dar) assay  
 
2-3 C. elegans N2 young adults were transferred to an NGM agar plate seeded with E.coli 
OP50 and incubated at 20°C for 4-5 days to allow generation of a large number of gravid 
adult worms. The plate was washed with 10 mL of buffer M9, transferred to a 15 ml conical 
tube and centrifuged for 2 minutes at 900 g. Supernatant was discarded and pellet 
resuspended in 15 mL of 0.25 M NaOH plus 5.25% commercial bleach. The mixture was 
mixed gently for 3 minutes. During this time lapse, worms are lysed and only eggs survive 
the treatment. Eggs were isolated by centrifugation at 2000 g for 2 minutes. Once the 
supernatant was discarded, the pellet was washed in sterile water and the eggs finally 
resuspended in M9 to a final concentration of 5-6 healthy eggs/l.  
E. coli OP50 and each of the C. albicans strains were grown overnight respectively in LB at 
37°C and YPD at 30°C. The E. coli and C. albicans cultures were centrifuged at full speed in 
a micro centrifuge and the pellets resuspend in PBS to a final concentration of 200 mg/mL 
and 10 mg/mL respectively. 10l of streptomycin solution 50 mg/mL were mixed with 2.5 l 
of the E. coli and 0.5l of C. albicans cultures. The strep-E. coli-C. albicans mixture was 
plated in the center of a NGM agar petri dish (6 cm diameter) together with  25-30 healthy C. 
elegans eggs (plated to the side of the Strep-E. coli-C. albicans mixture). The plates were 
incubated at 20°C and the percentage of worms showing Dar manually scored under the 
dissecting microscope day 4 post spotting.   
 
3.2.3 C. albicans - C. elegans survival assay  
 
E.coli OP50 and C. albicans were grown overnight respectively in LB at 37°C and YPD at 
30°C. The E.coli culture was centrifuged at full speed and the pellet resuspended to a final 
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concentration of 200 mg/mL in sterile water while C. albicans strains were diluted in sterile 
water to OD600=3. 10l of streptomycin solution 50 mg/mL were mixed with 2.5 l of the E. 
coli and 0.5l of C. albicans culture. The strep-E. coli-C. albicans mixture was plated on 
NGM agar small petri dishes (3.5 cm diameter) and incubated overnight at 20°C. 20 young 
synchronized C. elegans N2 were added to the spotted plate. Plates were incubated at 20°C 
and worms were scored daily by gentle prodding with a platinum wire. Dead worms were 
discarded, while live ones were transferred to new plates seeded with the strep-E. coli-C. 
albicans mixture and grown overnight at room temperature. Worms accidentally killed while 
transferring or found dead on the edges of the plates were censored in our analysis.   
 
3.2.4 In vitro phenotypic characterization   
 
For growth rate experiments, three independent colonies from each C. albicans strain were 
inoculated in YPD and grown overnight at 30°C. Cultures were resuspended to OD600 = 0.1 
in fresh YPD and transferred to a microplate reader (Bio-Tek Synergy H4) that measured 
OD600 every 15 minutes for a total of 48 hours. Growth curves were generated by averaging 
the individual reads and plotting them over time.   
To quantify the strain’s ability to form biofilm we essentially followed the protocol detailed 
here (Reynolds and Fink, 2001). Briefly, liquid cultures were grown in SC + 0.15% glucose 
at 30° C overnight, resuspended to OD600 = 0.5 in fresh SC + 0.15% glucose and transferred 
to flat bottom 96 well plates (200l per well). The plates were incubated for 4 hours at 37°C, 
the content of each well was decanted and the cells attached to the bottom of the wells stained 
by adding 50 l of 0.5% crystal violet. After 45 minutes at room temperature, the plate was 
washed ten times by alternate submerging in water and decanting. After having gently tapped 
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the plates to remove the excess water, 200 l of 75% methanol was added to each well and 
the plate incubated at room temperature for 30 minutes. Absorbance of each well at 590nm 
was finally measured using a micro plate reader (Gemini XPS fluorescence microplate 
reader).    
For the in vitro spotting assay, strains were grown overnight at 30°C in a roller drum, 
resuspended to OD = 1 in sterile water, serially diluted 1:5 in sterile water and spotted on 
agar plates containing  SDS, Calcofluor White, NaCl, Sorbitiol or paraquat (methyl viologen 
dichloride) at the various concentrations suggested here (Homann et al., 2009). Plates were 
incubated overnight at 30°C and photographed using the BioRad Gel Doc XR. For 
filamentation, strains were spotted on Spider media (1% nutrient broth, 1% D-mannitol, 0.2% 
K2HPO4), incubated at 37°C for 7 days before being photographed.   
 
3.2.5 Ex vivo macrophage assay   
 
The ex vivo macrophage assay was adapted from (Lopes da Rosa et al., 2010). Briefly, two 
T75 flasks of RAW 264.7 (Raschke et al., 1978) were grown to 80-90% confluency in 
DMEM + 10% FBS. Cells were scraped off the flasks, resuspended in DMEM + 10% FBS 
and 2x10
6
 cells were plated in 6 well plates (total volume 1 mL). Control wells with just 
DMEM + 10%FBS were also set up. Cells were allowed to adhere for 5 hours at 37°C, 5% 
CO2 and then 1.3 x 10
5
 C.albicans cells resuspended in DMEM + 10% FBS spiked in each 
well (including the controls lacking macrophages). Plates were incubated at 37°C, 5%CO2, 
overnight. The following day cells were scraped off each well and resuspended in 10 mL 
0.02% Triton-X 100 (vol/vol) to osmotically lyse the macrophages. The solution was 
vortexed at max speed for 1 minute and subsequently centrifuged at 3000 g for 5 minutes. 
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The pellet was resuspended in 1 mL sterile water and 200 l of the solution transfer to a 96 
well plate. A 1:10 serial dilution was set up and 100 l of the 104 and 105 dilution plated on 
YPD plates. Wells containing both macrophages and C. albicans were plated to a 10
4
 dilution 
while control wells containing just C. albicans were plated using the 10
5
 dilution. After 
incubating the plates overnight at 30°C, colonies were counted and yeast susceptibility to 
macrophage killing measured by survival percentage. Survival percentage was measured as a 
ratio between the number of colonies recovered from wells containing only yeast cells over 
the number of colonies recovered from wells containing both yeast and macrophage cells.    
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3.3  Results  
 
3.3.1 C. albicans reverse genetic in C. elegans identifies four putative virulence factors  
 
In order to identify novel C. albicans virulence determinants, a team of four undergraduate 
students (Margaret Chiasson, Benjamin Landry, Kurtis McCannel and Kelly Pastor) screened 
a collection of 724 C. albicans transposon insertion mutants (~12% of the genome) for their 
abilities to induce the Dar phenotype (Jain et al., 2009) in C. elegans.  
The mutant library is freely available at the Fungal Genetic Stock Center and it is detailed in 
Table 3.1. Mutants were obtained using a transposon-based insertional mutagenesis strategy 
that lead to the disruption of both alleles of the targeted gene. The strategy relied on the 
bacterial transposon Tn7 (Craig, 1991) for the insertion and the UAU1 cassette for selection 
(Enloe et al., 2000). As detailed in Table 3.1, the insertional strategy was used in two 
different ways. Davis et al. 2002 and the Sanglard lab used a random insertional strategy to 
obtain 308 homozygous insertion mutants in various ORFs (the identities of the mutated 
genes were determined by sequencing the genomic regions flanking the inserted DNA). On 
the other hand, Blankenship et al., 2010; Nobile and Mitchell, 2005; Norice et al., 2007; 
Rauceo et al., 2008 used a targeted approach that yielded 416 insertion mutants in genes 
coding for transcription factors, cell wall proteins and protein kinases.  
Overall, as shown in Figure 3.1 A the library contained 98 mutants in cell wall proteins, 84 
mutants in protein kinases, 234 mutants in transcription factors and 308 mutants in various 
other ORFs. 
As shown in Figure 3.1 B and C, the team of undergraduate students identified 7 mutants that 
have a reduced ability to induce the Dar phenotype in C. elegans. C. albicans  insertion 
mutants in CMP1, IFF11, SAP8, DOT4, ZCF15, orf19.1219 and orf19.6713 induced the Dar 
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phenotype only in 54%, 50%, 82%, 48%, 29%, 61% and 59% of the nematodes compared to 
nearly 100% for wildtype C. albicans.  Three of these seven mutants (CMP1, IFF11 and 
SAP8) are known virulence factors (Bader et al., 2003; Bates et al., 2007; Schaller et al., 
2000) and their presence in our screen validated the approached we used.    
These preliminary data obtained by the team of undergraduate students were promising but 
they needed further validation. In particular, it has been recently shown that the selection 
marker used to obtain these mutants (URA3) can interfere with wild type morphogenesis, 
adhesion and virulence (Brand et al., 2004; Noble et al., 2010a), possibly confounding 
interpretation of the results. In addition, integration biases, partial loss of function (especially 
when the insertion occurs near the 3’ end of the gene) and genomic rearrangements following 
transposon insertions have been reported (Green et al., 2012) adding another layer of 
complexity to the interpretation of the results.   
To validate our preliminary results we obtained homozygous knockout mutants in the genes 
originally shown to reduce incidence of the Dar phenotype. These knockout mutants were 
obtained by targeted gene replacement through two rounds of transformation to inactivate 
both alleles of a targeted gene (Noble et al., 2010). This approach doesn’t have off-target 
effects and relies on auxotrophic markers (ARG4, HIS1 and LEU2) that don’t impact 
virulence (Noble and Johnson, 2005). We obtained knockout mutants in four of the seven 
genes originally identified and their reduced ability to cause the Dar phenotype in C. elegans 
was confirmed. Homozygous knockout mutants in DOT4, ORF19.1219, ZCF15 and SAP8 all 
showed a reduced ability to induce Dar (39%, 66%, 43% and 62% respectively) that was in 
line with what obtained with the transposon insertion mutants by the team of undergraduate 
students (48%, 61%, 59% and 82% respectively). The fact that mutants in the same genes but 
obtained with different strategies showed reduced virulence in C. elegans validated their 
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original findings. As shown in Figure 3.1 B, three (CMP1, IFF11, SAP8) of the seven genes 
identified in the screen were known virulence factors.   
 
Figure 3.1 Reverse genetic screening identifies four novel putative virulence factors  
(A) Transposon insertion mutant library composition, a total of 585 mutants were screened, 
88 mutants in protein kinases, 98 mutants in cell wall proteins, 162 mutants in transcription 
factors and 237 mutants in various other ORF (B) Transposon insertion mutant library 
composition and relative papers describing them. (C) Table summarizing the Dar data 
obtained using either transposon insertion mutants (TR library) or homozygous knockout 
mutants (KO library). ZCF15 has been poorly characterized in the literature, is required to 
induce Dar in nematodes and doesn’t have a human homolog making it a good candidate for 
potential drug targeting.   
CMP1 codes for the catalytic subunit of calcineurin, a serine/threonine protein phosphatase 
that regulates physiological processes like cell cycle progression, polarized growth, and 
resistance to salt and alkaline pH (Bader et al., 2003; Sanglard et al., 2003). CMP1 loss of 
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function leads to reduced virulence in a mouse model of disseminated candidiasis and a 
significantly reduced ability to colonize mouse kidney (Bader et al., 2003). 
IFF11 codes for a secreted protein required for cell wall architecture, and null mutants not 
only are hypersusceptible to cell-wall damaging agents but they showed attenuated virulence 
in a mouse model of systemic infection (Bates et al., 2007). Sap8 is part of a large family of 
secreted aspartyl protease that plays a crucial role in hydrolyzing host epithelial tissues 
allowing C. albicans to simultaneously penetrate deeper tissues and use the products of the 
epithelial hydrolysis as N-source for growth (Aoki et al., 2011). Sap8 has also been found to 
be upregulated in an in vitro model of cutaneous candidiasis (Naglik et al., 2003b) and to 
have a prominent role in biofilm formation (Ramage et al., 2012). The fact that mutations in 
genes already known to be important for virulence in mammals were hits in our screen 
validated our approach and underscored the relevance of studying C. albicans infection in a 
much simpler and genetically tractable host like C. elegans.    
 
 
3.3.2 ZCF15 is a novel virulence factor with no human homologs    
 
As shown in Figure 3.1, in addition to known virulence factors, we identified three genes 
(DOT4, ORF19.1219 and ZCF15) that have been poorly characterized in the literature and, to 
the best of our knowledge, have never been associated with C. albicans virulence. In order to 
gain some insights on their functions, we identified their S. cerevisiae closest homologs and 
explored their roles in baker’s yeast. This process needed to be done cautiously since these 
two species last shared a common ancestor some 300-900 million years ago (Pesole et al., 
1995) and there are many examples in the literature of S. cerevisiae genes that in C. albicans 
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have been rewired to have different biological functions (Coste et al., 2008; Murad et al., 
2001).  
The closest homolog of C. albicans DOT4 is S. cerevisiae is UBP10, a ubiquitin-specific 
hydrolase primarily located in the nucleus and able to deubiquitinate ubiquitin-protein 
moieties (Kahana and Gottschling, 1999). This class of enzymes usually has a role in 
promoting protein degradation by clearing the proteasome of ubiquitinated peptides and 
facilitating ubiquitin recycling. However UBP10 is involved in preventing, rather than 
promoting protein degradation (Hochstrasser, 1996). Assuming that the function of UBP10 is 
conserved in C. albicans, it is reasonable to believe that DOT4 loss of function leads to an 
impaired protein turnover, a trait that has been recently hypothesized to be important for 
virulence (Liu and Xue, 2011). In addition DOT4 has a close homolog in human USP36 
(Blastp E value = 1e
-24
), a poorly characterized gene that contains a well-known ubiquitin 
carboxyl-terminal hydrolase domain (Chung and Baek, 1999). The purpose of the de-
ubiquitination is thought to be two folds: preventing protein degradation on the one hand and  
recycling of the ubiquitin on the other (Quesada et al., 2004).  
Interestingly C. albicans ORF19.1219 is also potentially involved in protein degradation. 
ORF19.1219 S. cerevisiae closest homolog is RKR1, a ubiquitin ligase with a functionally 
important Ring finger domain located at its carboxyl terminus (Bengtson and Joazeiro, 2010). 
Rkr1 is predominately cytoplasmic, it colocalize with ribosomes and is an active player of the 
cells translation quality control machinery (Braun and Johnson, 2000). mRNA lacking stop 
codons can arise from errors in gene expression and encode aberrant proteins; Rkr1 
ubiquitinates nascent nonstop proteins with ubiquitin to signal their proteasomal degradation 
(Brandman et al., 2012). Interestingly, in the presence of hygromycin B, an antibiotic that 
affects translation fidelity, cells lacking RKR1 exhibited greater sensitivity to the drug. C. 
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albicans ORF19.1219 also has a close human homolog in Listerin (LTN1) (Blastp E value = 
6e
-11
) a ubiquitin ligase involved in protein quality control (Bengtson and Joazeiro, 2010). 
Mice knockout in Listerin,have been shown to experience early-onset and progressive 
neurological dysfunction (Chu et al., 2009). The working hypothesis is that loss of Listerin 
cause accumulation of aberrant proteins that ultimately lead to neurodegeneration. Assuming 
that the function of RKR1 is conserved in C. albicans ORF19.1219, it is not surprising its loss 
of function leads to virulence reduction.  
Although interesting, both DOT4 and ORF19.1219 are involved in a very fundamental aspect 
of C. albicans cellular biology and, most importantly, have two clear human homologs in 
USP36 and LTN1. The presence of human homologs makes them significantly less attractive 
for drug design because potential drugs against these genes will likely have many off target 
effects and severe toxicities.  
In contrast with orf19.1219 and Dot4, Zcf15 doesn’t have an homolog in non-pathogenic S. 
cerevisiae nor in humans making it a potentially drug targetable novel C. albicans virulence 
factor.  ZCF15 belongs to a family of 77 transcription factors that are unique to the fungal 
kingdom (Maicas et al., 2005). This family of genes is characterized by a zinc binuclear 
cluster domain called  Zn(II)2Cys6 because six cysteins in the domain bind two zinc in order 
to achieve proper protein folding (Maicas et al., 2005). ZCF15 is an uncharacterized 
transcription factor and, to the best of our knowledge, it is the first time to be reported to have 
a role in virulence. In the next paragraphs we’ll describe a series of experiments that we run 
in order to explore its mechanism of action.   
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3.3.3 ZCF15 deletion mutant is sensitive to paraquat 
In order to explore ZCF15 mechanisms of action, we extensively characterized zcf15/zcf15 in 
vitro looking for phenotypes that could explain its reduced virulence in the nematode model. 
We tested the knockout’s ability to grow on minimal media, to adhere to polystyrene, to 
filament under N-starvation conditions and to resist various stresses like hyperosmotic, 
oxidative and cell wall stressors. We tested these conditions because the C. albicans’ ability 
to limit/alternate nutrient utilization, form biofilms, switch from a yeast to hyphal forms and 
resist various stresses are all traits that have been postulated to be important for virulence 
(Heller and Tudzynski, 2011; Mitchell, 1998; Ramirez and Lorenz, 2007; Wachtler et al., 
2011). As shown in Figure 3.2, under many of these conditions zcf15/zcf15 behaves like wild-
type. In particular zcf15/zcf15 has wild type ability to grow in minimal media (Figure 3.2 A), 
to form biofilms on commonly used medical devices (Figure 3.2 B), to switch from yeast-to-
hyphal form under N-starvation conditions (Figure 3.2 C) and to resist hyperosmotic (NaCl-
Sorbitol) and cell wall (SDS-Calcofluor) stresses (Figure 3.2 D). These experiments suggest 
that the zcf15/zcf15 hypo virulence in C. elegans is not connected to any of these important 
virulence traits.  
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Figure 3.2 zcf15/zcf15 does not differ from wild-type in several in vitro assays.  
(A) zcf15/zcf15 has wildtype ability to growth in minimal media. Overnight cultures were 
resuspended in SC media at OD600 = 0.1 and absorbance monitored for 48 hours. Values from 
3 independent biological replicates was averaged and plotted over time. Error bars indicate 
standard deviations.  (B) zcf15/zcf15 has wildtype ability to form biofilm. Overnight cultures 
were resuspended to OD600=0.5 and let adhere in filamentation inducing condition for 4 hours 
to polystyrene plates. The plates were thoroughly washed and the cells remained attached to 
the plate (biofilm) stained with crystal violet and quantified by reading absorbances at 590 
nm. edt1/edt1 is a non-adherent control strain (C)  zcf15/zcf15 has wildtype ability to filament 
under N-starvation conditions. chp1/cph1 efg1/efg1 double mutant was used as a negative 
control and isolate 4639 (Perea et al., 2001b) as a positive control. (D) zcf15/zcf15 has wild 
type ability to resist cell wall stressors (SDS and Calcofluor white) and hyperosmotic stresses 
(NaCl and Sorbitol).  
However, when we tested the ability of zcf15/zcf15 to grow in the presence of reactive 
oxygen species generator paraquat, we found that ZCF15 is required for wildtype resistance 
(Figure 3.3 A). This evidence made us hypothesize that zcf15/zcf15 reduced virulence in C. 
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elegans may be connected to its inability to cope with ROS, a commonly used host immune 
defense mechanism.  
Paraquat is a well-established model of intracellular superoxide-mediated cell injury (Castell 
et al., 2005) and its mechanism of action is depicted in Figure 3.3 B.  
 
Figure 3.3: zcf15/zcf15 is hypersuseptible to ROS generator paraquat.     
A) ZCF15 is required for wild-type resistance to reactive oxygen species generator paraquat. 
Wild-type and zcf15/zcf15 strains were grown overnight, resuspended to OD = 1, serially 
diluted 1:5 and plated on YPD + 1mM paraquat. 
B) Paraquat is reduced to its free radicals (PQ2+●) with concomitant oxidation of NADPH. 
This reaction reduces the NADPH/NADP+ ratio altering pentose cycle and lipid 
metabolism. In aerobic conditions, PQ2+● is oxidized back to paraquat in a process that 
leads to the formation of superoxide radicals (O2-●). Superoxide radicals (O2-●) can then 
lead to the formation of even more toxic reactive oxygen species like hydroxyl radicals 
(OH●) that cause cellular damages via lipid peroxidation or DNA damage. Figure 
adapted from Castell et al,. 2005. 
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Paraquat is reduced in the mitochondria to its free radical PQ
2+●
 with concomitant oxidation 
of NADPH to NADP
+
. In the presence of atmospheric oxygen, the reduced paraquat is 
recycled back to paraquat by cytochrome P-450 in a process that leads to the formation of 
superoxide radical (O2
-●
). Superoxide radicals can then either be converted to oxygen and 
hydrogen peroxide by superoxidase dismutase (SOD) or spontaneously form even more toxic 
radicals like hydroxyl radicals (OH
-●
). In the presence of transition metal (M+) hydrogen 
peroxide can also be converted in hydroxyl radicals (OH
-●
). Unlike superoxide, which can be 
detoxified by superoxide dismutase, hydroxyl radicals cannot be eliminated by enzymatic 
reaction and cause protein degradation, DNA damage and lipid peroxidation (Bus et al., 
1976).  
To confirm that zcf15/zcf15 hypersensitivity to paraquat was a result of the intended deletion, 
we reintegrated a wild type copy of ZCF15 into zcf15/zcf15 knockout to obtain the 
corresponding complemented strains (zcf15/ZCF15
c
). As shown in Figure 3.4 we used two 
different strategies to obtain the complemented strains. On one side we used a gap repair 
cloning strategy to reintegrate ZCF15 into the highly expressed LEU2 locus (Figure 3.4 A), 
on the other, we used traditional cloning techniques to reintegrate ZCF15 to its endogenous 
locus (Figure 3.4 B). Complementing gene deletion in the highly expressed LEU2 locus is the 
most commonly used strategy by the C. albicans community however integration of 
exogenous genes at ectopic location can have position effects on gene expression (Gerami-
Nejad et al., 2013) and confound phenotypic analysis. Complementing in the endogenous 
locus is more laborious but allowed reintegration of ZCF15 in its endogenous locus and so its 
gene expression is controlled by its own regulatory sequences.  
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 Figure 3.4: zcf15/zcf15 complementation strategies  
(A) ZCF15 reintegrated in zcf15/zcf15 knockout in the ectopic locus LEU2. ZCF15 open 
reading frame was amplified with primers containing 40 bp homologous sequences to 
BmgBI digested pSN105 (blue lines). BmgBI digested pSN105 and ZCF15 were 
cotransformed into S. cerevisiae BY4741 to obtain plasmid pLI103. Plasmid pLI103 was 
digested with PmeI to liberate the ZCF15-ARG4 integrating cassette flanked by ~500 bp 
sequences homologous to the upstream and downstream region of LEU2 (green boxes). 
Digested pLI103 was transformed in C. albicans zcf15/zcf15 to introduce a wild-type 
copy of ZCF15 in LEU2 locus (chromosome VII). ZCF15 integration was confirmed by 
PCR checking the presence of the new 5’ and 3’ junctions at the LEU2 locus.  
(B) ZCF15 reintegrated in zcf15/zcf15 knockout at the endogenous locus. ZCF15 wild-type 
sequences (plus ~700 bp upstream of the gene) and ~700 bp sequence downstream of 
ZCF15 were cloned into pSN69 to obtain pLI102. This step was achieved using 
traditional cloning in E. coli and restriction enzymes BamHI, AFlII, XbaI and XhoI. 
pLI102 was subsequently digested with BamHI and XbaI to liberate ZCF15-ARG4 which 
integrates at the ZCF15 endogenous locus on chromosome IV. Proper integration of 
ZCF15 was confirmed by PCR checking the presence of the new 5’ and 3’ junctions.   
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As shown in Figure 3.5 A, reintegration of ZCF15 in either LEU2 or in its endogenous locus 
fully restores wild-type ability to resist paraquat, confirming that the phenotype observed in 
the deletion is caused by ZCF15 loss of function and not by other off target effects obtained 
during the deletion. To the best of our knowledge, this is the first time that ZCF15 has been 
associated with the C. albicans ability to withstand reactive oxygen species. 
 
 
3.3.4 ZCF15 is required to withstand C. elegans generated ROS  
 
It is well known that C. elegans produces ROS upon both bacterial and fungal infections 
(Chavez et al., 2007; Jain et al., 2009a; Moy et al., 2004) as part of its defense mechanism. 
ROS have a biocidal effect on invading organisms and play a major role in innate immunity. 
zcf15/zcf15 hypersusceptibility to ROS in vitro made us hypothesize that its reduced 
virulence in C. elegans was due to a reduced ability to withstand the host’s generated ROS. 
To test our hypothesis we determined the zcf15/zcf15 ability to kill either wild-type worms or 
worms with an impaired ability to produce ROS. 
As shown in Figure 3.5 B C. elegans responds to pathogen’s ingestion by producing 
extracellular ROS in the intestinal lumen via Ce-Duox1, an NADPH oxidase coded by the 
gene bli-3. During ROS production, the intestinal cells also produce intracellular antioxidants 
via DAF-16 to protect its own tissues from the ROS damaging effects (Chavez et al., 2007; 
Hoeven et al., 2011). Ce-Duox1 is a protein with an N-terminal peroxidase domain, a C-
terminal superoxide-generating NADPH-oxidase domain and two central calmodulin-binding 
sites (Meitzler and Ortiz de Montellano, 2009). Upon microbial infection, this protein uses 
cytosolic NADPH to generate extracellular toxic ROS in the intestinal lumen to counteract 
the infection. Throughout a series of biochemical assays, Jain et al., 2009 showed that ROS 
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are abundantly produced upon yeast infections and that bli-3 loss of function via bli-3(e767) 
dramatically reduces the nematode ability to produce ROS. 
 
Figure 3.5: ZCF15 is required to withstanding C. elegans generated ROS 
(A)  ZCF15 is required for wild-type resistance to reactive oxygen species generator 
paraquat. Wild-type, knockout or complemented strains were grown overnight, resuspended 
to OD = 1, serially diluted 1:5 and plated on either YPD or YPD + 1mM paraquat (B) C. 
elegans fights pathogens present in the intestinal lumen by producing ROS via bli-3 and 
contemporarily producing intracellular antioxidant via DAF-16 to protect its own tissues. 
Figure adapted from Adapted from  (Hoeven et al., 2011)   (C) Kaplan-Meier survival curves 
showing that ZCF15 deletion reduces C. albicans’ ability to kill wildtype worms. (D) 
Kaplan-Meier survival curve showing comparable killing kinetics between zcf15/zcf15, wild-
type and complemented strain when ROS-deficient C. elegans bli-3(e767) were challenged.  
As shown in Figure 3.5 B C. elegans responds to pathogen’s ingestion by producing 
extracellular ROS in the intestinal lumen via Ce-Duox1, an NADPH oxidase coded by the 
gene bli-3. During ROS production, the intestinal cells also produce intracellular antioxidants 
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via DAF-16 to protect its own tissues from the ROS damaging effects (Chavez et al., 2007; 
Hoeven et al., 2011). Ce-Duox1 is a protein with an N-terminal peroxidase domain, a C-
terminal superoxide-generating NADPH-oxidase domain and two central calmodulin-binding 
sites (Meitzler and Ortiz de Montellano, 2009). Upon microbial infection, this protein uses 
cytosolic NADPH to generate extracellular toxic ROS in the intestinal lumen to counteract 
the infection. Throughout a series of biochemical assays, Jain et al., 2009 showed that ROS 
are abundantly produced upon yeast infections and that bli-3 loss of function via bli-3(e767) 
dramatically reduces the nematode ability to produce ROS. 
As shown in Figure 3.5C, worms challenged with zcf15/zcf15 survived significantly longer 
than wild-type or complemented strains (p < 0.01 by the log-rank test) indicating that ZCF15 
is required for wildtype virulence. However, when we challenged ROS-deficient C. elegans 
bli-3(e767), we obtained kinetics of killings that were comparable between zcf15/zcf15, wild-
type and complemented strain (Figure 3.5D). This evidence indicates that zcf15/zcf15 fail to 
kill nematodes unless the host ability to produce ROS is compromised. Taken together, these 
results suggest that ZCF15 is required for full virulence and that this gene is likely involved 
in the pathogen’s ability to resist host generated ROS. To the best of our knowledge, this is 
the first time that ZCF15 has been shown to be involved in pathogenicity and ROS resistance.  
 
3.3.5 ZCF15 is required for resistance to murine macrophage killing  
 
After having shown that ZCF15 is required for virulence in nematodes, we wanted to explore 
its role in a mammalian model of infection. Macrophages, together with other phagocytic 
cells like neutrophils, monocytes and dendritic cells, play a fundamental role in protecting 
mammals against C. albicans (Ashman et al., 2004; Newman and Holly, 2001). In particular, 
since there is no evidence that antibodies can mediate the lysis of C. albicans, macrophages 
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and other phagocytic cells are considered the prime effectors in fighting yeast infections 
(Vazquez-Torres and Balish, 1997). As shown in Figure 3.6 A, when C. albicans is 
coincubated with mouse macrophage cell line RAW264.7 ex vivo, C. albicans is quickly 
phagocytized, compartmentalized in the phagosome and killed by a combination of different 
mechanisms (Lorenz et al., 2004; Marcil et al., 2002). As shown in Figure 3.6 A, these 
mechanisms include reactive oxygen species (ROS), reactive nitrogen species (RNS), acidic 
pH and hydrolytic enzymes like lysozyme. We used mouse macrophage RAW264.7 because 
their ability to produce ROS can be pharmacologically modulated by adding NADPH 
inhibitor diphenyleneiodium chloride (DPI) (Lopes da Rosa et al., 2010).  
We exposed wildtype, zcf15/zcf15 knockout and the complemented strain to murine 
macrophages at 1:15 multiplicities of infections (15 macrophage cells per each C. albicans 
cell) and quantified yeast cell survival by end point dilution. As shown in Figure 3.6 B, the 
zcf15/zcf15 knockout is significantly more susceptible to macrophage killing compared to 
either wild-type or complemented strains (Figure 3.6 A). Survival percentages were 
respectively 25.6 ± 4.0 for ZCF15/ZCF15, 10.8 ± 2.6 for zcf15/zcf15 and 23.7 ± 7.0 for 
zcf15/ZCF15
c
 (p < 0.01 for ZCF15/ZCF15 vs zcf15/zcf15). We hypothesized that the 
zcf15/zcf15 increased susceptibility to macrophage killing was due to its inability to withstand 
macrophage generated ROS. To test this hypothesis we repeated the experiments in the 
presence of NADPH inhibitor diphenyleneiodium chloride (DPI), which it has been 
previously shown to inhibit macrophage ROS production in the phagosome (Donini et al., 
2007). Remarkably, pharmacological inhibition of NADPH oxidase rescued zcf15/zcf15 
hyper susceptibility to macrophage killing suggesting that ZCF15 is required to neutralize the 
oxidative environment within the phagosome. 
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Figure 3.6 ZCF15 is required to withstand mouse macrophage generated ROS 
A) Electron micrograph of a macrophage 2 hours post C. albicans phagocytosis (top). 
Upon phagocytosis C. albicans is compartmentalized in the phagosome (bottom) where 
a combination of acidic pH, reactive oxygen species (ROS), reactive nitrogen species 
(RNS) and hydrolytic enzymes (lysozyme) contribute to C. albicans killing. The 
macrophage ability to ROS can be pharmacologically modulated by adding 
diphenyleneiodium chloride (DPI). Figures adapted from (Haas, 2007; Heinsbroek et 
al., 2005). 
B) C. albicans growing to early-exponential phase were coincubated with mouse 
macrophage RAW264.7 at 1:15 multiplicities of infections (1 yeast cell per 15 
RAW264.7 cells) and survival percentage determined as the ratio between the number 
of colonies recovered from wells containing only yeast cells over the number of 
colonies recovered from wells containing both yeast and macrophage cells. zcf15/zcf15 
was statistically significanlty more suseptible to macrophage killing compared to either 
wild-type or complemented strains unless the macrophage ability to produce ROS was 
pharmacologically inhibted by adding 0.05M of DPI. 
 
 
Taken together, these results suggest that ZCF15 is required not only for virulence in 
nematodes but also for virulence in a more relevant mammalian model of infection. In 
addition, our data suggests that ZCF15 plays a vital role in the pathogen’s ability to withstand 
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host generated ROS, an evidence that was mirrored in both nematodes and murine 
macrophages. 
 
3.3.6 ZCF15 deletion has a limited effect in disseminated Candidiasis 
Note: This experiment was performed by Alex Hopke under the supervision of Dr. Robert 
Wheeler at the University of Maine  
 
As described in chapter 1.3 C. albicans can infect the human gastrointestinal tract, causing 
epithelial infections but, under certain conditions it can reach the blood stream and cause life 
threatening systemic infections. In the blood stream a combination of innate and adaptive 
immune mechanisms are responsible for fighting the infection, including CD4
+
 T cells, 
phagocytic cells, IL-12 and TNF- (Ashman et al., 2004; Romani, 2000). Both C. elegans 
and murine macrophage systems represent great models to study innate immunity and 
showed that ZCF15 plays a critical role in C. albicans virulence. Here, we wanted to explore 
its role in the context of a blood stream infection, where both innate and adaptive immunity 
contribute to fungal resistance. 1x10
5
 cells of wild-type, zcf15/zcf15 or complemented strain 
were injected into the blood stream of BALB/c mice by tail vein injection and morbidity and 
mortality were monitored daily. As shown in Figure 3.7, ZCF15 deletion has only a mild and 
non-statistically significant impact in  virulence.  
Mice injected with zcf15/zcf15 knockout survived longer than those injected with wild-type  
(mean time to death for zcf15/zcf15 23.2 ± 1.7 days versus 19.1 ± 2.1 days for 
ZCF15/ZCF15) however, this difference was not statistically significant (Log Rank p values 
= 0.193).  On the other hand, mice injected with the complemented strain survived 
statistically significantly longer than those injected with zcf15/zcf15 knockouts (mean time to 
death for mice injected with zcf15/ZCF15c = 16.6 ± 1.7, Log Rank p values = 0.030).  This 
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data suggest that ZCF15 deletion has a modest effect in virulence in a murine model of 
hematogenously disseminated candidiasis an evidence corroborated by the fact that 
reintegrating a wild type copy of ZCF15 slightly increased knockout virulence.  
 
Figure 3.7: ZCF15 loss of function has a limited impact in survival of mice 
intravenously challenged. 
A) Kaplan-Meier survival curves of mice injected with 1x105 cells of C. albicans wild type 
(ZCF15/ZCF15), zcf15/zcf15 or zcf15/ZCF15
c
.  
B) Pairwise statistical comparison between survival curves using the Log Rank test. While 
the difference between the knockout and the complemented strain was statistical 
significant (p = 0.030), the difference between wildtype and the knockout was not (p = 
0.193).   
 
Taken together, our data suggests that ZCF15 plays an important role in models of infections 
like C. elegans or mouse macrophages that heavily rely on the oxidative burst and innate 
immunity as their main mechanisms of host response to infections. However, in a much more 
complex environment like the mouse bloodstream where a wide variety of innate and 
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adaptive immunity contribute to fight the infection ZCF15 loss of function has a limited 
impact on virulence. 
 
3.4 Discussion  
 
As discussed in previous chapters, C. albicans infections have alarming incidence, morbidity 
and mortality rates. C. albicans infections are common comorbidities in patients affected by 
various immunodeficiency disorders. Unfortunately, the pharmacological options available to 
these patients are limited, especially considering that C. albicans have found various clever 
ways to develop drug resistance. In addition, the antimycotics available are all targeting a 
very limited number of cellular processes and have less than ideal toxicological profiles. For 
all of these reasons, there is a pressing need for more research in order to identify new targets 
that can be used for better drugs and diagnostics.  
Here we leveraged our nematode in vivo model system and the availability of a large 
collection of C. albicans mutants to identify ZCF15, a fungal specific transcription factor 
involved in virulence. Our reverse genetic approach allowed us to screen a total of 724 C. 
albicans mutants (~12% of the genome) and lead to the identification of four novel putative 
virulence factors: DOT4, ORF19.1219, ORF19.6713 and ZCF15. Between these four genes 
we focused on ZCF15 because, in contrast to the other three genes, it doesn’t have a human 
homolog and can potentially be used for drug targeting. We showed here that ZCF15 is 
required for virulence in our nematode model and that it it plays a critical role in the 
pathogen’s ability to withstand host generated ROS.   
To the best of our knowledge, this is the first time that this gene has been associated with 
virulence in C. albicans. In addition, although its role in a disseminated model of infection 
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has been shown to be limited, this gene is required for wild type resistance to mammalian 
macrophage. Macrophages together with dendritic cells and natural killers are a fundamental 
component of the human innate immunity and are considered the first line of defense against 
C. albicans infections. In particular we have shown here that ZCF15 is required to withstand 
macrophage generated reactive oxygen species.  
In addition, although the possibility of targeting ZCF15 for therapeutic purposes goes well 
beyond the scope of this dissertation, it is worth mentioning that there is growing evidence 
that transcription factor based therapeutics holds great potential. Transcription factors have 
been historically considered difficult targets however, significant progress has been made in 
the last two decades and targeting them is becoming a realistic option (Flood et al., 2011; Yeh 
et al., 2013). Transcription factor targeting is complicated by the fact that transcription is a 
nuclear event and many essential components involved in transcription lack enzymatic 
activity suitable, for chemical intervention (Yan and Higgins, 2013). However in recent years 
many different strategies that directly inhibit transcription factor expression (RNAi, 
microRNAs), transcription factor DNA binding (with small molecules competing for binding 
partners or peptide mimetic that disrupt transcription post translational modifications) have 
been developed and have recently entered clinical trials (Flood et al., 2011; Ghosh and 
Papavassiliou, 2005; Kletsas and Papavassiliou, 1999). Transcription factors are the focal 
points that drive cell signaling and the pathogen’s ability to cause disease. Because ZCF15 is 
not conserved in humans, it represents a potentially suitable target for therapeutic 
intervention. As described in the next chapter, we further elucidated ZCF15 mechanisms of 
action by identifying its transcriptional targets by RNASeq and its DNA binding partners by 
ChIP-Seq.    
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4 ZCF15 and ZCF29 mechanisms of action, some insights from 
RNASeq and ChIP-Seq  
 
4.1 Introduction 
 
In the previous chapter we described ZCF15, a C. albicans transcription factor with a clear 
role in resistance to host generated reactive oxygen species (ROS). This transcription factor 
belongs to a family of 77 C. albicans Zn(II)2Cys6 transcription factors. These proteins contain 
the well-conserved CysX2CysX6CysX5-16CysX2CysX6-8Cys domain (Maicas et al., 2005) in 
which six cysteins (Cys) bind two zinc atoms and coordinate both the proper folding of the 
protein and its ability to bind DNA (Campbell et al., 2008; Vallee et al., 1991). Figure 4.1 
depict the location of the Zn(II)2Cys6 DNA binding domain in the Zcf15 sequence. The 
domain is located at the C-terminus and it contains a highly conserved lysine (Figure 4.1, red 
box), which is believed to be a key player in coordinating DNA binding. Indeed, that lysine is 
conserved in 57 of the 77 C. albicans Zn(II)2Cys6 transcription factors, and in 13 of the 
remaining 20, lysine is replaced by another basic amino acid like histidine or arginine.  
C. albicans Zn(II)2Cys6 transcription factors regulate a large variety of biological processes 
ranging from control of meiosis, cell wall architecture, amino acid utilization and multi-drug 
resistance (Maicas et al., 2005). This family of transcription factors is found in various fungi 
like Saccharomyces cerevisiae, Aspergillus flavus, Fusarium solani, Aspergillus niger, 
Kluyveromyces lactis and Neurospora crassa but not in humans, other eukaryotes or 
prokaryotes. Since they are unique to the fungal kingdom and fundamental to C. albicans 
biology, these transcription factors have the potential to be used for either drug targeting or as 
epitopes for vaccine design (Vandeputte et al., 2011).  
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Figure 4.1: canonical structure of Zn(II)2Cys6 DNA binding domain and relative 
location in Zcf15 
Zcf15 has the Zn(II)2Cys6 located near its C-terminus end. This domain is made of 35 amino 
acids in which six cysteins bind to 2 zinc atoms (yellow circles) and drive proper protein 
folding and DNA binding.    
  
Here, we analyzed this family of transcription factors and looked for genes that (a) have a 
role in resistance to reactive oxygen species (b) are conserved in pathogenic fungi but not in 
non-pathogenic ones. This dual approach allowed us to look for genes that, on one side are 
potentially conferring resistance to host effectors and, on the other, are evolutionarily 
conserved in fungal pathogenesis. We identified ZCF29, a transcription factor that has been 
previously shown to be upregulated in the presence of H2O2 (Enjalbert et al., 2006), required 
for resistance to ROS generator menadione (Homann et al., 2009) and that is present only in 
pathogenic fungi.   
In order to gain some insights into ZCF29 and ZCF15 biological roles, we leveraged here the 
power of RNASeq to discovered genes controlled by these two transcription factors.  
Remarkably, ZCF29 deletion leads to the misregulation of a staggering number of genes 
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(1440 genes, ~25% of the genome), indicating that this transcription factor is a master 
regulator of C. albicans metabolism. These genes are mainly involved in amino acid 
biosynthetic processes and proteolysis, two biological processes highly interconnected with 
each other. In particular, ZCF29 deletion leads to downregulation of genes involved in the 
synthesis of important amino acids like threonine, methionine, tryptophan, tyrosine, lysine 
and histidine and concomitant upregulation of genes involved in proteolysis. This evidence 
suggests that upon ZCF29 deletion C. albicans favors amino acids recycling through 
proteolysis over de novo biosynthesis. While both pathways can produce free amino acids as 
a final product, amino acid biosynthesis is more energy demanding than proteolysis and C. 
albicans wild type favors proteolysis over de novo synthesis under N-starving condition 
(Ramachandra et al., 2014). We believe that ZCF29 plays a critical role in the C. albicans 
ability to regulate nitrogen metabolism an evidence corroborated by the hyper susceptibility 
of zcf29/zcf29 to nitrogen-starvation mimicking caffeine (Homann et al., 2009; Rallis et al., 
2013).    
On the other hand, ZCF15 loss of function leads to a more modest transcriptional rewiring 
with a total of 168 genes differentially expressed compared to wild-type. Many of these genes 
are involved in carbon metabolism and energy production with genes like HGT7, SHA3, 
TYE7, PCK1 and EHT1 directly involved in glucose transport, acetyl-CoA production or 
TCA cycle. Many of these genes have been shown to be downregulated in the presence of 
ROS (Lorenz et al., 2004) and this down regulation is believed to liberate significant energy 
resources for other cellular processes like DNA repair or cellular detoxification processes. 
Here, we showed that the C. albicans ability to downregulate these genes in the presence of 
ROS and contemporarily upregulate key enzymes for cellular detoxification processes is 
compromised in zcf15/zcf15. Our working hypothesis is that, in the presence of ROS, ZCF15 
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plays a critical role in rechanneling energy resources from carbon metabolism/energy 
production to cellular detoxification processes. This hypothesis fits well with the in vivo, in 
vitro and ex vivo phenotypes observed so far for zcf15/zcf15 and may be the reason for its 
hyper susceptibility to ROS.  
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4.2 Materials and methods 
 
4.2.1 Media and growth conditions 
 
Starting from single colonies, 5 mL cultures were grown overnight in YPD at 30 
○
C. Cells 
were collected by centrifugation (2000 g for 5 min), and resuspended to a final OD=0.1 in 
fresh YPD media. Cultures were allowed to grow for 4-6h to reach mid-exponential phase 
(OD=0.6-0.8) and then 5mM H2O2 was added to the samples. Cells were cold methanol 
quenched before and 5 and 15 minutes after the addition of H2O2. To methanol quench cells 
conical tubes containing 30 mL 100% methanol were stored at -80 
○
C overnight. Conical 
tubes were taken out of the -80 
○
C and placed in a dry-ice ethanol bath to keep the methanol 
at around -40 
○
C. Once the sample (20 mL) was added to the methanol, the conical tubes 
were centrifuged at 2000 g for 5 minutes and the methanol and media removed.  The pellets 
containing the cells were flash frozen in liquid nitrogen and the tubes stored at -80 
○
C 
overnight. The cell pellets were thawed, washed in 5 mL nuclease free water and centrifuged 
for 5 min at 2000 g at 4 
○
C. The supernatant was discarded and the pellets re-suspend in 1.5 
mL of RNAlater (Ambion) and transferred to smaller tubes for storage. Samples were left at 4 
C for 24 hours before being moved to the -80 
○
C freezer.  
 
4.2.2 RNA-Seq: RNA extraction and library preparation  
 
RNA was extracted using the Qiagen RNeasy Plus Mini Kit. Briefly, 5x10
8
 total cells were 
re-suspended in 600 l RLT+2-mercaptoethanol (10 l of 2-mercaptoethanol for 1 mL RLT) 
in 2 mL bead beating tubes. 500 l RNAse free Zirconia beads were added and cells lysed in 
a bead beater at max speed for 3 minutes. The tubes were centrifuged at 1000g for 5 minutes 
at 4 °C, the supernatant transferred to a gDNA eliminator column, and RNA isolated 
  
88 
 
 
following the manufacturer instructions. RNA concentration was determined using a 
NanoDrop ND-1000 UV-Vis Spectrophotometer (Thermo Scientific) while RNA integrity 
was determined using an Agilent 2200 Tape Station (RIN score). From total RNA, mRNA 
was purified using Dynabeads mRNA DIRECT and 300-600 bp fragments obtained by 
incubating the sample in RNA Storage Solution (Ambion) for 30 min at 98 °C. The 
fragmented mRNA was reverse transcribed to cDNA using AffinityScript Multiple 
Temperature Reverse Transcriptase (Agilent) by priming with Oligodt (12,13,14,15,16,17,18) 
primers. Single stranded cDNA was converted into double stranded cDNA by using 
NEBNext Second Strand Synthesis Module (New England Biolabs). Double stranded cDNA 
was purified using Agencourt AMPure XP beads (Beckman Coulter) and strand nonspecific 
cDNA libraries were prepared for Illumina sequencing (MiSeq) according to the method 
previously described here (Mardis, 2008a). Once the library was prepared, a size distribution 
around 300 bp was confirmed by using the Agilent 2200 Tape station and the total DNA 
concentration (expressed in ng/l) was measured using a Qubit Fluorometer. DNA 
concentration in ng/l was converted in nM using the equation reported below. The equation 
assumes that the MW of each nucleotide is 650 D and the average length of library is 300bp.   
              (  )  
              (
  
  )    
 
           
 
As an alternative to the Qubit, we used a Kapa library Quant kit that uses a qPCR approach to 
specifically quantify only PCR-competent DNA molecules (properly ligated to the adaptors).  
 
4.2.3 RNA-Seq: sample preparation and sequencing   
 
Each of the samples were resusped in water to a final concentration of 4 nM and pooled 
together by adding 5 l of each sample to a 1.5 mL microcentrifuge. 5 l of the pooled 
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sample were denatured by adding 5l of NaOH 0.2 N and incubated for 5 minutes at room 
temperature. 990 l of HT1 (hybridization buffer) were added to the 10 l of the denatured 
libraries to obtain 20 pM denatured library in 1 mM NaOH.  
2 l of 10 nM PhiX library were added to 8 l 10 mM Tris-Cl (pH 8.5) with 0.1% Tween 20 
to obtain a final concentration of 2 nM. 10l of this solution was added to 10 l of 0.2N 
NaOH, vortexed and incubated at room temperature for 5 minutes to denature the PhiX into 
single strands and obtain a final PhiX concentration of 1 nM. 8 l of denatured PhiX is added 
to 992 l of HT1 (hybridization buffer) to obtain a final concentration of 8 pM.  
300 l of the 20 pM denatured library was added to 300 l of 8 pM denatured PhiX library 
and loaded into the Illumina cartridge for a HiSeq run.  
 
4.2.4 ChIP-Seq: Zcf15 and Zcf29 HA tagging 
 
Zcf15 and Zcf29 were C-terminus HA tagged using a PCR-mediated homologous 
recombination strategy described here (Lavoie H, 2008). Figure 4.25 depicts a schematic of 
the approach used. Briefly, primers pair including ∼70 bp of homology flanking ZCF15 and 
ZCF29 stop codon were used to amplify the HA-ARG4 cassettes from pFA-HA-ARG4 
plasmid. The plasmid was a generous donation of Dr. Malcom Whiteway (McGill University, 
Montreal, Canada) and its complete sequence can be found in GenBank, accession number 
FJ160463.1. Primers pair 551-552 and 561-562 were used to target ZCF15 and ZCF29 
respectively. The 2.4 Kb PCR products obtained were transformed in C. albicans strains 
SN250 (Noble and Johnson, 2005) using standard LiAc protocol (Hernday et al., 2010). Arg
+
 
colonies were streaked in media lacking arginine and genomic DNA prepared using standard 
chlorophorm:phenol protocols. In order to verify the correct insertion of the HA-ARG4 
  
90 
 
 
cassettes we verify the presence of the new 5’ and 3’ junctions using primers 546-553 and 
559-560 for Zcf15-HA tagged strain and 617-553 and 559-616 for Zcf29-HA tagged strain.   
Primer 
number 
Primer sequence 
551 
GACAGATTCATTAGATGTATTTATGTATAATGTTGAATTGAGTGATATTTTA
TATGATGTGAAACCCAATGGTCGACGGATCCCCGGGT 
552 
TTGTTAGTAGTTAATTGATTAGTTTATTTATTTTATAAAGTTATTTATTTAAT
CAATATATGTAAAAAAACGATGAATTCGAGCTCGTT 
546 ACGAACCATCTGCCAGAATCCGTA 
553 TCATAGGGATAGCCCGCATAGTCA 
559 AGAGATGCTCTTGGTGGTACTGCT 
560 AGAATGGAGTACTTTACTATGTTGACGA 
561 
AAATACATTGATTGATATGAATAATTTATTTGAGAATGTTCCGTTCGATGAG
TTGTTCAAAGATTTTTCCGGTCGACGGATCCCCGGGT 
562 
ATATATAAAAAAAAGGGACAGGGGAATAAAAATGAGCACAGCACATTCAA
GACCTCCTCCCAAACAGAATCGATGAATTCGAGCTCGTT 
617 AGCACTGGTGTCAGCATAAA 
553 TCATAGGGATAGCCCGCATAGTCA 
559 AGAGATGCTCTTGGTGGTACTGCT 
616 
CTATCTCTCTTTTTTTTGCCCATTTGAGTTAGTGCATGACCACCACCAACAAA
CAGAACA 
Table 4.1: Primers used in this study 
 
We confirmed the expression of the HA tagged proteins by Western Blot using monoclonal 
anti HA antibody (Thermo Scientific 2-2.2.14) and a Western Blot protocol optimized for C. 
albicans described here (Gerami-Nejad et al., 2009). 
 
4.2.5 ChIP-Seq: Immunoprecipitation, library preparation, sequencing and peak calling   
 
In order to compare our ChIP-Seq results with the RNA-Seq one we run our experiment in 
analogous conditions. Zcf15-HA and Zcf29-HA tagged strains were grown to mid-
exponential phase in YPD and samples were crosslinked with formaldehyde either before or 
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5 and 15 minutes after the addition of 5mM H2O2. Once crosslinked, cells were lysed and 
chromatin immunoprecipitated as described here (Hernday et al., 2010). Briefly, 37% 
formaldehyde was added to a final concentration of 1%, and crosslinked for 15 min at room 
temperature. The crosslink was quenched by adding glycine to a final concentration of 125 
mM, cells were washed twice in TBS and pellets frozen in liquid nitrogen and archived at -
80C. Pellets were thawed in ice-cold lysis buffer with fresh protease inhibitor and cells lysed 
by adding 500m zirconia beads and using 10 one minutes strokes (6m/s) with a FastPrep 
Instrument (MP Biomedicals). Lysate was subsequently recovered by piercing the bottom of 
the tube with 26-gauge needle and chromatin sheered by sonication in a Diagenode Bioruptor 
(15 min, high settings, 30s on 30 s off). Samples were split between “pulldowns” and 
“inputs” and while “pulldowns” samples were immunoprecipitated using monoclonal anti-
HA antibody (Thermo Scientific 2-2.2.14), “inputs” were not and they were used as controls 
samples. After immunoprecipitation, crosslinking was reversed by incubating samples at 65C 
for 16 hours and residual proteins hydrolyzed by adding proteinase K. DNA was finally 
purified using standard phenol:chloroform protocol. DNA libraries were multiplex using 
standard Illumina protocols, size selected using SPRIselect reagents (Beckman Coulter 
#B23317) and the presence of a sharp peak at 300 bp confirmed using Agilent 2100 
Bioanalyzer. Samples were finally pooled together and sequenced using Illumina HiSeq 
2500. Un-demultiplexed FASTQ files were aligned to the C. albicans genome to obtained 
sequence alignment data (BAM files) that were visualized in IGV (Robinson et al., 2011b). 
BAM files from immunoprecipitated and input controls libraries were used by MACS peak 
caller (Zhang et al., 2008) in the web-based genomic platform Galaxy (Goecks et al., 2010) to 
call Zcf15 and Zcf29 bound regions. Peaks were considered statistically significant only if p 
< 1e-3.   
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4.3 Results  
 
4.3.1 In silico analysis of C. albicans (Zn(II)2Cys6) transcription factors 
 
ZCF15 belongs to a family of 77 Zn(II)2Cys6 transcription factors that are fungal specific and 
absent in humans. This unique feature makes them attractive targets for potential drug design 
(Vandeputte et al., 2011). Here, we run an in silico analysis to identify other transcription 
factors in the same family that (a) are conserved in pathogenic fungi (b) have a role in 
resistance to ROS (c) have been shown to be required for virulence in mammals. This 
approach allowed us to identify genes that are evolutionarily conserved in virulence and may 
modulate virulence by conferring resistance to host effectors.  
A previous screen (Maicas et al., 2005) identified a total of 77 C. albicans Zn(II)2Cys6 
transcription factors in the C. albicans genome. Forty-two of these transcription factors have 
clear S. cerevisiae homologs and their functions are conserved between C. albicans and 
baker’s yeast. As shown in Table 4.2 (highlighted in grey), these transcription factors retain 
the names of their S. cerevisiae homologs. For example, C. albicans orf19.3012 is called 
ARO80 because in both organisms it has a key role in regulating aromatic amino acid 
catabolism (Ghosh et al., 2008; Nobile et al., 2003). We therefore focused on the remaining 
35 “orphan” transcription factors (highlighted in yellow in Table 4.2) because their biological 
functions is yet to be fully determined. These 35 genes have been assigned the generic name 
ZCFs (Zinc Cluster transcription Factors) and progressively numbered from 1 to 35. Of these 
35 ZCFs we wanted to identify genes that are conserved in pathogenic fungi but absent in 
non-pathogenic one. 
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Allele name 
Standard 
name 
Allele name 
Standard 
name 
Allele name 
Standard 
name 
Allele name 
Standard 
name 
orf19.7381 AHR1 orf19.4776 LYS143 orf19.6888 ZFU3 orf19.3876 ZCF19 
orf19.4766 ARG81 orf19.5380 LYS144 orf19.3187 ZNC1 orf19.4145 ZCF20 
orf19.2748 ARG83 orf19.7372 MRR1 orf19.255 ZCF1 orf19.4166 ZCF21 
orf19.3012 ARO80 orf19.3986 PPR1 orf19.431 ZCF2 orf19.4251 ZCF22 
orf19.166 ASG1 orf19.6203 PUT3 orf19.1168 ZCF3 orf19.4450 ZCF23 
orf19.5097 CAT8 orf19.2747 RGT1 orf19.1227 ZCF4 orf19.4524 ZCF24 
orf19.7374 CTA4 orf19.4998 ROB1 orf19.1255 ZCF5 orf19.4568 ZCF25 
orf19.4288 CTA7 orf19.3753 SEF1 orf19.1497 ZCF6 orf19.4573 ZCF26 
orf19.1499 CTF1 orf19.3308 STB5 orf19.1685 ZCF7 orf19.4649 ZCF27 
orf19.5849 CWT1 orf19.7319 SUC1 orf19.1718 ZCF8 orf19.4767 ZCF28 
orf19.3127 CZF1 orf19.3188 TAC1 orf19.2077 ZCF9 orf19.5133 ZCF29 
orf19.3252 DAL81 orf19.6985 TEA1 orf19.2280 ZCF10 orf19.5251 ZCF30 
orf19.6817 FCR1 orf19.7570 UGA3 orf19.2423 ZCF11 orf19.5924 ZCF31 
orf19.5729 FGR17 orf19.6038 UGA32 orf19.2623 ZCF12 orf19.5940 ZCF32 
orf19.6680 FGR27 orf19.7317 UGA33 orf19.2646 ZCF13 orf19.6182 ZCF34 
orf19.5338 GAL4 orf19.2745 UME7 orf19.2647 ZCF14 orf19.5992 ZCF33 
orf19.3190 HAL9 orf19.391 UPC2 orf19.2753 ZCF15 orf19.7371 ZCF35 
orf19.4225 LEU3 orf19.1035 WAR1 orf19.2808 ZCF16 
  
orf19.5548 LYS14 orf19.5992 WOR2 orf19.3305 ZCF17 
  
orf19.4778 LYS142 orf19.6781 ZFU2 orf19.3405 ZCF18 
  
Table 4.2: list of all 77 Zn(II)2Cys6 transcription factors present in C. albicans. 
42 of these genes have been named after their S. cerevisiae orthologs because their functions 
are conserved between the two organisms. 35 of them (yellow) have been called with the 
generic name ZCF (Zinc Cluster transcription Factors ) because they either don’t have a S. 
cerevisiae orthologs or, if they do, their functions don’t seem to be conserved between the 
two organisms.    
  
We performed a comparative genomic study using a previously developed algorithm 
(Wapinski et al., 2007) that allowed us to search for C. albicans ZCFs homologs in 23 other 
sequenced ascomycetes. These 23 ascomycetes included 7 species (Candida tropicalis, 
Candida parapsilosis, Candida guilliermondii, Candida lusitaniae, Lodderomyces 
elongisporus, Candida albicans and Debaryomyces hansenii) that are considered pathogenic 
to humans (Chai et al., 2010; Hawkins and Baddour, 2003; Lockhart et al., 2008; Pfaller et 
al., 2006; Singh and Parija, 2012) and 16 species that are non-pathogenic. These species 
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include baker’s yeast Saccharomyces cerevisiae, Saccharomyces bayanus (commonly used 
by the wine making industry), Saccharomyces kluyveri (a strict plant pathogen) and Ashbya 
gossypii (commonly found in cotton plants).  
For each ZCF we determine the number of homologs present in the 23 other ascomycetes and 
summarized the result in the heat map depicted in Figure 4.2. Overall this study highlights 
that ZCFs are overrepresented in pathogenic fungi compared to non-pathogenic ones as each 
ZCF has an average 1.58 homologs in pathogenic fungi and only 0.55 homologs in non-
pathogenic ones. This evidence suggests that this family of transcription factors might have 
important roles in virulence that are evolutionary conserved.   
 
Figure 4.2: C. albicans ZCFs conservation across ascomycetes.  
For each of the 35 C. albicans ZCFs we determined the number of homologs present in 7 
other pathogenic ascomycetes and 16 nonpathogenic one. Number of homologs is represented 
on a grey scale ranging from 0 to 5. The number of homologs was calculated using 
SYNERGY as detailed here (Wapinski et al., 2007) and with the help of George Bell, senior 
Bioinformatic Scientist at the Whitehead Institute.   
The fact that ZCFs are expanded in pathogenic fungi was encouraging, so we wanted to see if 
any of them had a role in ROS resistance. ROS plays a fundamental role in the host ability to 
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counteract infection so a defect in the pathogen’s ability to resist ROS may suggest a 
virulence deficiency. Enjalbert et al., 2006 reported a C. albicans gene expression profiling 
study under oxidative, osmotic and heavy metal stresses. Global transcriptional responses 
were recorded using microarrays containing ~6000 C. albicans probes (~97% of the C. 
albicans genome). When we looked at the ZCFs transcriptional changes upon ROS challenge 
(5 mM H2O2) we noticed that ZCF2, ZCF5 and ZCF17 were mildly downregulated 
(expression ratio w/o H2O2 = 0.81, 0.79 and 0.58 respectively), ZCF20 mildly upregulated 
(expression ratio w/o H2O2 = 1.48) and ZCF29 strongly upregulated (expression ratio w/o 
H2O2 = 2.6).  
 
Figure 4.3: ZCFs gene expression in the presence of oxidative stress (Ox), osmotic stress 
(Os) and heavy metal stress (Hm) 
5mM H2O2, 0.3M NaCl and 0.5 mM CdSO4 were added to cells growing in mid-exponenetial 
phase to trigger Ox, Os and Hm stress respectively. Expression ratios were calculated by 
comparing stressed cells with their unstressed controls. Data was extracted from (Enjalbert et 
al., 2006).   
Interestingly, ZCF15 was found not to be upregulated in the presence of H2O2, suggesting 
that its role in ROS resistance might take place post transcriptionally or post translationally.  
The strong ZCF29 upregulation was observed only in the presence of H2O2 and not in the 
presence of 0.3M NaCl or 0.5M CdSO4, suggesting a specific role of this gene in ROS 
resistance but not in osmotic or heavy metal stresses.  In addition, ZCF29 has six homologs in 
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pathogenic fungi and no homologs in non-pathogenic ones (Figure 4.2), potentially indicating 
a conserved role in virulence. Indeed, Vandeputte et al., 2011 recently demonstrated that 
zcf29/zcf29 has a reduced ability to colonize mice kidney when mice were infected by 
intravenous injection.   
In order to gain some insights into ZCF29 mechanism of action, we obtained the zcf29/zcf29 
knockout from the Fungal Genetic Stock Center and extensively characterized various 
phenotypes. zcf29/zcf29 knockout is dramatically susceptible to ROS generator menadione at 
both 80 M and 90 M (Figure 4.4 A).  
 
Figure 4.4: ZCF29 is required for wildtype ability to resist reactive oxygen species 
A) zcf29/zcf29 and wild-type C. albicans were serially diluted and spotted in SC media 
containing 80 and 90 M of menadione and photographed 3 days post spotting. 
B) Menadione mechanism of action: menadione is reduced in the mitochondria to its free 
radical form which is subsequently oxidized back to menadione with concomitant production 
of highly toxic superoxide radicals (O2
-.
). Figure adapted from Loor et al., 2010. 
In the mitochondria, menadione is reduced to its free radical with concomitant oxidation of 
NADPH to NADP
+ 
(Loor et al., 2010). In aerobic condition, menadione radicals are oxidized 
back to menadione with simultaneous reduction of O2 to superoxide anion radicals O2
-●
 
(Figure 4.4 B). Superoxide anion radicals are an extremely toxic form of reduced oxygen that 
can lead to protein denaturation, DNA damage and lipid peroxidation (Cooke et al., 2003).  
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The fact that ZCF29 is upregulated in the presence of H2O2 and that its loss of function leads 
to increased sensitivity to menadione suggests that it plays an important role in ROS 
resistance.  
In addition, as shown in Figure 4.5, ZCF29 deletion caused an increased sensitivity to both 
caffeine and Sodium Dodecyl Sulfate (SDS).  
 
Figure 4.5: ZCF29 is required for wildtype resistance to purine analogue caffeine and 
cell wall stressor SDS.  
A) zcf29/zcf29 and wild-type C. albicans were serially diluted and spotted in SC media 
containing 15mM caffeine and photographed 3 days post spotting. B) zcf29/zcf29 and wild-
type C. albicans were serially diluted and spotted in 0.04% SDS and photographed 7 days 
post spotting.  
Caffeine is a purine analogue and it interferes with the TOR pathway by directly inhibiting 
the TOR-1 complex (Kuranda et al., 2006). The TOR pathway is a highly conserved protein 
kinase cascade that, in the presence of abundant nutrients, promotes cell growth and represses 
genes involved in alternative nutrients utilization. Conversely, when nutrients are limiting, 
the TOR pathway slows cell growth and redirects cellular resources to scavenge for nutrients 
(Loewith and Hall, 2011). Caffeine mimics nitrogen starvation conditions and represses the 
TOR pathway.  
SDS is a detergent that interferes with the cell wall polarity and is commonly used to 
determine cell wall integrity (Delley and Hall, 1999). These two experiments combined 
suggest that ZCF29 is required not only for ROS resistance and virulence but also for nutrient 
regulation and cell wall integrity. 
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Taken together, our data described in chapter 3 together with data shown here by us and 
others (Enjalbert et al., 2006; Homann et al., 2009; Vandeputte et al., 2011) indicate that 
ZCF15 and ZCF29 are fungal specific transcription factors important for virulence and ROS 
resistance. In order to gain some insights into ZCF15 and ZCF29 mechanisms of action we 
leveraged the power of RNASeq to find out which genes and biological pathways are 
controlled by these two transcription factors.   
 
4.3.2 ZCF15 and ZCF29 RNA-Seq QC  
 
The goal the RNASeq experiment was to compare gene expressions of wild type C. albicans 
with zcf15/zcf15 and zcf29/zcf29 deletion both in the presence and absence of ROS. We 
determined expression profiles of C. albicans wildtype, zcf15/zcf15 and zcf29/zcf29 either 
before or 5 and 15 minutes after the addition of 5 mM H2O2. We chose these time points 
because the transcriptional response of C. albicans to H2O2 has been previously shown to 
peak around 10-15 minutes post H2O2 addition (Roy et al., 2013) and named these three data 
points T0, T5 and T15 respectively. 
We decided to use H2O2 to mimic ROS stress in vitro because (a) it is the most common ROS 
used by the immune system to induce respiratory burst (Iles and Forman, 2002) (b) in 
contrast with other charged ROS, it passes through the cell membrane easily reaching the 
cytoplasm quickly (Kohchi et al., 2009) (c) various gene expression profiling experiments in 
wildtype C. albicans have been reported and can be used for internal validation of our data 
(Bruno et al., 2010; Enjalbert et al., 2006).  
In order to compare the transcriptome of the different strains in the various condition tested, 
we performed high-throughput sequencing of cDNA made from poly(A) selected RNAs. The 
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sequencing libraries were prepared using a strand-specific approach that preserved gene 
transcription directionality. This approach allowed us to assign every read to a single gene, 
with no ambiguity. This aspect was especially critical considering that C. albicans has a very 
compact genome with many neighboring genes transcribed in opposite directions. For each 
strain, three biologically independent samples were analyzed and we estimated gene 
expression abundance using a pipeline developed at the Broad Institute. The pipeline 
essentially consisted in 5 steps:  
1. RNASeq reads were aligned to the C. albicans reference genome using Tophat 
(Trapnell et al., 2012). 
2. Libraries quality was determined using RNA-SeQC, a recently developed tool that 
provides key measurement of data quality (DeLuca et al., 2012) like number of reads 
aligned, sequencing depth, continuity of coverage etc.  
3. Gene expression for every gene was quantified using Cufflinks (Anders et al., 2012) 
4. Reads were normalized by gene length and sample size and expressed as reads per 
kilobases per million of reads (RPKM) as described here (Li and Dewey, 2011)  
5. Gene statistically significantly differentially expressed between conditions were 
identified using EdgeR (Robinson et al., 2010). 
We obtained a total of 153,693,150 reads of which 113,140,942 reads mapped uniquely to the 
genome. The mapped uniquely rate was therefore ~74%, in line with what seen by others 
(Tuch et al., 2010).  Reads were evenly distributed across strains and time points and a 
snapshot of their distribution is depicted in Figure 4.6.  
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Figure 4.6: RNASeq reads distribution across strains and time points 
Reads obtained from the RNASeq experiment were equally distributed across strains and 
time points as shown by the total number of reads per sample (○). We obtained an average of 
5.6 million of reads per sample and 70-80% of these reads were uniquely mapped to the 
genome (●).   
For wild-type, zcf15/zcf15 and zcf29/zcf29 we obtained 49,251,867, 50,665,642 and 
53,775,641 total reads respectively of which 34,408,368, 38,408,587 and 40,323,987 were 
uniquely aligned to the genome. Total number of reads was also evenly distributed across 
time points with 44,548,377, 66,575,585 and 42,569,188 for samples extracted at To (before 
the addition of H2O2), T5 (5 minutes post addition of H2O2) and T15 (15 minutes after the 
addition of H2O2) respectively. Overall we obtained between 2 and 10 million of reads per 
sample and 70-80% of these reads uniquely aligned to the genome. This number of reads is 
adequate to draw meaningful conclusions in C. albicans as it is estimated that high quality 
gene expression profiling can be with 20 million reads in humans, 4 million for worms and 
flies and above 2 million for yeast (Bailey et al., 2013).  
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Overall we detected expression of 6376 genes of the 6467 genes annotated in the C. albicans 
and the 91 genes for which we couldn’t detect expression (for example ORF19.7340 and 
ORF19.3186) are ORFs annotated as dubious and unlikely to encode for a protein (Inglis et 
al., 2012).   
Figure 4.7 shows read distribution between intronic, exonic and intergenic regions. Spurious 
reads that aligned to intergenic region of the genome (possibly due to unannotated genes or 
sequencing error) were minimal (~2-4%) in accordance with what shown by others 
(Dhamgaye et al., 2012). In addition, very few reads aligned to intronic regions (~3-4%), 
suggesting that our initial poly-A selection was effective in removing most of the genomic 
DNA and that only mature mRNAs were sequenced in our samples.  
 
Figure 4.7: RNA-Seq reads distribution between exons, introns and intergenic regions 
across samples.  
The large majority of the reads mapped to exonic region (~90-92%) with only few reads 
mapping to intronic regions (3-4%) and intergenic regions (2-3%). The low levels of intronic 
reads confirmed that our initial poly-A selection was effective in removing most of the 
genomic DNA.  
We also calculated sequencing depth by determining coverage for the top 1000 most 
expressed genes (highly expressed genes), middle 1000 expressed genes (medium expressed 
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genes) and bottom 1000 expressed genes (low expressed genes). Sequencing depth is used as 
a measure of the number of times a nucleotide is read during sequencing. Highly expressed 
genes were sequenced at a depth ranging from 354x to 69x, genes expressed at medium levels 
were sequenced at a depth ranging from 17x to 3x and those expressed at low levels at a 
depth between 3x and 2x. Figure 4.8 shows sequencing coverage across different samples and 
time points.  
 
Figure 4.8: RNA-Seq coverage distribution metrics across different strains and time 
points.  
Highly expressed genes were sequenced at a depth ranging from 69x to 354x, medium 
expressed genes at a depth ranging from 3x to 17x and low expressed gene at a depth ranging 
between 2x and 3x.   
Overall, our RNA-SeQC quality control confirmed that we sequenced our samples at very 
high depth of sequencing and obtained reads that are equally distributed across time points 
and samples. Assessing sequencing performance and library quality was critical before 
proceeding to further computational our analysis.  
In addition to the RNA-SeQC quality control, we manually confirmed that ZCF15 and 
ZCF29 were not expressed from the respective knockouts. We used Interactive Genomics 
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Viewer (IGV), an algorithm developed for large genomic dataset visualization (Robinson et 
al., 2011b) to visualize expression levels in the knockout loci. As shown in Figure 4.9 we 
couldn’t detect ZCF15 and ZCF29 expression from zcf15/zcf15 and zcf29/zcf29 strains 
suggesting that the genes were properly deleted. 
 
Figure 4.9: ZCF15 and ZCF29 expression was not detected in the respective knockout 
strains.  
The density of the reads piling up in the ZCF15 (chromosome IV) and ZCF29 (chromosome 
VII) locus were visualized using Integrative Genome Viewer (IGV). ZCF15 expression was 
not detected in any of the three zcf15/zcf15 biological replicates. ZCF29 expression was not 
detected in any of the three zcf29/zcf29- biological replicates.     
Once we confirmed that the libraries obtained in our experiment were high quality, we 
estimated gene expression abundance using the algorithm Cufflinks. Cufflinks determined the 
absolute number of reads coming from each gene. However, the absolute number is not 
informative because it is a function of sequencing depth and gene lengths. Longer transcripts 
are more likely to have sequences mapping to their regions. Concurrently, deeper sequencing 
results in higher absolute number of reads. In order to control for these biases, we determined 
gene expression levels using reads per kilobases per million of reads mapped (RPKM) as 
described here (Li and Dewey, 2011). RPKMs are standard measurements of gene expression 
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that can be used for comparative studies since their absolute values don’t depend on gene size 
or sequencing depth.   
We first used RPKM to evaluate gene expression reproducibility across biological replicates. 
We used the log2(RPKM) as our variable and made pairwise comparison across all 27 
samples. Sample correlation was measured using the Pearson Correlation Coefficient (PCC) 
which measures the strengths of a linear relationship between variables. We obtained a total 
of 729 (27 x 27) correlation coefficients and summarized them as a heat map in Figure 4.11.  
Biological replicates were highly correlated between each other (Figure 4.10, small black 
boxes for example) reassuring us on the reproducibility of our replicates. This high degree of 
transcriptional correlation between biological replicates was observed both before (Figure 
4.10, black box 1) and after the addition of H2O2 (Figure 4.10, black box 2 and 3). In contrast, 
transcriptional profiles obtained from the same strains before and after the addition of H2O2 
were dramatically different as suggested by their poor degree of correlation (Figure 4.10 
dashed blue rectangle). This evidence indicates clearly that H2O2 triggered a large 
transcriptional rewiring especially if we compared samples at T0 and T15. Interestingly, 
samples at T5 were highly correlated within each other but poorly correlated with samples at 
both T0 and T15 (Figure 4.10, yellow dashed rectangle), suggesting that the T5 samples 
effectively captured an intermediate step in the H2O2 driven transcriptional rewiring obtained 
between T0 and T15. 
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Figure 4.10: Pearson’s correlation coefficients heat map for each of the 27 gene 
expression profiles obtained in this study.   
Black boxes indicate high degree of correlation between biological replicates. Blue dashed 
rectangle indicates a progressively decreasing degree of correlation between samples at T0, T5 
and T15 suggesting that the addition of H2O2 triggered a large transcriptional change across all 
strains. Yellow dashed rectangle shows low degree of correlation between T5 samples and 
both T0 and T15 samples. This evidence highlights that T5 samples effectively captured an 
intermediate step in the H2O2 driven transcriptional change observed between T0 and T15.  As 
rule of thumb, PCC is typically from 0.3-0.4 for unrelated samples to > 0.9 for highly 
correlated replicate samples (Bailey et al., 2013).    
Biological replicates were highly correlated within each other but we wanted to check if this 
high degree of correlation was observed for both high and low expressed genes. We therefore 
plotted genes expressions levels of one replicate against another. As an example (Figure 4.11 
A) when we plotted gene expression of wild type (replicate A) at T0 against gene expression 
of wild type (replicate B) at T0 we observed a high degree of correlation (r
2
 = 0.948). The 
high degree of correlation was observed across genes expressed at both low levels (Figure 
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4.11 A green box) and high levels (Figure 4.11 A, yellow box), demonstrating the robustness 
of our RNA-Seq experiments and the absence of biases towards genes expressed at different 
levels. In contrast, when we compared expression profiles of the same replicate before and 
after the addition of H2O2, (Figure 4.11 B) we observed a poor degree of correlation (r
2
 = 
suggesting that H2O2 triggered a large transcriptional change).    
 
Figure 4.11: Transcriptional correlation between biological replicates and within the 
same replicate before and after the addition of H2O2.  
A) At T0, transcriptional profiles of C. albicans wildtype replicate A is highly correlated with 
replicate B. The high degree of correlation was observed for both highly expressed genes 
(yellow box) and lowly expressed genes (green box). r
2 
= 0.86 for lowly expressed genes, 
r
2
 = 0.97 for highly expressed genes and r
2
 = 0.948 across genes expressed at all levels.   
B) Linear correlation between transcriptional profiles of the same replicate before (X-axis) 
and after (Y-axis) the addition of H2O2. The poor correlation between the two samples 
suggests that H2O2 triggered a large transcriptional change.        
Once we normalized gene expression for all samples, we used the algorithm EdgeR to 
identify genes statistically significantly differentially expressed between conditions. EdgeR 
has been coded so reads coming from biological replicates are combined and pairwise 
comparisons between conditions can be assessed using an overdispersed Poisson model 
(Robinson et al., 2010). 
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4.3.3 ZCF15 and ZCF29 are not regulating canonical genes involved in ROS 
detoxification  
 
We first explored the possibility that ZCF15 and ZCF29 are regulating the canonical genes 
involved in ROS detoxification processes. In C. albicans two major pathways are known to 
be involved in ROS resistance: the Hog1 and the Cap1 pathway (Figure 4.12).  
 
Figure 4.12: The Hog1 and Cap1 pathway are the two major known pathways involved 
in oxidative stress response.  
A) In the absence of oxidative stress the histidine kinase Sln1 is autophosphorylated on its 
histidine (H) and aspartate (D) residues. In these conditions, Sln1 phosphorylates Ypd1, 
which subsequently transfer its phosphate group to Ssk1. Ssk1 phosphorylation inhibits 
the activation of the MAPK pathway and cause Hog1 cytoplasmic retention. Figure 
adapted from (Chauhan et al., 2006).  
B) In the presence of oxidative or osmotic stress, the Sln1-Ypd1-Ssk1 phosphotransfer 
cascade is inhibited and Ssk1 activates the MAPK pathway. Activation of the MAPK 
pathway leads to the phosphorylation of Hog1 that translocate to the nucleus and activates 
oxidative/osmotic stress genes.  
C) Cartoon that summarizes the pathways involved in C. albicans resistance to various 
stresses. In addition to the MAPK pathway, oxidative stress activates the transcription 
factor Cap1 that controls the expression of catalase and efflux pumps like Multi Drug 
Resistance genes (Mdr1).  Figure adapted from Enjalbert et al., 2006 
The Hog1 pathway (high osmolality glycerol) is a general stress response pathway involved 
in oxidative, osmotic and heavy metal stress (Smith et al., 2004). This pathway is believed to 
be activated only at the high concentration of peroxide and relies on a series of signal 
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transducer proteins that phosphorylate the transcription factor Hog1 in the presence of 
oxidative stress (Figure 4.12 A and B). The Hog1 pathway plays a central role in regulation 
of stress response genes and various mutants in this pathway have been shown to be 
hypersensitive to ROS (Nagahashi et al., 1998).  
In addition to the Hog1 pathway, C. albicans relies on the Cap1 pathway to withstand ROS 
stress. Cap1 is a bZIP transcription factor that is activated at both high and low ROS 
concentrations and controls the expressions of detoxifying enzymes like superoxide 
dismutase (SOD1 and SOD2), catalase (CAT1) and Multi Drug Resistance efflux pumps like 
MDR1 (Figure 4.12 C). 
Together, Hog1 and Cap1 control the expression of genes involved in ROS defense 
mechanisms like SOD-CAT superoxide detoxification, thioredoxin antioxidant mechanism 
and glutathione radical scavenging process (Figure 4.13 A). In order to evaluate if any of 
these canonical ROS resistance processes are controlled by Zcf15 or Zcf29 we measured their 
H2O2 dependent upregulation in wildytpe and deletion strains. As shown in Figure 4.13, 
genes involved in these pathways were upregulated in zcf15/zcf15 and zcf29/zcf29 to the same 
extent as wildtype. This evidence suggests that ZCF15 and ZCF29 don’t control these 
detoxifying processes and are likely involved in novel pathways that likely don’t crosstalk 
with the very well characterized Hog1 and Cap1 pathways. 
Our analysis allowed us to compare the degree of upregulation we observed in our dataset 
with literature results. Wang et al., 2006 reported a 20, 35 and 13 folds upregulation for 
CAP1, TRR1 and GLR1 respectively upon exposure of 1 mM H2O2 (Figure 4.13 C). We 
obtained similar results with CAP1, TRR1 and GLR1 upregulated on average 12, 37 and 16 
folds (Figure 4.13 B), suggesting that our results recapitulate what has been shown by others 
and confirming experimental reproducibility between microarray and RNA-Seq data.  
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Figure 4.13: ZCF15 and ZCF29 are not regulating canonical ROS resistance pathways. 
A) Upon ROS exposure C. albicans upregulates superoxide dismutase SOD1 and SDO2 that 
convert superoxide ions to H2O2 which is subsequently converted into H2O by CAT1.  
The thioredoxins pathway acts as an electron donor to various peroxidases and other 
reductases and helps in scavenging toxic ROS. 
The glutathione pathway functions as a cellular redox buffer scavenging toxic ROS 
trough the action of GLR1, orf19.86 and orf19.4436. 
B) Genes involved in SOD-CAT superoxide detoxification and thioredoxin/glutathione ROS 
scavenging are upregulated in zcf15/zcf15 and zcf29/zcf29 to the same extent as wildtype. 
This evidence suggests that ZCF15 and ZCF29 don’t control these detoxifying processes 
and are likely involved in novel pathways. 
C) The upregulation observed in our dataset is comparable to what has been shown by Wang 
et al., 2006 confirming experimental reproducibility between microarray and RNA-Seq 
experiments.     
Taken together, our results showed that a) the addition of H2O2 activated the canonical genes 
involved in ROS detoxification processes in both wild type and deletions strains b) the 
upregulation in our dataset is comparable to what have been observed by others (Wang et al., 
2006) c) ZCF15 and ZCF29 are likely not controlling the canonical ROS resistance pathways. 
This evidence suggests that ZCF15 and ZCF29 are likely controlling novel uncharacterized 
ROS resistance pathways.   
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4.3.4 ZCF29 plays a critical role in N-metabolism  
  
4.3.4.1 ZCF29 deletion leads to misregulation of N-metabolism  
  
We first identified genes differentially expressed between wildtype and zcf29/zcf29 strains 
growing in mid- exponential phase in the absence of H2O2 (T0). Genes differentially 
expressed between these two conditions are represented using Volcano Plots (Figure 4.14), a 
type of scatter-plot in which statistical significance (pvalues) is plotted against fold-change 
(FC) on the y- and x-axes respectively. Obviously, pvalues and FC are expressed in a 
logarithmic scale since both variables are heavily skewed in a linear scale (Li, 2012). As 
shown in Figure 4.14, genes statistically significantly differentially expressed (p < 0.01) are 
reported as red dots, while genes whose differential expression is not statistically significant 
are reported as black dots. Genes upregulated in zcf29/zcf29 compared to wildtype are 
reported on the right side of the graph, while genes downregulated in zcf29/zcf29 compared to 
wild-type are reported to the left side of the graph. 
As shown in Figure 4.14, deletion of ZCF29 causes a major transcriptional change with a 
total of 1402 genes statistically significantly differentially expressed. This large genes set 
correspond to a remarkable 22% of the genome suggesting that this transcription factor may 
regulate a variety of biological functions. The fact that ZCF29 deletion causes a pronounced 
transcriptional change in C. albicans recapitulates the variety of different phenotypes 
observed for the deletion. These phenotypes include hypersuseptability to cell wall stressor 
SDS, ROS and caffeine (Figure 4.4 and Figure 4.5).   
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Figure 4.14: Volcano plots showing genes differentially expressed between wild type and 
zcf29/zcf29.  
ZCF29 deletion leads to the statistically significant differential expression of 1402 genes: 955 
upregulated and 447 downregulated. Differential gene expression was reported as log2FC on 
the X-axis and statistical significance (–log10 (pvalue)) on the Y-axis. Genes statistically 
significantly upregulated in zcf29/zcf29 compared to wildtype are reported as red dots on the 
right side of the graph while genes statistically significantly downregulated as red dots to the 
left of it. Genes not statistically significantly differentially expressed are reported as black 
dots.   
 
In order to extract biological insights from the group of genes differentially expressed in 
ZCF29 deletion, we used a powerful analytical algorithm called GSEA (Gene Set Enrichment 
Analysis). GSEA identifies statistically over-represented functions given the differentially 
expressed genes and an a priori set of genes and biological functions that are known in C. 
albicans (Marotta et al., 2013; Subramanian et al., 2005). Once we obtained the biological 
functions enriched in our dataset we used Cytoscape (Shannon et al., 2003; Smoot et al., 
2011) and the Enrichment map plugin (Merico et al., 2010) to clearly visualize enriched 
biological functions. Figure 4.15 shows the enrichment map for zcf29/zcf29 strains compared 
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to wildtype. Enrichment maps are network representations made of nodes (circles) connected 
within each other by edges (lines). Blue nodes represent downregulated biological functions, 
red upregulated one. Node size represents the number of genes differentially expressed 
present in that function while edges indicate the relatedness between nodes (the larger the 
number of genes in common between biological functions the thicker the line). When ZCF29 
is deleted the two most statistically significant enriched biological functions are amino acid 
biosynthesis (p = 4.1 x 10
-13
) and proteolysis (p = 6.9 x 10
-11
).   
 
Figure 4.15: Enrichment map of biological functions overrepresented in zcf29/zcf29  
compared to wildtype. 
Circles (nodes) represent biological functions enriched in zcf29/zcf29 deletion compared to 
wildtype. Blue nodes represent downregulated biological functions, while red one 
upregulated one. The two most statistically significant enriched biological functions are 
amino acids biosynthesis and proteolysis. Lines (edges) connecting nodes indicate the 
relatedness between nodes, the larger the number of genes in common between biological 
functions the thicker is the line. 
Amino acid biosynthesis and proteolysis are two highly interconnected biological functions 
as C. albicans is constantly striking a balance between amino acids de novo synthesis and 
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amino acid recycling through proteolysis. Interestingly, wild type C. albicans favors the latter 
over the former under N-starvation condition (Ramachandra et al., 2014). While both 
pathways can produce free amino acids as a final product, amino acid biosynthesis is more 
energy demanding than proteolysis and this is believed to be the reason why C. albicans 
favors the latter under N-starving condition. ZCF29 deletion causes a transcriptional change 
that resembles the transcriptional change observed in wild type C. albicans under N-limiting 
conditions (Ramachandra et al., 2014).  
In particular, when we looked more in depth at the specific metabolic pathways differentially 
expressed in zcf29/zcf29 we found that essentially every gene involved in methionine and 
threonine biosynthesis were downregulated. The biological pathways that lead to the 
synthesis of these two amino acids are reported in Figure 4.16 A. These two pathways are 
highly interconnected within each other as the first three steps (from aspartate to homoserine) 
are in common between them. Each of the five genes involved in the synthesis of threonine 
are statistically significantly down regulated (blue dots Figure 4.16 B) in zcf29/zcf29 and the 
same is true for 5 of the 6 genes involved in the synthesis of methionine (green dots Figure 
4.16 B). The 5 genes involved in threonine biosynthesis (HOM3, HOM2, HOM6, THR1 and 
THR4) are statistically significantly downregulated between 2.5 to 1.5 folds while genes 
involved in the methionine biosynthesis (HOM3, HOM2, HOM6, MET2 and MET6) between 
2.1 and 1.7 folds. In addition to methionine and threonine, many other genes involved in 
amino acid biosynthesis were statistically significantly downregulated. These genes include 
ARO3, ARO4, ARO2, TRP2 and TRP4 required for the biosynthesis of aromatic amino acids 
and LYS4, LYS12, HIS1, HIS4, HIS5, SER1, SER2, LEU1, LEU2, LEU4 required for the 
biosynthesis of lysine, histidine, serine and leucine. This data suggest that overall amino acid 
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biosynthesis is highly downregulated in zcf29/zcf29 a condition commonly observed in C. 
albicans under N-starvation conditions.   
 
Figure 4.16: ZCF29 deletion causes misregulation of threonine, methionine and arginine 
biosynthesis. 
A) C. albicans threonine and methionine biosynthetic pathway. The first 3 steps of the 
pathways are in common between the two amino acids. Once homoserine is synthesized, 
it can either be acetylated leading to the subsequent formation of methionine or 
phosphorylated leading to the subsequent formation of threonine. 
B) Volcano plot showing that ZCF29 deletion leads to the statistically significant 
downregulation of genes involved in threonine and methionine biosynthesis (blue and 
green dots) and concurrent upregulation of genes involved in arginine biosynthesis 
(purple dots). 
C) C. albicans arginine biosynthetic pathway. There are 7 genes involved in this pathway, 6 
of the 7 genes are upregulated in ZCF29 deletion. Interestingly, the only gene in the 
pathway not upregulated in our data is ARG2, a gene that is largely regulated post-
transcriptionally in S. cerevisiae  (Wipe and Leisinger, 1979)                
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Interestingly, in this context of extensive downregulation of amino acid biosynthesis, we 
found that the arginine biosynthetic pathway was substantially upregulated in zcf29/zcf29. 
This data was somewhat surprising as 6 of the 7 genes involved in this pathway (ARG1, 
ARG3, CPA1, ARG8, CPA2, ARG5,6) were upregulated between 23 and 6 folds and the only 
gene in the pathway not upregulated in our dataset is ARG2, a gene that in S. cerevisiae has 
been shown to be largely regulated posttranslationally (Wipe and Leisinger, 1979). This 
result was surprising especially considering that many other genes involved in amino acid 
biosynthesis were downregulated in zcf29/zcf29. However, arginine biosynthetic pathway has 
been recently linked to ROS resistance. Jimenez-Lopez et al., 2013 recently showed that C. 
albicans upregulates the arginine biosynthetic pathway upon exposure to macrophage 
generated ROS. Interestingly, similarly to what we have seen, the only gene in the pathway 
not upregulated upon exposure to macrophage generated ROS was also ARG2. Although the 
biological reasons behind this upregulation are still under active investigation, our data 
reinforce a yet poorly understood connection between arginine biosynthesis upregulation and 
reactive oxygen species resistance.  
As shown in Figure 4.15, the second most enriched biological function upon ZCF29 deletion 
is proteolysis. Proteolysis is a complex biological process that in C. albicans includes 4 major 
steps: proteasome assembly, protein target ubiquitination, protein degradation and amino 
acids recycling. Interestingly genes involved in each of these four major steps were 
upregulated in zcf29/zcf29. Genes directly involved in protein degradation like APE3, CPY1, 
LAP3, LAP41, PRC2, PRC3 coding for various amino- and carboxy-peptidases were 
upregulated between 2 and 18 folds in ZCF29 knockout. In addition genes involved in 26s 
proteasome assembly, ubiquitination and amino acid recycling like DOA1, DOA4, HRT1, 
PR26, RPN1, RPN2, RPT1, RPT2, RPT4, RPT5, RPT6 and UBP6 were all statistically 
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significantly upregulated. In wild type cells many of these genes have been shown to be 
upregulated after switching cells from rich media to media lacking nitrogen (Ramachandra et 
al., 2014) reinforcing the idea that ZCF29 deletion leads to a transcriptional response that 
recapitulates the one observed in wild type cells under N-starvation.  
Our RNAseq experiments allowed us to identify genes differentially expressed upon ZCF29 
deletion. Although we can’t discriminate if these genes are directly or indirectly controlled by 
Zcf29 and further biological experiments are required to pinpoint its regulatory network, we 
believe that ZCF29 plays a critical role in the C. albicans ability to regulate amino acids 
biosynthesis, proteolysis and N-metabolism. This evidence is corroborated by the fact that 
ZCF29 deletion leads to an increased sensitivity to caffeine, which mimics N-starvation 
(Figure 4.5 A).      
 
4.3.4.2 ZCF29 plays a critical role in down regulating ribosome biogenesis upon ROS 
challenge  
 
In order to identify genes and pathways regulated by ZCF29 upon ROS challenge we 
compared the transcriptional changes caused by H2O2 in wildtype with the once observed in 
zcf29/zcf29 15 minutes after the addition of H2O2. We found a total of 668 genes statistically 
significantly differentially expressed (Figure 4.17) and clustered them in four groups. Group 
1 and 2 represents genes downregulated by H2O2 in wild type (blue bars) but to a statistically 
significant lower (group 1) or higher (group 2) degree in zcf29/zcf29 (red bars). Group 3 and 
4 represents genes that are upregulated by H2O2 in wild type but to a statistically significant 
higher (group 3) or lower (group 4) degree in zcf29/zcf29. 
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Figure 4.17: Genes differentially expressed upon H2O2 exposure between wildtype and 
zcf29/zcf29.  
Group 1 and 2 represents genes that are downregulated by H2O2 but to a statistically 
significant lower (group 1) or higher (group 2) degree in zcf29/zcf29 compared to wild type. 
Full list of enriched biological functions in group 1 is reported in Figure 8.1 Group 3 and 4 
represents genes that are upregulated by H2O2 but to a statistically significant higher (group 
3) or lower (group 4) degree in zcf29/zcf29. Full list of enriched biological functions in group 
4 is reported in Figure 8.2  
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To identify enriched biological functions in our dataset we ran a GO term analysis (Inglis et 
al., 2012) on each of the four groups reported in Figure 4.17. This analysis highlighted 
ribosome biogenesis as one of the most overrepresented biological functions of group 1 
(corrected p value 1.4x10
-18
) suggesting that wild type downregulation of genes involved in 
ribosome biogenesis is hampered in ZCF29 deletion. Figure 4.18 shows 35 genes involved in 
ribosome biogenesis that are downregulated to a statistically lower degree in ZCF29 
knockout compared to wildtype.   
 
Figure 4.18: ZCF29 plays an important role in down regulating ribosome biogenesis 
upon ROS challenge. 
35 genes downregulated upon H2O2 exposure in wildtype (blue) are downregulated to a 
statistically significant lower extend in ZCF29 deletion (red).  
Ribosome assembly in C. albicans requires a dynamic series of steps in which protein-
protein, RNA-protein, and RNA-RNA interactions needs to be carefully orchestrated. 
Biogenesis begins in the nucleolus where rRNA is transcribed and subsequently goes through 
a series of maturation steps including RNA folding, spacer sequence removal, and ribosomal 
protein binding (Woolford and Baserga, 2013). This maturation continues as preribosomal 
particles like the 90s Preribosome bind to rRNAs-protein complexes and translocate from the 
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nucleolus to the nucleoplasm to the cytoplasm ultimately forming the two mature subunits 
(60s subunit and 40s subunits). Overall the ribosome is an enormous machine composed of 
four rRNAs and more than 80 ribosomal proteins and yeast cells in log-exponential phase are 
believed to produce 40 ribosomes per second (Warner, 1999). Ribosome biogenesis is very 
energetically demanding and under ROS stress, C. albicans coordinately downregulate 
ribosome biogenesis in order to liberate significantly energy resources for other cellular 
processes (Loar et al., 2004). Our data suggests that the ability to downregulate ribosome 
biogenesis upon ROS challenge is compromised in zcf29/zcf29 as many of the genes involved 
in the various steps of ribosome biogenesis are downregulated to a significant lower degree in 
zcf29/zcf29. For example UTP21, NAN1, UTP5, UTP20, UTP13 five U3 snoRNA proteins 
involved in pre-rRNA processing, DBP2 and DBP3 two DEAD-box RNA helicases involved 
in rRNA maturation, RCL1 an endonuclease involved in 90S preribosome processing and 
REI1, a cytoplasmic pre-60S subunit protein are all downregulated to a statistically  
significantly lower degree in zcf29/zcf29 compared to wildtype. Many of these genes have 
been shown to be downregulated upon macrophage generated ROS (Lorenz et al., 2004), and 
suggesting that these genes are downregulated not only in the presence of ROS in vitro but 
also in the context of a mammalian infection.  
Taken together our data suggests that the canonical downregulation of ribosome biogenesis 
under ROS stress is compromised in zcf29/zcf29. The C. albicans ability to downregulate this 
very energy demanding process upon ROS exposure is critical and we believe that the 
zcf29/zcf29 inability to do so may be the underlying cause of its hypersuseptability to ROS.   
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4.3.5 ZCF15 plays an important role in C-metabolism and regulates key thiol 
peroxidases upon ROS exposure  
 
We identified genes and pathways regulated by ZCF15 using a strategy similar to the one 
described in paragraph 4.3.1.1. We first looked at genes differentially expressed between wild 
type and zcf15/zcf15 strains growing in mid exponential phase in the absence of H2O2. In 
these conditions, the deletion of ZCF15 leads to the statistically significant differential 
expressions of 168 genes, 95 downregulated and 73 upregulated (Figure 4.19).      
 
Figure 4.19: Volcano Plots showing the number of genes differentially expressed 
between wildtype and zcf15/zcf15 in the absence of H2O2.  
When we run a GSEA analysis we found that carbon metabolism, TCA cycle and energy 
production are all downregulated in zcf15/zcf15 compared to wild type (p values between 
0.00123 and 0.00410). In particular glucose transporters like SHA3, HGT7 and HGT6 are 
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downregulated between 16 and 3 folds, genes involved in glycolysis/TCA cycle like 
glycolysis regulator TYE7, phosphoenolpyruvate carboxykinase (PCK1) and pyruvate 
carboxylase (PYC2) between 8 and 2 folds and genes involved in cellular respiration like 
NADH dehydrogenase (NDE1) and malate dehydrogenase (MAE1) between 4 and 2 folds. 
This data suggests that ZCF15 plays an important role in regulating C-metabolism and energy 
production an hypothesis that was confirmed when we compared the transcriptional changes 
triggered by H2O2 in wildtype versus zcf15/zcf15.  
As shown in Figure 4.20:, when we run the EdgeR generalized linear model as described in 
4.3.3.2 we found 210 genes statistically significantly differentially expressed. We clustered 
these genes in four groups. Group 1 and 2 represents H2O2 repressed genes downregulated to 
a statistically significant lower (group 1) or higher (group 2) degree in zcf15/zcf15 compared 
to wild type. Group 3 and 4 represents H2O2 induced genes upregulated to a statistically 
significant higher or lower degree in the zcf15/zcf15. When we looked for biological 
functions enriched in group 1 and 4 using GO term analysis (Inglis et al., 2012) we found that 
carbon utilization and oxidation-reduction processes were the two most highly statistically 
significant enriched processes (carbon utilization p = 2.5 x 10
-5
, oxidation reduction process p 
= 1 x 10
-4
). These two biological processes are highly interconnected as it has been shown 
that in the presence of ROS C. albicans goes in a “staravation like” mode by downregulating 
genes involved in carbon metabolism and simultaneously upreglating genes involved in 
oxidation reduction processes and ROS detoxification (Lorenz et al., 2004).   
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Figure 4.20: genes differentially expressed between wild type and zcf15/zcf15 upon H2O2 
challenge. 
Group 1 represents genes downregulated by H2O2 in wildtype but to a statistically significant 
lower degree in zcf15/zcf15. Full list of enriched biological functions in group 1 is reported in 
Figure 8.3. Group 2 represents genes downregulated in wildtype but to a statistically 
significant higher degree in zcf15/zcf15. Using the same logic group 3 and 4 represents H2O2 
induced genes but to a significant higher (group 3) or lower degree (group 4) in zcf15/zcf15. 
Full list of enriched biological functions in group 4 is reported in Figure 8.4. 
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As shown in Figure 4.21 many of the genes involved in carbon metabolism like CRC1, CAT2, 
FAA21, FOX2 and CIT1 are dowregulated to a statistically significant lower degree in the 
mutant compared to wild type. Concurrently genes involved in oxidation reduction 
processes/ROS detoxification like DOT5 (a thiol peroxidase), IFD6 (a aldo-keto reductase), 
OFD1 (prolyl hydroxylase) and AMO1 (a peroxisomal oxidase) are upregulated in 
zcf15/zcf15 to a statistically significantly lower extent.  
 
Figure 4.21: ZCF15 is required for down regulating genes involved in C-metabolism 
and simultaneously upregulating genes involved in oxidation reduction processes/ROS 
detoxification.   
This evidence suggests that the canonical wildtype abiltity to simultaneously dowregulate 
genes involved in carbon metabolism and upregulate genes involed in ROS detoxification 
upon H2O2 exposure is compromised in zcf15/zcf15. We believe that zcf15/zcf15 inability to 
downregulate carbon metabolism and rechannel energy resources towards oxidation 
reduction processes/ROS detoxification is the underlying cause of its increased suseptability 
to ROS.  
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4.3.6 Genes involved in iron homeostasis are potentially coregulated by ZCF15 and 
ZCF29 
 
As discussed in the previous chapters, in the absence of H2O2, ZCF29 deletion leads to the 
differential expression of 1402 genes while the deletion of ZCF15 leads to a more modest 
transcriptional rewiring of 168 genes. In order to find biological functions potentially 
coregulated by both transcription factors we identified genes differentially expressed in both 
mutants. As shown in Figure 4.22 A, we found 1295 genes differentially expressed only in 
zcf29/zcf29, 61 genes differentially expressed only in zcf15/zcf15 and 107 genes differentially 
expressed in both mutants. Remarkably the expression directionality of these genes is highly 
conserved in both deletions with only 2 out of the 107 genes found differentially expressed in 
both mutants but in opposite directions (Figure 4.22 B). This evidence suggests that the 
remaining 105 genes are not only co-occurring in the lists of differentially expressed genes 
but that they are likely regulating common biological functions.   
When we looked for enriched biological functions in these 105 genes we found that cellular 
iron homeostasis was the most statistically significant enriched functions (Figure 4.22 C). In 
particular we found that genes involved in iron utilization like IRO1, CRP1 and orf19.5334  
(Garcia et al., 2001; Weissman et al., 2000) are downregulated in both mutants and 
contemporarily genes involved in iron uptake like HAP43, HMX1, CSR1 and MAC1 (Kim et 
al., 2008; Lan et al., 2004) are upregulated. This transcriptional response resembles the 
transcriptional response observed by Lan et al., 2004 in wildtype C. albicans grown under 
low iron conditions. When iron is limiting C. albicans upregulates genes involved in iron 
uptake and downregulates genes involved in iron utilization.  
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Figure 4.22: genes involved in iron homeostasis are differentially expressed in both 
ZCF15 and ZCF29 deletions.   
A) Deletion of ZCF15 and ZCF29 leads to the differential expression of a common set of 
107 genes. 
B) The directionality of the potentially coregulated genes is respected in both mutants. 
log2FC of genes differentially expressed upon ZCF15 deletion is plotted against log2FC of 
the same genes upon ZCF29 deletion. 105 of the 107 genes are co-differentially expressed 
in the same direction and only 2 genes are differentially expressed in both deletion but in 
opposite directions.      
C) Cellular iron homeostasis is the most statistically significantly biological function in the 
107 genes differentially expressed in both zcf15/zcf15 and zcf29/zcf29. 
D) Deletion of ZCF15 and ZCF29 leads to the upregulation of HAP43, HMX1, CSR1, MAC1 
and simultaneous downregulation of orf19.5334, CRP1 and IRO1. Upregulation of 
HAP43, HMX1 and simultaneous dowregualtion of IRO1 is commonly observed in 
wildtype C. albicans under nitrogen limiting conditions. 
In C. albicans iron uptake is tightly regulated. Too little iron can cause core metabolic 
processes such as TCA cycle to be shut down and too much iron can cause the formation of 
toxic oxygen radicals (Blankenship and Mitchell, 2011). In addition, iron homeostasis plays a 
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major role in virulence since C. albicans needs to quickly adapt and thrive in both the iron 
replete environment of the mammalian gut as well as in the iron limited environment of the 
blood stream. As shown in Figure 4.23, genes involved in iron homeostasis are tightly 
regulated by three transcription factors: Sfu1, Sef1 and Hap43 (Chen et al., 2011). Sfu1 is 
major repressor of iron uptake and its expression is repressed by regulated by Hap43. In other 
words, Hap43 activates iron uptake by repressing the repressor. (Blankenship and Mitchell, 
2011).  
 
Figure 4.23: Iron homeostasis is tightly regulated by three major transcription factors, 
Sef1, Sfu1 and Hap43. Figure adapted from Blankenship and Mitchell, 2011 
 
In our dataset the expression of Hap43 is statistically significantly upregulated in both 
zcf15/zcf15 and zcf29/zcf29. Our working hypothesis is that upon deletion of ZCF15 and 
ZCF29, HAP43 upregulation represses Sfu1 leading to upregulation of iron uptake genes like 
HMX1 and downregulation of genes involved in iron utilization like IRO1 (Figure 4.23).   
The fact that ZCF15 and ZCF29 deletion resembles the transcriptional response observed in 
wildtype under low iron conditions suggests that these two transcription factors may play a 
role in the regulating cellular iron uptake and utilization.    
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4.3.7 ZCF15 and ZCF29 ChIP-Seq 
 
The RNA-Seq experiment described in the previous paragraphs gave us some insights on the 
genes regulated by ZCF15 and ZCF29. However, genes differentially expressed in 
transcription factor (TF) knockouts can be either directly or indirectly regulated by the TF. In 
the former case, the TF binds to specific region of the genome directly regulating the 
expression of genes flanking that region. In the latter case, the regulation is indirect because, 
for example, the TF can either be a distant-acting regulator or can control the expression of 
other regulators (silencer/enhancer) which control the expression of the differentially 
expressed gene.   
In order to identify Zcf15 and Zcf29 transcriptional targets in vivo, we used a chromatin 
immuneprecipitation approach coupled with DNA Sequencing (ChIP-Seq). This method 
allowed us to explore protein-DNA interaction of Zcf15 and Zcf29 with their respective 
transcriptional binding sites. This approach allowed us to retroactively look back at our 
transcriptomic experiments and identify genes directly controlled by Zcf15 and Zcf29. 
Combining RNA-Seq and ChIP-Seq data have been shown to be a powerful way to explore 
novel transcriptional mechanisms (Hull et al., 2013).  
The ChIP-Seq experimental approach we used relies on five steps (Figure 4.24): 
 Crosslink DNA binding proteins and their transcriptional targets with formaldehyde.  
 Selectively immunoprecipitate protein-DNA complexes. 
 Reverse formaldehyde cross-links, hydrolyze residual proteins and purify DNA. 
 Prepare DNA multiplexed libraries and deep sequence them. 
 Map reads to the genome and identifies transcriptional binding sites.   
These five steps are summarized in Figure 4.24 and are thoroughly reviewed in  Botcheva et 
al., 2011. 
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Figure 4.24: An overview of the ChIP-Seq procedure used 
In our ChIP-Seq experiment we first cross-linked DNA binding proteins to their 
transcriptional targets. We subsequently immunoprecipitate our protein-DNA complexes of 
interest, reverse the crosslink and purified DNA. The purified DNA was used for library 
preparation and sequencing. Reads obtained from the sequencing were mapped to the C. 
albicans genome and binding sites identifies using the algorithm MACS. Figure adapted from 
(Botcheva et al., 2011)   
 
In order to selectively immunoprecipitate Zcf15 and Zcf29 protein-DNA complexes we first 
epitope tagged Zcf15 and Zcf29 at their C-termini with an HA-containing epitope. A cassette 
containing 3-tandem copies of the HA-epitope was integrated at the 3’ end of each gene using 
a PCR-mediated homologous recombination strategy (Figure 4.25).  
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 Figure 4.25: ZCF15 and ZCF29 HA epitope tagging  
A) HA-ARG4 insertion cassette is amplified from pFA-HA-ARG4 plasmid using primers 
containing ~70bp sequence homology for the region upstream and downstream of ZCF15 
stop codon.   
B) Wildtype C. albicans is transformed with the HA-ARG4 insertion cassette that integrates 
by homologous recombination at the 3’ end of ZCF15 and consequently HA tagging 
Zcf15 at its C-terminus. 
C) Proper insertion of the HA-ARG4 insertion cassette was confirmed by diagnostic PCR 
targeting the new 5’ and 3’ junctions. Two independent transformants (T1 and T2) were 
confirmed.  
D) Proper expression of the Zcf15-HA tagged protein was confirmed by Western Blot. Four 
independent transformants (T1, T2, T3 and T4) were tested and Cdc3-HA described here 
(Gerami-Nejad et al., 2009) was used as a positive control. 
E-F-G-H) Zcf29p was tagged using different primers but essentially the same logic described 
in A-B-C-D for ZCF15.   
In order to epitope tag Zcf15 and Zcf29 we first amplified the integrating cassette with 
primers containing overhanging sequences of homology for the regions flanking their 
respective stop codons (Figure 4.25 green-blue for ZCF15 and red-purple for ZCF29). Upon 
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transformation, proper genomic integration was confirmed by diagnostic PCR (Figure 4.25 C 
and G) and proper expression of the tagged protein by Western Blot (Figure 4.25 D and H). 
We decided to epitope tagged our transcription factors at their 3’ and not 5’ end so that their 
expression remained under the control of their own regulatory sequences.  
In order to compare the ChIP-Seq results with the transcriptomics studies described in 4.3.3, 
we ran our experiments in analogous conditions. We identified Zcf15 and Zcf29 DNA 
binding partners 5 and 15 minutes after the addition of 5mM H2O2 and compared them to 
unexposed samples. Upon H2O2 exposure samples were quickly cross-linked with 
formaldehyde, TF-bound DNA purified and DNA libraries prepared and sequenced.   
Our sequencing runs yielded a total of 148 million 25-base sequence reads with an average of 
4.2 million reads per sample. Reads were successfully aligned to the C. albicans genome and 
we obtained a mean coverage between 50x and 75x. Zcf15 and Zcf29 bound regions were 
obtained using MACS peak caller (Zhang et al., 2008) in the web-based genomic platform 
Galaxy (Goecks et al., 2010). Peaks were called by comparing reads between anti-HA 
pulldown samples and input controls.  
In the absence of H2O2, we identified 37 and 28 regions bound by Zcf15 and Zcf29 
respectively. In the presence of H2O2, we identified 30 and 29 regions bound by Zcf15 and 
Zcf29 respectively. These genomic regions were identified using MACS and only enriched 
regions with p values < 1e-3 were considered. The average length of these TF bound regions 
is 3.9 kb and these regions are evenly distributed across the genome in all samples suggesting 
no biases toward specific chromosomes or genomic locations.    
In order to evaluate if the addition of H2O2 drove our TF to different genomic loci, we 
identified TF-bound regions that remain bound both before and after the addition of H2O2. As 
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shown in Figure 4.26, only 7 and 18 of the Zcf15 and Zcf29 bound regions remained bound 
both before and after the addition of H2O2. This evidence suggest that, upon H2O2 exposure, 
Zcf15 and Zcf29 switch many of their genomic targets and relocate themselves to other 
genomic loci likely controlling different genes sets. This evidence confirms and validates our 
RNA-Seq experiments that showed that Zcf15 and Zcf29 control different biological 
functions in the presence and absence of H2O2 (paragraph 4.3).  
 
Figure 4.26 Zcf15 and Zcf29 change many of their genomic targets upon H2O2 exposure.  
Zcf15 has 30 and 23 unique genomic binding sites in the absence and presence of H2O2 
respectively and only 7 that are present in both conditions. Zcf29 has 10 and 11 unique 
genomic binding sites and 18 that are present in both conditions. Together these evidences 
suggest that Zcf15 and Zcf29 relocate to different genomic loci upon H2O2 exposure 
confirming our transcriptome analysis that showed regulations of different sets of genes in 
the presence or absence of H2O2. Genomic regions between conditions were considered in 
common if the location of their summits were within 2 kb of each other.   
 
In order to validate these ChIP-Seq results and define Zcf15 and Zcf29 regulons we 
compared the ChIP-Seq data with our transcriptome analysis. Overall, we found various 
examples in which the genes differentially expressed in our RNA-Seq experiment were 
flanked by TF-bound regions. For example, in the absence of H2O2 14 of the 28 ZCF29 DNA 
binding sites are flanking genes differentially expressed upon ZCF29 deletion (Figure 4.27 A 
genes highlighted in yellow).  In addition, 7 of the 29 DNA binding sites that ZCF29 
recognizes in the presence of H2O2 are flanking genes that we considered H2O2 responsive 
and ZCF29 dependent (Figure 4.27 B, genes highlighted in yellow).  
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Figure 4.27: various ZCF29 DNA binding sites flank genes differentially expressed in 
ZCF29 deletion. 
A) In the absence of H2O2, 14 of the 28 ZCF29 genomic binding sites (ChIP-Seq data) flank 
genes that are differentially expressed upon ZCF29 deletion (RNA-Seq data). Genes 
reported in bold indicate ZCF29 genomic binding partners bound both in the presence and 
absence of H2O2 (18 total, shown also in Figure 4.26 B)  
B) In the presence of H2O2, 7 of the 29 ZCF29 DNA binding sites (ChIP-Seq data) flank 
genes that are shown to be H2O2 responsive and ZCF29 dependent.  
 
Figure 4.28 depicts two genes that are likely directly regulated by Zcf29 in the absence of 
H2O2. The ChIP-Seq experiment showed a peak (3.5 folds enriched, p < 0.01) right upstream 
of orf19.7204 (Figure 4.28 A) and the same gene was shown to be statistically significantly 
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upregulated in zcf29/zcf29 (Figure 4.28 C blue dot). Together these results suggest that 
orf19.7204 is a direct Zcf29 target and that Zcf29 functions as a repressor of this gene (Figure 
4.28 D). On the other hand Zcf29 is likely a direct activator of orf19.7042 since we found a 
Zcf29 bound region just upstream of this gene in wild type C. albicans (Figure 4.28 B) and 
contemporarily showed that this genes is statistically significantly downregulated in 
zcf29/zcf29 (Figure 4.28 C green dot).  
orf19.7204 is an uncharacterized gene with orthologs that have glyoxysome localization. 
Glyoxysome are specialized peroxisomes in which fatty acids are hydrolyzed to acetyl-Coa 
leading to the production of ROS (Michels et al., 2005). Various antioxidant proteins are 
expressed in this organelle to detoxify ROS and it is possible that orf19.7204 is one of them. 
orf19.7042 is also an uncharacterized gene but it has been shown to be induced in MDR1 
overexpressing strains (Karababa et al., 2004). MDR1 is a multidrug efflux pump that is 
commonly overexpressed in drug resistant clinical isolates (White, 1997a) and is directly 
involved in cellular detoxification processes (Morschhauser et al., 2007). We believe that 
orf19.7042 is activated by Zcf29 and that it cooperates in cellular detoxification process, an 
hypothesis that is corroborated by the fact that this gene was found to be upregulated upon 
nitric oxide exposure (Hromatka et al., 2005).  
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Figure 4.28: Zcf29 directly controls the expressions of orf19.7204 and orf19.7042. 
A) A 4.5 kb span of C .albicans genome displayed in IGV (chromosome 7 location 
coordinates 838,098-842,672). The two tracks labeled Zcf29_pulldown and Zcf29_input 
represent reads from pulldowns samples and control respectively. A large statistically 
significant peak is present right upstream of orf19.7204 
B) A 4.5 kb span of C. albicans genome displayed in IGV (chromosome 7 location 
coordinates 144,116-148,690) showing a large Zcf29 binding region right upstream of 
orf19.7042 
C) RNASeq:Volcano Plots showing that orf19.7042 and orf19.7204 are statistically 
significantly up and downregulated upon ZCF29 deletion.    
D) orf19.7204 is a direct Zcf29 targets and its expression is likely repressed by Zcf29. 
E) orf19.7042 is a direct Zcf29 targets and its expression is likely activated by Zcf29. 
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In addition to genes directly regulated by Zcf29 in the absence of H2O2, the ChIP-Seq 
experiment allowed us to determine H2O2 responsive genes whose expression is directly 
controlled by Zcf29.  
For example, as shown in Figure 4.29A and B upon H2O2 exposure Zcf29 binds to the 
regions directly upstream of orf19.1048 and orf19.251 (Figure 4.29 A and B). The presence 
of these two Zcf29 bound regions upon H2O2 exposure validates our RNA-Seq experiments 
which showed that Zcf29 is required for the H2O2 dependent upregulation of these two genes. 
While in wild type C. albicans these two genes are upregulated 11 and 7 folds upon H2O2 
exposure, the same genes were only 3 and one fold upregulated in zcf29/zcf29 (Figure 
4.29D). Together these results suggest that upon H2O2 exposure Zcf29 binds the regions right 
upstream of these two genes directly upregulating their expressions.  
orf19.251 is a glutathione-independent glyoxalase that has a critical role in stress response 
and in glycocalyx detoxification (Hasim et al., 2014), while orf19.251 is an alpha-keto 
reductase that is induced in strains overexpressing the cellular detoxification efflux pump 
MDR1 (Rogers and Barker, 2003). To the best of our knowledge this is the first time that the 
expression of these two H2O2 responsive genes have been shown to be directly controlled by 
Zcf29.    
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Figure 4.29: The upregulation of orf19.251 and orf19.1048 upon H2O2 is directly 
controlled by Zcf29.  
A) A 3.8 kb span of C. albicans genome displayed in IGV (chromosome 1 location 
coordinates 865,375 - 869,215). The two tracks labeled Zcf29_pulldown and Zcf29_input 
represent reads from pulldowns samples and controls obtained after the addition of H2O2. 
A large statistically significant peak is present right upstream of orf19.1048 (3.5 fold 
enriched p < 0.01). 
B) A 4.3 kb span of C. albicans genome displayed in IGV (chromosome 3 location 
coordinates 564,048-568,382) showing a large peak (2.7 fold enriched p < 0.01) right 
upstream of orf19.251. 
C) RNASeq experiment showing that the upregulation upon H2O2 is hampered in ZCF29 
deletion. 
D) Zcf29 is likely a direct activator of orf19.1048 and orf19.251 upon H2O2 exposure.   
 
Overall, we were able to find many examples of Zcf29 bound regions flanked by 
differentially expressed genes. On the other hand, we found a significantly smaller correlation 
when we repeated the analysis for Zcf15.  
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Figure 4.30: few ZCF15 DNA binding sites flank genes differentially expressed in 
ZCF15 deletion. 
A) In the absence of H2O2, 3 of the 37 ZCF15 genomic binding sites (ChIP-Seq data) flank 
genes that are differentially expressed upon ZCF15 deletion (RNA-Seq data). Genes 
reported in bold indicate ZCF15 genomic binding partners bound both in the presence and 
absence of H2O2 (7 total, shown also in Figure 4.26 A)  
B) In the presence of H2O2, 3 of the 30 ZCF29 DNA binding sites (ChIP-Seq data) flank 
genes that are shown to be H2O2 responsive and ZCF29 dependent.  
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For example in the absence of H2O2, we found that only 3 of the 37 ZCF15 DNA binding 
sites are flanking genes differentially expressed upon ZCF15 deletion (Figure 4.30 A, genes 
highlighted in yellow). Moreover, 3 of the 30 DNA binding sites that ZCF15 recognizes in 
the presence of H2O2 are flanking genes that are H2O2 responsive and ZCF15 dependent 
(Figure 4.30 B highlighted in yellow). This evidence wasn’t surprising because (a) compared 
to Zcf29 we showed that the deletion of Zcf15 causes a significantly more modest 
transcriptional rewiring (168 differentially expressed  genes for ZCF15 deletion versus 1402 
differentially expressed genes for ZCF29, Figure 4.19 and Figure 4.14) (b) it is not 
uncommon for TF to binding regions not to flank differentially expressed genes. For example 
it is possible that many of the Zcf15 bound regions either regulate more distal transcripts or 
that the binding is structural (help maintain chromosome structure). The presence of distant-
acting silencers or enhancers is well documented in C. albicans (Tuch et al., 2010) and it is 
possible that many of the genes controlled by Zcf15 are located to genomic loci not flanking 
Zcf15 bound regions.  
In addition, we can’t rule out the hypothesis that our stringent requirements for differential 
expression identification have partially limited our ability to correlate Zcf15 ChIP-Seq and 
RNASeq data. For example, as shown in Figure 4.31, we found a large Zcf15 bound regions 
upstream of orf19.2724 (Figure 4.31 A) in the absence of H2O2 and a large Zcf15 bound 
region upstream of orf19.871 in the presence of H2O2 (Figure 4.31 B). These two genes were 
found to be differentially expressed in analogous conditions in our RNASeq but not to 
statistically significant levels. In particular, in the absence of H2O2, deletion of ZCF15 leads 
to the upregulation of orf19.2724 (1.5 folds) but not to statistically significant levels (p = 
0.081), Figure 4.31 C. Similarly, upon H2O2 exposure, orf19.871 is upregulated 2 fold and 3 
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fold in wild type and zcf15/zcf15 respectively but their differential expression was not 
statistically significant (p = 0.16) Figure 4.31 D.   
 
Figure 4.31: Zcf15 may control the expression of orf19.7224 and orf19.871. 
A) A 4.3 kb span of C. albicans genome displayed in IGV (chromosome 4 location 
coordinates 572,340 – 576,653). The two tracks labeled ZCF15_pulldown and 
ZCF15_input represent reads from pulldowns samples and controls obtained before the 
addition of H2O2. A large statistically significant peak is present right upstream of 
orf19.2724 (3.1 fold enriched p < 0.01). 
B) A 5.3 kb span of C. albicans genome displayed in IGV (chromosome 2 location 
coordinates 792,482 – 734,858). The two tracks labeled represent pulldown and controls 
samples obtained after the addition of 5mM H2O2. A large statistically significant peak is 
present right upstream of orf19.871 (3.6 fold enriched p < 0.01). 
C) Volcano plot showing that Zcf15 deletion leads to a non-statistically significant (p = 
0.081) upregulation of orf19.2724.  
D) orf19.871 is upregulated 2 folds upon H2O2 exposure in wildtype and 3 folds in Zcf15 
deletion but their difference in non-statistically significant (pvalue = 0.16).   
Overall the ChIP-Seq data validated many of the genes found to be differentially expressed in 
our RNA-Seq experiment. We were able to find many examples in which genes differentially 
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expressed were bound by Zcf29 in their respective upstream regulatory sequences. We 
highlighted here four emblematic examples in which the expression orf19.7042, orf19.7204, 
orf19.1048 and orf19.251 is directly regulated by Zcf29. Zcf29 functions as a direct activator 
and repressor of orf19.7042 and orf19.7204 respectively in the absence of H2O2. On the other 
hand, upon H2O2 exposure Zcf29 binds to the orf19.1048 and orf19.251 upstream regulatory 
sequences directly up regulating their expressions.  
Overall our data showed that Zcf15 and Zcf29 relocate themselves to different genomic loci 
upon H2O2 exposure and sheds some light on the genes that are directly regulated by these 
two transcription factors. This study also highlights that many of the TF bound regions are 
not flanking differentially expressed genes, in agreement with evidence previously shown by 
others (Tuch et al., 2010) and that reiterates that distant acting TF regulation is common in C. 
albicans.  
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4.4 Discussion 
 
In the previous chapter we described ZCF15, a C. albicans transcription factor poorly 
characterized in the literature that has a key role in resistance to host generated reactive 
oxygen species (ROS). Encouraged by the fact that this gene belongs to a family of 
transcription factor that is not conserved in humans and therefore can be potentially used for 
either epitope-based vaccine approaches or drug targeting, we expanded our study to other 
genes within the same family. We looked for genes that (a) have a role in resistance to 
reactive oxygen species (b) are conserved in pathogenic fungi but not in non-pathogenic one. 
We identified ZCF29, a transcription factor that has been previously shown to be upregulated 
in the presence of H2O2 (Enjalbert et al., 2006), required for resistance to ROS generator 
menadione (Homan et al., 2009) and present only in pathogenic fungi.   
In order to explore the biological roles of Zcf15 and Zcf29, we leveraged the power of RNA-
Seq and ChIP-Seq. Our analysis showed that zcf29 deletion leads to the misregulation of a 
staggering number of genes (1440 genes, ~25% of the genome). These genes are mainly 
enriched for biological functions involved in N-metabolism. ZCF29 deletion leads to the 
downregulation of genes involved in biosynthesis of threonine, methionine, tryptophan, 
tyrosine, lysine and histidine and simultaneous upregulation of genes involved in proteolysis. 
This evidence suggests that upon ZCF29 deletion C. albicans favors amino acids recycling 
through proteolysis over de novo biosynthesis. Overall, amino acid de novo biosynthesis is 
repressed in zcf29/zcf29 but we found one noticeable exception in our dataset: arginine 
biosynthesis. Six of the seven genes of the arginine biosynthetic pathway are upregulated 
between 23 and 6 folds in zcf29/zcf29 and the only genes not upregulated in this pathway is 
largely regulated post transcriptionally in S. cerevisiae. In murine macrophages, C. albicans 
is killed by a variety of different mechanisms that are dependent on arginine availability. In 
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particular, as shown in Figure 3.6, reactive nitrogen species (RNS) are produced by nitric 
oxide synthase an enzyme that converts arginine to citrulline with simultaneous production of 
nitric oxide (Marletta et al., 1988). Nitric oxide is subsequently converted to more toxic RNS 
like nitrogen dioxide radicals (NO2
●
) and peroxynitrite (ONOO
-
) that have the fungicidal 
effect on C. albicans. We hypothesized that the upregulation of arginine in zcf29/zcf29 can be 
the underlying cause of the reduced virulence reported by Vandeputte et al. 2011. We believe 
that the availability of more arginine in zcf29/zcf29 leads to a more efficient production of  
macrophage generated RNS and this leads to the zcf29/zcf29 hypo-virulence. Although this 
hypothesis requires further biological validations, our data reinforce the yet poorly 
understood connection between arginine and virulence that have been recently reported by 
others (Jimenez-Lopez et al., 2013). In addition, our RNASeq experiment revealed for the 
first time that Zcf29 plays a critical role in the well-documented ability of the pathogen to 
rechannel energy resources from ribosome biogenesis to ROS detoxification processes upon 
ROS exposure.  
In contrast with what has been shown for ZCF29 deletion, the deletion of ZCF15 caused a 
significantly more modest transcriptional rewiring with only 168 differentially expressed 
genes at T0. This result can potentially be explained by gene redundancy which is defined as 
the existence of several genes in the genome that perform the same or similar functions. In 
particular, while ZCF29 doesn’t have any homologs in C. albicans, ZCF15 has three other 
homologs that can potentially compensate for the lack of this gene in the knockout. This 
hypothesis is further supported by the fact that the deletion of ZCF15 causes 
hypersusceptibility to ROS only while deletion of ZCF29 caused hypersusceptibility not only 
to ROS but also to cell wall stressor and nitrogen starvation mimicking caffeine.  
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Overall, while Zcf29 plays a critical role in N-metabolism, we found that Zcf15 plays a 
critical role for C-metabolism, TCA cycle and energy production. In particular our RNASeq 
experiment showed for the first time that Zcf15 plays a critical role in the well-documented 
ability of the pathogen to downregulate genes involved in C-metabolism and contemporarily 
up regulate key enzymes involved in ROS detoxification processes like thiol peroxidases.  
Taken together, our data suggests that ZCF15 and ZCF29 play an important role in regulating 
two of the most important cellular nutritional requirement: C- and N- metabolism. As 
discussed in paragraph 1.4, during the infection the main nutrient sources for C. albicans are 
likely to be host-derived glucose, proteins, amino acids and lipids whose concentration varies 
dramatically in the different anatomical niches. The ability of C. albicans to rapidly and 
dynamically respond to host changes in micro-environmental nutrient availability contributes 
to its success as a pathogen. Our data suggests that genes involved in these processing are 
miss regulated in zcf15/zcf15 and zcf29/zcf29 and may be the cause of their reduced 
virulence.  
While our RNASeq experiment highlighted genes that are either directly or indirectly 
controlled by Zcf15 and Zcf29, the ChIP-Seq analysis allowed us to find direct DNA binding 
targets. Our analysis revealed that Zcf15 and Zcf29 relocate themselves to different genomic 
loci upon H2O2 exposure. This evidence, on one side reiterates the fact these two TFs play 
key roles in ROS resistance and, on the other, validate our RNASeq data that suggested 
different roles of these two TFs in the presence or absence of H2O2. The ChIP-Seq data 
showed that Zcf29 plays a critical role in the H2O2 dependent upregulation of a glutathione-
independent glyoxalase and of an aldo-keto reductase. Both of these genes have been shown 
to be important for cellular detoxification processes and, to the best of our knowledge, this is 
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the first time that the expression of these two critical H2O2 responsive genes have been shown 
to be directly controlled by Zcf29. 
Overall, our data shed some lights on the genes and biological functions controlled by Zcf15 
and Zcf29, two new virulence determinants that plays a critical role in resistance to reactive 
oxygen species in C. albicans.   
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5 Filastatin, a new antimycotic? 
 
5.1 Introduction and contribution to the paper 
 
In this chapter we described how we used our C. albicans - C. elegans virulence model for 
small molecule screening. Data described in chapter 2 showed that this model can be 
pharmacologically modulated (Figure 2.4 C), hence potentially useful for drug discovery. In 
particular, we showed that the addition of 50 M of fluconazole significantly extended the 
survival of C. albicans infected worms (Figure 2.4). Encouraged by this proof of principle 
experiment, we expanded our study and tested both fluconazole and amphotericin B at 
various concentrations for their abilities to alter the course of infection as measured by extend 
worm’s life spans and reduce Dar. These two drugs are the most commonly prescribed drugs 
against C. albicans infections, but they have very different mechanisms of action. 
Fluconazole reduces cell growth by inhibiting the synthesis of ergosterol (a sterol that 
maintains membrane fluidity) and it is considered fungistatic because it can inhibit growth 
but not cause cell death. On the other side, amphotericin B is fungicidal, because it directly 
binds ergosterol depolarizing the cell membrane causing leakage of intracellular cations and 
ultimately cell death. Fluconazole is more commonly prescribed (can be delivered orally) but 
poses the threat of generating drug resistance; amphotericin B is more potent but it can only 
be administrated intravenously and is associated with high nephrotocity. Here, we show that 
both drugs added to our assays at the optimal concentration can reduce the Dar phenotype 
and increase nematode survival.  
Once we optimized our assay and showed that it responds to commonly prescribed 
antimycotics, we used it to test a series of 26 compounds recently identified in collaboration 
with the Kaufman lab at the University of Massachusetts Medical School (UMMS) for their 
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abilities to inhibit C. albicans adhesion to polystyrene. These 26 compounds were identified 
from a library of 30,000 using a stratified screening method combined with a chemical 
structure analysis. We treated infected C. elegans with each of these 26 compounds and used 
the Dar assay to test for efficacy and toxicity. We found that one of these compounds, named 
filastatin, was very potent in reducing Dar. We rigorously tested filastatin alongside with 
fluconazole and amphotericin B and found that it also alleviate disease and improves 
nematode survival to levels comparable to fluconazole. Our data in nematodes was 
subsequently validated by our collaborators at UMMS and at Louisiana State University, who 
showed that filastatin is also capable of inhibiting binding to human epithelial cells and 
mouse mucosal infection assays. Overall our collaboration with UMMS led to the publication 
of the following paper in the Proceedings of the National Academy of Sciences (PNAS) 
(Fazly et al., 2013). My contribution to the paper is described in the narrative of the paper 
(paragraph titled “Filastatin Exhibits Antifungal Activity in a Nematode Model of Infection”) 
and summarized in Figure 5.  
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Infection by pathogenic fungi, such as Candida albicans, begins with adhesion to host 
cells or implanted medical devices followed by biofilm formation. By high-throughput 
phenotypic screening of small molecules, we identified compounds that inhibit adhesion 
of C. albicans to polystyrene. Our lead candidate compound also inhibits binding of C. 
albicans to cultured human epithelial cells, the yeast-to-hyphal morphological 
transition, induction of the hyphal-specific HWP1 promoter, biofilm formation on 
silicone elastomers, and pathogenesis in a nematode infection model as well as alters 
fungal morphology in a mouse mucosal infection assay. We term this compound 
filastatin based on its strong inhibition of filamentation, and we use chemical genetic 
experiments to show that it acts downstream of multiple signaling pathways. These 
studies show that high-throughput functional assays targeting fungal adhesion can 
provide chemical probes for study of multiple aspects of fungal pathogenesis. 
 
5.3 Introduction 
 
In humans, the most widespread fungal pathogen is Candida albicans, which is also one of 
the most frequent causes of hospital-acquired infections (1, 2). As an opportunistic pathogen, 
C. albicans is responsible for common clinical conditions, including oral thrush and vaginitis, 
but it can also lead to life-threatening systemic infections (candidemia) in 
immunocompromised patients (3), resulting in ~30–50% mortality rates (2). Further-more, 
the estimated annual cost of treating systemic Candida infections exceeds $1 billion per year 
(1, 2). A contributing factor to these statistics is the ability of C. albicans to develop 
resistance to antifungal drugs (4). For these reasons, new strategies for combating fungal 
infections without toxicity to humans are a high medical priority. 
Adhesion to surfaces is the first step in establishing a fungal infection. Candida cells with a 
planktonic yeast morphology initiate adhesion, and a subsequent transition from yeast to 
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hyphal morphology leads to tissue invasion and biofilm formation (5–8). Biofilm formation is 
an important step in pathogenesis, because after biofilms form on intravascular devices and 
catheters, they normally do not respond to conventional treatment and subsequently, can give 
rise to life-threatening systemic infections (9). Therefore, biofilm-associated medical devices 
often have to be surgically replaced (10). 
Here, we report a chemical screen for compounds that prevent adhesion of C. albicans to 
polystyrene surfaces. One of the identified compounds also inhibited adhesion to human 
cells. Further-more, this compound prevented adhesion of other Candida species to 
polystyrene, diminished the C. albicans yeast-to-hyphal transition, impaired biofilm 
formation on silicone elastomers, reduced fungal pathogenesis in a nematode infection 
model, and altered biofilm morphology in a mouse mucosal infection model. Based on its 
strong inhibition of filamentation, we term this compound filastatin, and we show that it 
blocks filamentation induced by some but not all external signals. In sum, our chemical 
screen identified an inhibitor of multiple pathogenesis-related functions that will also be a 
useful probe of morphological mechanisms as well as a lead for the development of unique 
antifungal therapeutics. 
 
5.4 Results 
  
Identifying Small Molecule Inhibitors of C. albicans Adhesion 
To detect small molecules that inhibit C. albicans adhesion, we modified a previous protocol 
for measuring adhesion of Saccharomyces cerevisiae to polystyrene (11). We observed that 
C. albicans cells bind strongly to 96-well polystyrene plates that have been optimized for 
protein binding (Methods), and we used this robustly bound substrate to set a high threshold 
for inhibitors of adhesion. Bound cells were stained with crystal violet followed by washing 
to remove unbound dye and cells. Cells that remained bound after washing were then 
quantified by measuring dye absorbance. Wells that displayed low A590 values were 
confirmed visually (Fig. 1A). 
We screened a library of 30,000 small molecules for com-pounds that inhibit adhesion of WT 
clinical isolate C. albicans strain SC5314 (12). All compounds were dissolved in DMSO, and 
therefore, we used SC5314 cells exposed only to DMSO as a negative control (Fig. 1A, 
column 12). As a positive control for poor adhesion, we used a C. albicans edt1
−/−
 strain (13) 
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that lacks a cell wall adhesion protein (Fig. 1A, column 1). We ranked the normalized scores 
for each compound (Methods). Of 30,000 compounds, 40 (1.3%) compounds inhibited 
adhesion by >75%, and many of these compounds fell into two scaffold families [1-benzoyl-
4-phenylpiperazines (termed Scaffold 1) and N-phenylbenzamides (termed Scaffold 2)] 
(Table S1). Omitting compounds within this list that were very similar, we reordered 26 of 
the candidate compounds (termed 1–26) (Table S1) for subsequent characterization. 
We prioritized the candidate compounds by testing the dose dependence of their effects. 
Because of the laborious washing required to remove background crystal violet staining, we 
used an alternative detection reagent, the vital dye alamarBlue. We found that, after two 
rounds of washing, alamarBlue robustly detected the adhesion differences between the WT 
SC5314 and edt1
−/−
 mutant cells (Fig. 1C and Fig. S1 A). The majority of the reordered 
compounds were effective at reducing Candida ad-hesion at 50 μM, which is the 
concentration originally tested during the screen (Methods). However, on reducing the con-
centration to 25 μM, some of these compounds were substantially less effective (Fig. 1B). 
However, many candidates were able to inhibit adhesion by >50%, even at concentrations as 
low as 7.5 μM (Fig. 1C). 
Because alamarBlue measures the metabolic activity of live cells, we confirmed these data 
with an assay that directly detec-ted cells, regardless of viability or metabolism, by measuring 
adhesion using a C. albicans strain encoding GFP (13). Both fluorescence measurements and 
microscopy (Fig. 1 D and E) of the GFP-expressing strain confirmed that all of the 
compounds effective in the alamarBlue based assay impair C. albicans adhesion to 
polystyrene. We conclude that our chemical screen detected compounds that block adhesion 
and yielded consistent results, regardless of the detection method. 
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Fig. 1. Chemical inhibition of C. albicans adhesion to polystyrene. (A) Crystal violet-stained 
plate from small molecule screen. WT C. albicans strain SC5314 or adhesion-defective 
edt1
−/−
 cells were plated in the presence of 1% DMSO vehicle or small molecules at 50 μM 
followed by extensive washing to remove unbound cells. Cells that remained were then 
stained with crystal violet and quantified by A590. (B) alamarBlue-based polystyrene adhesion 
assay. Using the vital dye alamarBlue as the detection reagent, 26 primary candidates from 
the screen were retested at 25 μM alongside a DMSO control. The mean and SD of data from 
eight wells are shown. (C) The same as in B but with com-pounds at 7.5 μM. The mean and 
SD of data from eight wells are shown. (D) GFP-based adhesion as-say. C. albicans strains 
expressing GFP (SC5314-GFP and edt1
−/−
-GFP) or untagged SC5314 were mixed with 
compounds at 25 μM or DMSO and bound to polystyrene plates. Unbound cells were 
removed by washing. GFP fluorescence was measured, and background fluorescence of wells 
containing un-tagged SC5314 was subtracted from signals. Mean and SD For eight wells are 
shown. (E) Wells from the experiment in D were photographed using a 20× objective and 
FITC filters. 
 
In addition to experiments with inert surfaces, we also tested how the candidate compounds 
would affect C. albicans adherence to human cells by measuring binding of GFP-encoding C. 
albicans cells to monolayers of human lung epithelial A549 cells, which are an effective 
substrate for Candida adhesion (14). We tested each of the reordered compounds and 
observed that compound 4 was, by far, the strongest inhibitor of adhesion to human epithelial 
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cells, which was shown by both fluorescence quantitation (Fig. 2A) and microscopy (Fig. 
2B). We, therefore, prioritized study of this compound (Fig. 2F), which we termed filastatin 
based on its inhibition of C. albicans filamentation as described below. We showed that 
filastatin does not affect the viability of human A549 cells, even at concentrations much 
larger than those concentrations used in the adhesion assay (e.g., 250M) (Fig.2C). We 
conclude that filastatin is not toxic to this human cell line under our assay concentrations, but 
it is unique among our candidates in that it can impair fungal adhesion to both inert surfaces 
and cultured human epithelial cells.  
We next tested whether filastatin could affect adhesion after cells had already bound 
polystyrene, because this activity could prove useful in a clinical setting. We compared cells 
continuously incubated with filastatin for 8 h with cells adhered for 4 h (as in our previous 
assays) (Fig. 1B) followed by 4 h in the presence of filastatin. We observed that filastatin did, 
indeed, reduce the amount of bound cells when added after adhesion, although not as 
efficiently as when the compound and cells are coincubated from the start of the experiment 
(Fig. 2D). We conclude that filastatin does display some activity against adhered cells, 
consistent with potential use against pathogen biofilms. 
To test the applicability of filastatin to other fungal pathogens, we examined adhesion by 
additional pathogenic Candida species (15). Specifically, we observed that filastatin inhibited 
polystyrene adhesion by C. dubliniensis and C. tropicalis and to a lesser extent, C. 
parapsilosis (Fig. 2E). Filastatin, therefore, inhibits adhesion by multiple pathogenic Candida 
species. Additionally, filastatin (molecular weight = 360 g/mol) has an IC50 ∼ 3 μM in the 
GFP-based adhesion assay (Fig. S1 B), equivalent to a concentration of ∼1.1 μg/ml. This 
value is similar to or less than the effective concentrations of existing antifungal compounds 
(16). 
Additionally, data in  Figs. S2,  S3, and  S4 compare the activities of filastatin with other 
compounds from this study and prior studies (17). Of all these studies, only filastatin 
inhibited C. albicans adhesion to human cell monolayers, and therefore, we focused 
additional studies on this molecule. 
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Filastatin Inhibits C. albicans Biofilm Formation  
Fungal biofilm formation on implanted medical devices is a serious medical problem, 
because these biofilms can lead to life-threatening systemic infections (18). An established in 
vitro assay to study device colonization measures biofilm formation on surgical silicone 
elastomers (19). In the presence of DMSO vehicle, we confirmed that WT C. albicans cells 
efficiently formed biofilms on silicone elastomers; in contrast, edt1
−/−
 mutant cells did not, 
resulting in the majority of the cells dispersing throughout the media rather than adhering to 
the elastomer surface (Fig. 3A). Visual inspection showed that filastatin, but not compounds 
6 or 9, effectively kept the cells dispersed in the media rather than on the elastomer surface 
(Fig. 3A). Measurements of the media turbidity and biofilm dry weight (Fig. S5) confirmed 
these assessments. Additionally, we observed that compounds 27, Q1, and Q2 also inhibited 
biofilm formation in this assay (Fig. S5). Therefore, filastatin has multiple activities, with 
inhibition of human cell adhesion unique among our candidate compounds (Tables S1 and  
S2). 
 
Filastatin Inhibits Hyphal Morphogenesis and Colony Morphology 
 
Visual inspection of cells remaining at the end of adhesion assays suggested that some of the 
candidate compounds inhibit generation of hyphae. Because the ability to interconvert 
between yeast and hyphal morphologies is usually correlated with pathogenicity (5, 7, 8), we 
explored this finding in more detail, examining induction of hyphae on carbon starvation 
(Spider media) (20). We used a strain that contains the Red Fluorescent Protein ORF driven 
by the hyphal-specific HWP1 promoter (21), which provides a molecular reporter for hyphae 
formation in addition to cell morphology. We observed that filastatin as well as a subset of 
the other compounds (Fig. S6 A and Table S1) blocked formation of hyphae. Together, our 
data indicate that the related compound pairs (filastatin/27 and Q1/Q2) were effective 
inhibitors of both hyphal morphogenesis and biofilm formation on silicone elastomers (Fig. 
3A and Figs. S5 and S6). Therefore, the shared backbone of these compounds correlates with 
inhibition of multiple activities (summarized in Table S2). On titration, we observed that 
filastatin is effective at inhibiting hyphae formation at concentrations > 2.5 μM (Fig. S6 B), 
similar to the results observed in the polystyrene adhesion assay (Fig. S1). Using this protein 
reporter assay, the effect of filastatin could be detected within 2 h of Spider media addition 
(Fig. S6 C). 
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Fig. 2. Filastatin is a nontoxic inhibitor of adhesion to human cells, and it affects multiple 
Candida species. (A) Adhesion to A549 cells. Human A549 cells were grown to confluence 
on 48-well plates. SC5314-GFP, edt1
−/−
-GFP, or untagged SC5314 were added to triplicate 
wells and incubated at 37 °C for 90 min with 1% DMSO or 25 μM indicated compounds in 
1% DMSO. Wells were washed extensively to remove unbound fungi, and GFP fluorescence 
was measured on a plate reader. Mean and SD for three wells are shown. (B) Representative 
differential interference contrast (DIC) and cor-responding GFP fluorescence images from 
the experiment in A. (C) Human cell toxicity. A549 cells were coincubated with 1% DMSO, 
250, 100, or 50 μM filastatin, or 1% NaN3 for 24 h, and cell viability was then measured 
using alamarBlue. Mean and SD for three wells are shown. (D) Reversal of adhesion. WT C. 
albicans SC5314 cells were seeded onto 96-well plates. One-half the samples were incubated 
continuously in the presence of 1% DMSO or 50 μM filastatin as indicated for 8 h at 37 °C 
(left black bar). One-half of the samples were allowed to adhere for 4 h in the absence of 
compounds, and then, 1% DMSO or 50 μM filastatin was added followed by additional 
incubation for 4 h at 37 °C (reversal; left striped bar). After incubations, plates were washed 
two times, and bound cells were detected with alamarBlue. Means and SDs (n = 5 
independent experiments, 24 wells measured for each) with P value comparisons are shown 
(unpaired two-tailed t test). (E) Other Candida species. Adhesion assays are the same as in 
Fig. 1B, with 25 μM filastatin tested for C. dubliniensis and C. tropicalis and 50 μM filastatin 
tested for C. parapsilosis. Mean and SD for 16 wells are shown. (F) Structure of filastatin. 
 
 
Also, because filastatin blocked filamentation, even after 16 h of incubation (Fig. S6 A), it 
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seemed unlikely that this inhibitory function relied on a reduced growth rate. Although 
filastatin did modestly reduce growth rates of yeast-form cells in rich media (Fig. S7 A), this 
effect was less pronounced during hyphal in-duction, where we assessed growth by both OD 
and metabolic activity (Fig. S7  B and  C). Furthermore, filastatin maintained the yeast 
morphology of cells throughout an 8-h time course ( Fig. S7 D). We conclude that filastatin is 
a long lasting inhibitor of C. albicans filamentation. 
Hyphal morphogenesis is induced by multiple stimuli that act through multiple signal 
transduction pathways (5, 22, 23) (Fig. 4E) and mediated by a complex transcriptional 
network (8, 24). In addition to nutrient-poor Spider media, mammalian serum also induces 
hyphae (25, 26), and we observed that filastatin inhibited the response to both these stimuli 
(Fig. 3B). We detected morphological difference between control and filastatin-treated 
cultures as early as 60 min in 10% (vol/vol) serum and 90 min in Spider media. Additionally, 
a wrinkled colony morphology is displayed by C. albicans when grown on solid Spider 
media, reflecting transitions between hyphal and yeast forms (5, 27). Notably, this wrinkled 
phenotype was also abolished by filastatin (Fig. 3B). Together, our data indicate that filastatin 
inhibits hyphal morphogenesis and colony morphology phenotypes that depend on the hyphal 
transition. 
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Fig. 3. Filastatin inhibits C. albicans biofilm formation and hyphal mor-phogenesis. (A) 
Biofilm formation on silicone elastomers. Biofilms formed by SC5314-GFP (or edt1
−/−
-GFP 
where indicated) cells were photographed after 60 h. Indicated compounds were added at 50 
μM. Turbid media indicate planktonic cells unattached to silicone elastomers when biofilm 
formation is inhibited. Clear media is observed when robust biofilm formed. Repre-sentatives 
of triplicate wells are shown. Additional biofilm data are in  Fig.  S5. (B) Hyphal 
morphogenesis. SC5314 cells were diluted into Spider media or Supplemented YNB + 10% 
bovine serum with DMSO or 50 μM filastatin as indicated, grown at 37 °C for the indicated 
times, and photographed. Ad-ditional hyphal development experiments are in  Fig. S6. (C) 
Colony mor-phology. SC5314 cells were spotted onto solid Spider media agar plates overlaid 
with either 1% DMSO or 50 μM filastatin and incubated at 37 °C for 2 d before photography. 
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Filastatin Inhibits Induction of Hyphal Morphogenesis by Multiple but Not All 
Signaling Pathways 
To explore the mechanism of filastatin action, we tested whether it would alter hyphal 
induction in hyperfilamentous mutants. For example, hyphal induction by Spider media 
requires the cAMP-PKA pathway (23, 26) (Fig. 4E). Cells constitutively overexpressing the 
G protein-coupled receptor Gpr1 become hyperfilamentous on solid Spider media by PKA 
stimulation (26, 28), and we observed that filastatin blocked hyphal morphogenesis in these 
cells (Fig. 4A). Stimulation of the PKA pathway also drives phosphorylation of transcription 
factor Efg1, activating Efg1 to increase expression of genes required for hyphal 
morphogenesis. We confirmed that cells with a hyperactive Ras1 signaling protein (ras1-
G13V) (29), an overexpressed, constitutively active G-α subunit that acts up-stream of Efg1 
(gpa2-Q355L) (28), or a constitutively expressed Efg1 transcription factor with a 
phosphomimetic mutation that simulates constitutive PKA signaling (PCKpr-efg1-T206E) 
(30), indeed, were all hyperfilamentous compared with WT cells in Spider media (Fig. 4B). 
However, in the presence of filastatin, cells from all these mutant strains retained a 
planktonic, budded morphology (Fig. 4A). Together, these data suggest that filastatin acts 
downstream of transcription factor Efg1 (Fig. 4E). 
However, other experiments suggested that filastatin affects more than one signaling 
pathway. For example, the modified sugar GlcNac also stimulates hyphal morphogenesis but 
does so independently of the cAMP-PKA pathway; instead, it activates the transcription 
factor Cph1 (26). On testing morphogenesis driven by GlcNac-containing media or 
constitutive overexpression of Cph1, we found that filastatin also inhibits formation of 
hyphae in these cases (Fig. 4C). These data indicated that filastatin may affect multiple 
signaling pathways or could act by destroying the ability of the cell to form elongated 
structures, regardless of the inducing signal. 
In addition to nutrient-mediated signals, genotoxic stress promotes hyphal morphogenesis in 
C. albicans, and the DNA damage signaling kinase Rad53 is required for the hyphal 
transition (31). In contrast to the above studies, cells treated with the DNA replication 
inhibitor hydroxyurea (HU) form hyphae, regardless of the presence of filastatin (Fig. 4D). 
Together, these data suggest that filastatin is not incompatible with hyphal morphogenesis per 
se but blocks multiple signaling mechanisms that promote it (Fig. 4E). 
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Fig. 4. Filastatin inhibits hyphal development induced by some but not all external signals. 
(A) Filastatin inhibits the hyperfilamentous growth of a strain that constitutively 
overexpresses Gpr1. Colonies were grown on solid Spider media agar overlaid with either 1% 
DMSO or 50 μM filastatin and incubated at 37 °C for 3 d. (B) Effects of filastatin on strains 
hyperactivating the cAMP-PKA pathway. Cells of the indicated genotypes were grown in the 
presence of 1% DMSO or 50 μM filastatin in Spider medium at 37 °C for 4 h, stained with 
Calcofluor, and photographed using DIC and fluorescence microscopy. (C) Filastatin blocks 
filamentation induced by GlcNAc or constitutive overexpression of the GlcNac-activated 
transcription factor Cph1. (D) Filastatin does not block genotoxic stress-induced 
filamentation. SC5314 cells were grown in yeast extract-peptone-dextrose (YPD)-rich media 
+ 50 μM HU at 30 °C. (E) Schematic diagram of some of the signaling pathways that govern 
hyphal morphogenesis (22, 26). For simplicity, only those genes investigated are shown. 
Filastatin is shown blocking hyphal development induced by Spider media and GlcNac but 
not genotoxic stress. 
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Filastatin Exhibits Antifungal Activity in a Nematode Model of Infection 
In addition to our in vitro assays, we tested whether filastatin affects fungal infections in 
vivo. We used the previously described deformed anal region (Dar) tail-swelling phenotype 
(16, 32) as a biomarker to monitor fungal infections in nematode hosts. A small quantity of 
C. albicans was introduced with the nematode’s standard diet of Escherichia coli OP50 cells, 
and E. coli growth was attenuated with the antibiotic streptomycin to avoid interactions with 
C. albicans (33). Here, we used a dose of C. albicans that caused all untreated worms to 
display Dar dis-ease (Fig. 5A). In contrast, ∼30% of worms treated with either 12.5 μM 
filastatin or fluconazole during this experiment maintained a healthy phenotype and did not 
display Dar disease. Worms treated with the same concentration of amphotericin B displayed 
an even larger decrease in Dar disease, perhaps due to amphotericin B being a fungicidal 
drug, while fluconazole is fungistatic (34). In any case, these data indicate that filastatin can 
ameliorate a fungal pathogenesis phenotype in vivo. 
We next tested whether filastatin protects Caenorhabditis elegans against killing by C. 
albicans. C. elegans was exposed to C. albicans in the presence of DMSO, fluconazole, or 
filastatin. The C. albicans infections greatly shortened the lifespan of the C. elegans hosts 
compared with uninfected controls (Fig. 5B). We observed that both fluconazole and 
filastatin increased the lifespan of the infected worms (Fig. 5 B and C), indicating that both 
these compounds are protective during infection of a live animal. In-creased lifespan in the 
presence of filastatin was statistically sig-nificant as confirmed by Kaplan–Meier statistical 
analysis (P value < 0.012 or less for all three experiments). Therefore, consistent with its in 
vitro activities, filastatin functions as an antifungal agent in this model infection system. 
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Fig. 5. Effects on metazoan hosts. (A) Nematodes were either cultured without C. albicans 
(Uninfected) or with WT C. albicans SC5314 cells with or without 12.5 μM indicated 
compounds. Dar disease rates were compared for worms treated with filastatin and untreated 
worms (P = 2.9 × 10
−3
). Infected worms were treated with antifungal agents fluconazole (P = 
2.6 × 10
−4
) and amphotericin B (P = 2.9 × 10
−3
) as positive controls. Experiments were done 
in triplicate, with 14–28 animals in each biological replicate sample, with 63–81 total animals 
for each experimental condition. Student t test (one tail, equal variance) was used to calculate 
P values. (B) Lifespan of C. elegans exposed to C. albicans treated with DMSO, 12.5 μM 
fluconazole (two experiments, plotted separately), or 50 μM fluconazole; n = 60 individuals 
for each experiment. All fluconazole-treated populations were significantly different from the 
DMSO control, with P values for each <0.0001 by the Mantel–Cox test. Lifespan of 
uninfected C. elegans is plotted on the same graph. (C) As in B, except worms were treated 
with filastatin at 12.5 (two experiments, plotted separately) or 50 μM. All filastatin-treated 
populations were significantly different from the DMSO control, with P < 0.012 for 12.5 μM 
experiment 1, P < 0.0001 for 12.5 μM experiment 2, and P < 0.0002 for the 50 μM 
experiment. (D) Microscopic analysis of ex vivo vaginal mucosal biofilm formation. Tissues 
were processed for scanning EM. (Magnification: 1,000×.) These representative images show 
areas of biofilm growth from two independent repeats (n = 6 vaginal explants per 
experiment). 
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Filastatin Alters Biofilm Morphology in a Mouse Model of Vulvovaginal Candidiasis 
As an initial test of filastatin in a mammalian infection model, we examined a mouse model 
of vulvovaginal candidiasis (VVC). This system is ideal for evaluating our compounds, be-
cause VVC infections depend on fungal morphogenesis and biofilm formation (35). This 
assay is medically important, because VVC affects 75% of all women at least once in their 
lifetimes, and because C. albicans is responsible for 85–95% of these infections (36). 
In this assay, excised murine vaginal mucosal tissue is tested as a substrate for infection by 
Candida cells. This protocol provides a rapid and simple method for optimizing treatment 
conditions before in vivo infection assays, although it does not measure adhesion to the 
tissue, because the tissue is not washed before processing for microscopy. One readout in this 
assay is a mea-sure of the number of viable fungal cells expressed as cfu. We did not observe 
significant differences between the cfu re-covered from untreated and filastatin-treated 
samples, al-though because unadhered cells were not washed away, direct comparison with 
the in vitro adhesion assays cannot be made. Also, in the presence of filastatin, the Candida 
cells still formed a carbohydrate-rich ECM, which was detected by Con A staining and 
confocal microscopy (Fig. S8). However, filastatin modulated the morphology of the C. 
albicans biofilm during ex vivo VVC, which was revealed by scanning EM (Fig. 5D), with a 
predominance of individual yeast-form cells appearing. Therefore, filastatin restrained 
formation of hyphae in this infection model, consistent with its hyphal inhibition activity in 
vitro (Figs. 3 and 4). Future experiments will be required to determine how filastatin affects 
ultrastructural aspects of biofilm formation and how it may affect adhesion during biofilm 
formation on mammalian cells. 
 
5.5 Discussion  
 
In recent years, the rate at which new drugs are brought to market has slowed (37). 
Traditional drug discovery methods have often relied on rational drug design, where agents 
that inhibit a particular protein are selected. However, this approach is time-consuming and 
can miss important but unanticipated tar-gets. Here, we describe an alternate function-based 
approach that relies on phenotypic screening without bias to a particular target. To our 
knowledge, there has not, to date, been a published screen that directly targets fungal 
adhesion. By targeting adhesion, our screen required removal of unbound cells. Al-though 
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laborious in a high-throughput setting, this extra effort allowed us to detect a class of 
compounds that has unique properties. Importantly, because our assays involve intact cells, 
we avoided the complication of compounds unable to cross the cell wall and/or membranes. 
Here, we report discovery of filastatin, which displays multiple activities related to fungal 
pathogenesis. Filastatin inhibits fungal adhesion to polystyrene and human cells (Figs. 1 and 
2), hyphal morphogenesis and colony morphology (Figs. 3 and 4), biofilm formation (Fig. 3), 
pathogenesis in a worm infection model (Fig. 5C), and biofilm morphology on mouse tissue 
explants (Fig. 5D). Notably, inhibition of hyphal morphogenesis occurs in liquid culture in 
the absence of adhesion, suggesting that filastatin affects multiple cellular processes. The 
effects on morphology were not selected in our primary screen, showing the need for 
multiple assays to characterize our candidate compounds fully. 
We find that small changes in the compounds can lead to different combinations of activities. 
This observation was most pronounced in the comparison of filastatin with compound 27, 
which differ by the substitution of a methyl group for a chlorine substitution on one aryl ring 
(Fig. S3 and Table S1). Filastatin, but not compound 27, effectively inhibited human cell 
binding, but these two compounds shared the ability to inhibit polystyrene binding, hyphae 
formation, and biofilm formation (Table S1). As another example, the quinoline ring-
containing compounds Q1 and Q2 do not inhibit polystyrene binding or human cell binding, 
but they do inhibit hyphae formation and biofilm formation. Conversely, filastatin is not 
synergistically toxic to fluconazole-resistant cells like Q1 and Q2 (Fig. S4). More systematic 
structure– activity relationship studies are underway to better understand the complex 
pharmacophore of filastatin and explore its molecular target(s). We note that the multiple 
activities of filastatin leave open the possibility that multiple targets exist. 
Several previous experiments suggest a strong link between hyphal morphogenesis and 
fungal pathogenesis, including tissue-associated biofilm formation. For example, experiments 
with a doxycycline-inducible transcription factor (NRG1) that governs hyphae formation 
have shown that the ability to form hyphae is continually required for the lethality associated 
with systemic candidaisis (6). Likewise, many mutants defective in hyphae formation are 
nonpathogenic (7) and poor at biofilm formation, although this correlation is not absolute 
(38). 
Our data show that filastatin blocks the transcriptional in-duction of the HWP1 promoter 
(Fig. S6), which is an early and essential event in the process of hyphal development (23). 
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No-tably, filastatin blocks hyphal formation induced by serum, Spi-der media, and GlcNac 
but not the genotoxic stress agent HU (Fig. 4). These data indicate that the structural 
machinery re-quired for cell elongation and hyphae formation is able to function in the 
presence of the compound. Therefore, our screen has provided a powerful chemical probe of 
the signaling mech-anisms that govern hyphal formation. Biochemical and molecu-lar 
genetics experiments are underway to better understand how filastatin affects hyphal 
development and fungal adhesion. 
 
5.6 Methods  
 
During the screen for small molecule adhesion inhibitors, one 5-mL culture of SC5314 cells 
and two 5-mL cultures of edt1
−/−
 cells were inoculated with single colonies in yeast nitrogen 
broth without amino acids supplemented with 30 μg/mL L-leucine, 20 μg/mL L-histidine, 20 
μg/mL L-tryptophan, and 25 μg/mL uridine (Supplemented YNB) + 0.15% glucose media 
and grown overnight with shaking at 200 rpm at 30 °C. The next day, these starter cultures 
were used to inoculate 100-mL cultures for each strain grown under the same conditions. One 
day later, OD at 600 nm was measured for both cultures. Cells were pelleted at 3,000 × g and 
resuspended in fresh Supplemented YNB + 0.15% glucose media to a final concentration of 
0.5 OD/mL; 200 μL/well 0.5 OD/mL edt1−/− cells were added to the first column of each 96-
well Immulon 2HB flat-bottom microtiter plate (Part No. 3455; Thermo Scientific), and 200 
μL/well 0.5 OD/mL SC5314 cells were added to the remaining columns. Cell plating was 
followed by robotic addition of 2 μL DMSO vehicle to columns 1 and 12; compounds from 
the University of Massachusetts Medical School Small Molecule Facility DIVERset Library 
(Chembridge) at a stock concentration of 5 mM were added to columns 2–11 (Fig. 1A). The 
wells were mixed by robotic pipetting three times, yielding a final compound concentration 
of 50 μM. The plates were covered with foil and incubated at 37 °C for 4 h. The contents of 
the wells were then decanted, and 50 μL 0.5% crystal violet (Sigma) in water were added to 
each well. The plates were covered again and incubated at room temperature for 45 min. The 
dye was removed by decanting, and the plates were gently rinsed by 10 rounds of submersion 
in an ice bucket filled with distilled water followed by decanting the water. The water in the 
bucket was changed after the fifth wash. The plates were then gently inverted onto a paper 
towel to remove excess water; 200 μL 75% methanol were then added to each well. The 
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plates were incubated for 30 min at room temperature, and then, absorbance at 590 nm was 
measured. 
Additional methods are in SI Methods. 
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6 Studying evolution of drug resistance in C. albicans clinical 
isolates  
 
6.1 Introduction and contribution to the paper 
 
In this chapter we described how we used our nematode virulence model together with other 
phenotypic analyses as part of a large-scale collaborative study to explore the evolution of C. 
albicans drug resistance. 43 C. albicans clinical isolates from 11 HIV patients were obtained 
and extensively characterized both genotypically (Broad Institute and University of 
Minnesota) and phenotypically (WPI and Broad Institute). These isolates were obtained 
before and after fluconazole was prescribed as a therapy and some patients were sampled 
multiple times post fluconazole prescription. These samples represent powerful time series to 
study the progressive evolution of C. albicans drug resistance in humans.    
The overall goal of the study was to identify genomic changes that alter C. albicans drug 
resistance and other phenotypes associated with virulence. We determined the ability of each 
of these strains to form biofilms by testing adhesion to polystyrene, to transition from yeast-
to-hyphae and to infect and kill nematodes. These three phenotype are highly linked to 
virulence as the ability to form biofilm on medical devices, to transition from yeast-to-hyphae 
and to kill nematodes have been all connected to mammalian virulence (Chandra et al., 2001; 
Jain et al., 2013b; Lu et al., 2011). On the other hand, genomic analysis included genome 
deep sequencing to study the occurrence of single-nucleotide polymorphisms (SNPs), copy 
number variations (CNV) and loss of heterozygosity (LOH) events.  
The study shows that LOH events were recurrent and tracked with increased in drug 
resistance while aneuploidies were transient and didn’t correlate with fluconazole resistance. 
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The study also identified 240 genes that accumulate persistent SNPs that recur between 
patients, suggesting that these genes might play a primary role in the complex process of host 
adaptation and fluconazole exposure. Although we found substantial variations in many of 
the phenotypes observed between isolates, we found that (a) C. albicans in vitro fitness is 
anti-correlated with phenotypic markers of virulence (b) a progressive increase in drug 
resistance in vitro is mirrored by a progressively increased virulence. Overall our combined 
data supports the notion that the process of C. albicans adaptation to the host during 
antimycotic therapy is complex and multifactorial and that its ability to adapt to the human 
environment relies on the C. albicans remarkable genotypic and phenotypic plasticity.  
Our contribution to the paper is described in the narrative of the paper (paragraph titled 
“Changes in virulence phenotypes in evolved drug-resistant isolates”) and summarized in 
Figure 6. The paper has been submitted to the journal eLIFE and is in the process of 
resubmission after many of the reviewers comments has been addressed. The paper reported 
below represented the most recent version (August 8
th
 2014).  
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6.3 Introduction 
 
Virtually all humans are colonized with Candida albicans, but in some individuals this 
benign commensal organism becomes a serious, life-threatening pathogen. C. albicans 
possesses an arsenal of traits that promote its pathogenicity, including phenotypic switching 
(Alby and Bennett, 2009), yeast-hyphae transition (Kumamoto and Vinces, 2005) and the 
secretion of molecules that promote adhesion to abiotic surfaces (Chandra et al., 2001). As a 
commensal, an intricate balance is maintained between the ability of C. albicans to invade 
host tissues and the host defense mechanisms (Kim and Sudbery, 2011; Kumamoto and 
Pierce, 2011). Alteration of this delicate host-fungus balance can result in high levels of 
patient mortality (Charles et al., 2003; Pittet et al., 1994): systemic C. albicans infections are 
fatal in 42% of cases (Wisplinghoff et al., 2003), despite the use of antifungal therapies, and 
C. albicans is the fourth most common infection in hospitals (Gudlaugsson et al., 2003b; 
Pappas et al., 2003). While compromised immune function contributes to pathogenesis 
(Berman and Sudbery, 2002), it is less clear how C. albicans evolves to better exploit the host 
environment during the course of infection.  
Two classes of antifungals in clinical use target ergosterol, a major component of the fungal 
cell membrane: polyenes and azoles. Polyenes (e.g., Amphotericin B) can cause high levels 
of morbidity when used at fungicidal levels and thus are used sparingly (Rex et al., 1994), 
whereas azoles (e.g., fluconazole) are used widely because they can be administered orally, 
and have few side effects (Rex et al., 2003). However, resistance to the azoles arises within 
the commensal population of the treated individual, primarily because azoles are fungistatic 
(inhibit growth but do not kill) (Cowen et al., 2002). Indeed, epidemiological data suggest 
that the intensity of fluconazole use is driving the appearance of resistant isolates (Pfaller et 
al., 1998). Studies of clinical isolates C. albicans suggest drug-resistance increases during an 
infection through the acquisition of aneuploidies (Selmecki et al., 2009) suggesting genomic 
plasticity and rapid evolutionary selection during infection. 
Previous studies have identified two main classes of azole resistance in C. albicans. First, 
increased activity or level of the enzymes of the ergosterol pathway (e.g., ERG11) (Asai et 
al., 1999; Oliver et al., 2007) reduces the direct effect on the drug target. Second, increased 
efflux of the drug from cells by ABC transporters (encoded by CDR1 and CDR2) (Coste et 
al., 2006) or by the major facilitator superfamily efflux pump (encoded by MDR1) (Dunkel et 
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al., 2008) reduces the effective intracellular drug concentration. In both cases, such 
alterations can result from point mutations in genes encoding the proteins (Marichal et al., 
1999), in transcription factors that regulate them (Coste et al., 2006; Dunkel et al., 2008; 
MacPherson et al., 2005), or from increased copy number of the relevant genes, via genome 
rearrangements such as whole chromosome and segmental aneuploidies (Selmecki et al., 
2006; Selmecki et al., 2008; Selmecki et al., 2009). Indeed, the genomes of drug resistant 
strains isolated following clinical treatment often exhibit large-scale changes, such as loss of 
heterozygosity (LOH)(Coste et al., 2006; Dunkel and Morschhauser, 2011), copy number 
variation (CNV), including short segmental CNV, and whole chromosome aneuploidy 
(Selmecki et al., 2010b) accompanied by point mutations.  
While we understand some aspects of the molecular basis of resistance, we understand less 
about the dynamic mechanisms that drive the evolution of drug resistance and overall 
pathogenicity in C. albicans. The diploid genome and lack of a complete sexual cycle have 
complicated efforts to use forward genetic approaches. An alternative approach is to use 
isolates sampled consecutively from the same patient to study the in vivo evolution of drug 
resistance and pathogenicity. Studies in evolved isolates have implicated multiple 
mechanisms in drug resistance, but have focused on large-scale aberrations (Selmecki et al., 
2008; Selmecki et al., 2009) or candidate genes (Perea et al., 2001a; White et al., 2002), and 
do not comprehensively chart the genetic basis of adaptation.  
Here, we used genome sequencing of isolates sampled consecutively from patients that were 
clinically treated with fluconazole to systematically analyze the genetic dynamics that 
accompany the appearance of drug resistance during oral candidiasis in human HIV patients. 
Most isolates from each individual patient were highly related, suggesting a clonal population 
structure and facilitating the identification of variation. As each clinical sample was colony 
purified, we cannot assess the population structure at any single time point; therefore, we 
focus on the occurrence of single-nucleotide polymorphisms (SNPs), CNV and LOH events 
in each isolate. Consistent with previous studies, we found that LOH events were recurrent 
and associated with increased drug resistance. To identify SNPs with likely functional impact 
in the context of substantial genetic diversity, we focused on those that were both persistent 
within a patient and recurrent across multiple patients. We found 240 genes that recurrently 
contain persistent SNPs, many of which may be related to the complex process of adaptation 
to the host and antifungal exposure. In contrast, aneuploidies were prevalent in the isolates, 
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yet they were more likely to be transient, and aneuploidy, per se, did not correlate with 
changes in drug resistance. Taken together, our study suggests new molecular mechanisms of 
emergent drug resistance and virulence in C. albicans, and provides a general model for such 
studies in other eukaryotic pathogens. 
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6.4 Results 
 
Whole genome sequencing of 43 serial clinical isolates from 11 patients  
To study the in vivo evolution of azole resistance in C. albicans, we analyzed 43 longitudinal 
isolates from 11 HIV-infected patients with oropharyngeal candidiasis (Perea et al., 2001a; 
White, 1997b) (Table 1).  
 
Table 1 C. albicans clinical isolates used in this study 
The isolates were collected during incidences of infection and form a time series from each 
patient (2-16 isolates per series; Figure 1, Figure 2A). Each isolate was derived from a 
single colony and thus represents a single diploid genotype sampled from the within-host C. 
albicans population at the respective time point. In each series, the first isolate (‘progenitor’) 
was collected prior to any treatment with azole antifungals and the remaining isolates were 
Publication 
Name Patient Strain Entry Date Drug Treatment
Dose 
(mg/day)
E-test MIC 
(ug/mL)
Depth of
Coverage Reads
Percent 
Aligned
White, T.C. 1 1 9/10/1990 Fluconazole 100 0.25 111.9610 9,896,468 87.17%
2 12/14/1990 Fluconazole 100 1 69.2023 12,797,328 87.43%
3 12/21/1990 Fluconazole 100 4 92.0415 16,987,814 86.87%
4 12/31/1990 Fluconazole 100 3 80.6876 14,858,710 87.81%
5 2/8/1991 Fluconazole 100 4 110.7990 20,484,584 86.75%
6 2/22/1991 Fluconazole 100 4 101.9360 18,837,954 86.63%
7 3/25/1991 Fluconazole 100 4 81.6485 15,123,020 86.66%
8 4/8/1991 Fluconazole 100 4 112.5280 20,778,562 86.64%
9 6/4/1991 Fluconazole 100 4 113.1840 22,223,228 83.20%
11 7/15/1991 Fluconazole 100 4 53.2780 9,896,468 87.17%
12 11/26/1991 Fluconazole 200 4 96.1041 18,282,472 85.54%
13 12/13/1991 Fluconazole 400 32 123.6710 22,070,518 89.13%
14 1/28/1992 Fluconazole 400 24 98.6643 18,114,916 87.41%
15 2/21/1992 Clotriminazole 50 24 120.9000 22,401,374 86.57%
16 4/1/1992 Fluconazole 400 96 87.4437 16,061,560 87.17%
17 8/25/1992 Fluconazole 800 96 97.8316 18,317,118 85.91%
Perea, S. et al. 7 412 2/15/1995 Fluconazole 0 0.25 93.1525 17,417,588 86.69%
2307 11/22/1995 Fluconazole 400 0.75 95.7885 18,014,242 85.25%
Perea, S. et al. 9 1002 4/20/1995 Fluconazole 100 0.125 188.4890 34,834,970 86.74%
2823 4/6/1996 Fluconazole 800 282.6230 52,839,288 86.30%
3795 2/26/1997 Fluconazole 800 128 77.6274 13,901,062 88.78%
Perea, S. et al. 14 580 3/13/1995 Fluconazole 0 1.5 77.0755 14,711,804 85.00%
2440 1/3/1996 Fluconazole 800 1.5 82.9294 15,446,882 85.69%
2501* 1/4/1996 Fluconazole 800 96 88.5917 17,480,274 81.98%
Perea, S. et al. 15 945 4/14/1995 Fluconazole 300 4 108.5880 20,591,044 85.19%
1619 7/11/1995 Fluconazole 500 64 93.1423 17,565,080 84.69%
Perea, S. et al. 16 3107 6/5/1996 Fluconazole 800 4 97.0099 18,361,266 84.84%
3119 6/5/1996 Fluconazole 800 96 87.9159 16,615,462 84.67%
3120 6/5/1996 Fluconazole 800 96 105.9450 19,442,016 86.79%
3184 7/1/1996 Fluconazole 800 101.8920 18,487,462 87.50%
3281 7/16/1996 Fluconazole 800 76.4442 14,327,376 85.69%
Perea, S. et al. 30 5106 1/7/1998 Fluconazole 800 0.5 87.2055 16,466,524 84.67%
5108 1/7/1998 Fluconazole 800 0.75 82.3160 17,480,274 81.98%
Perea, S. et al. 42 1691 8/3/1995 Fluconazole 100 122.5980 22,072,562 88.38%
3731 12/27/1996 Fluconazole 400 256 119.8970 21,436,034 88.72%
3733 12/27/1996 Fluconazole 400 256 95.5084 17,295,888 88.00%
Perea, S. et al. 43 1649 7/19/1995 Fluconazole 0 0.125 102.0970 19,545,530 84.08%
3034 5/15/1996 Fluconazole 400 0.75 92.9746 17,300,040 85.64%
Perea, S. et al. 59 3917 2/19/1997 Fluconazole 800 2 113.2650 21,549,704 83.86%
4617 8/28/1997 Fluconazole 400 64 75.3678 15,242,904 81.42%
4639 9/2/1997 Fluconazole 400 128 115.3160 25,468,190 75.69%
Perea, S. et al. 64 4018 4/2/1997 Fluconazole 200 110.1550 20,118,736 86.78%
4380 7/14/1997 Fluconazole 200 18.0328 20,970,946 9.26%
Not clonally derived from progenitor
* isolated on same day from same patient as previously published strain, 2500 
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collected at later, typically consecutive, time points, culminating in the final ‘endpoint’ 
isolate (Table 1). 
 
Figure 1 Overview of study design 
(A) Background, persistent, transient, recurrent, and driver mutations in patient time courses. 
Shown is a schematic illustration of the genomes of isolates (gray bars) from two patient time 
courses (Patient A and B, left and right panels, respectively), ordered from the first isolate 
(progenitor, top) to the last (evolved, bottom). Background mutations (purple) exist in the 
progenitor; persistent mutations (yellow) are not in the progenitor, but found in all subsequent 
isolates; transient mutations (pink) are not in the progenitor and only in some later isolates; 
recurrent mutations are persistent mutations that occur in the same gene in more than one 
patient. LOH events were also evaluated for persistence (light teal bar). Driver mutations, 
where a new persistent homozygous allele appears (e.g. G/T > A/A) are annotated in 
association with persistent LOH events (dark teal) and independent of these events (not 
shown). Each of these can be associated with a change in phenotype, such as drug resistance 
(boxes, right). (B) Sampling in the context of de novo mutation and selection bottlenecks. 
Each strain is a single clone (circle) isolated from an evolving population (represented by a 
phylogenetic tree). The population evolves and undergoes selective sweeps (dashed lines), 
with phenotypic changes occurring during the course of infection and treatment (i.e. drug 
resistance, black: high, white: low; gray scale at bottom). Persistent mutations (yellow 
lightning bolt) have likely swept through the population, whereas transient mutations (pink 
lightning bolt) have not.  (C) Sampling in the context of selection on existing variation. 
Selection acts to vary the frequency of different pre-existing genotypes in the population. 
Persistent mutations (yellow lightning bolt) have risen in the population to a frequency that 
they are repeatedly sampled (large circles) whereas transient mutations (pink lightning bolt) 
have not (small circle).  
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The progenitor isolates were more sensitive to fluconazole than subsequent isolates, as 
defined by the minimum inhibitory concentration (MIC) (Table 1, Methods). Previous studies 
with some of these patient isolates identified several mechanisms that may contribute to azole 
resistance, including segmental aneuploidy (Selmecki et al., 2006), increased expression of 
drug efflux genes (Coste et al., 2006), loss of heterozygosity (LOH) across large 
chromosomal segments (Coste et al., 2006; Dunkel et al., 2008), mutations in ergosterol 
biosynthetic genes (Asai et al., 1999; Oliver et al., 2007), and facilitation by the chaperone 
heat shock protein 90 (Hsp90) (Cowen and Lindquist, 2005). 
 
Figure 2: Most isolates from the same patient are clonal. (A) Two possible models of 
infection may underlie serial isolates. In the ‘clonal model’ (top) each subsequent sample 
(circle) is related to the other isolates. In the non-clonal model (bottom) isolates in a series 
are un-related. (B) Determining clonal infections from SNP calls. The phylogenetic 
relationship of the isolates (black) from 11 patients (blue) was inferred based 201,793 
informative SNP positions using maximum parsimony in PAUP*.  Isolates from the same 
patient separated by a branch distance greater than 20,000 were considered non-clonal (3281, 
2823, 3184, 1691, red).  Most nodes were supported by 100% of 1,000 bootstrap replicates 
(indicated by *), expect as indicated (in grey). Clade identifiers were included as appropriate. 
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We sequenced the genomic DNA of each of the isolates as well as the C. albicans lab strain, 
SC5314, using Illumina sequencing (average coverage, 100X, Methods, Table 1) and 
identified in each series point mutations, LOH events and aneuploidies that were not present 
in the progenitor of that series. All mutations were defined relative to SC5314, the C. 
albicans genome reference strain. We validated our pipeline for detection of point mutations 
using the Sequenom iPlex genotyping technology (Methods, (Storm et al., 2003). We 
interrogated 2499 randomly chosen SNPs in 27 isolates from 9 clinical series, and found that 
the iPlex base calls matched 2270 (90.8%, Table 2) of the calls from the computational 
pipeline used to analyze the sequencing data.  
 
Most series are clonal, but there is significant genetic diversity between isolates  
We designated polymorphisms common to all isolates in a series, including the progenitor 
(Figure 1, purple) as background polymorphisms. Based on background SNPs, we first 
determined that most isolates within most series were clonal, suggesting a single (primary) 
infection source (Figure 1B, Figure 2, Figure 3, Methods). To distinguish between a single 
primary infection (Figure 2A, top) and repeated, independent infections (Figure 2A, bottom) 
we determined the distance between every two isolates based on their SNP profile, and used 
as a heuristic a neighbor-joining algorithm to construct a phylogenetic tree from this distance 
metric, with the reference strain SC5314 as an outgroup for rooting (Methods, Figure 2B). 
All but one (10/11) of the series were predominantly clonal (Figure 2B, Figure 2-figure 
supplement 1). Nevertheless, we detected at least one non-clonal isolate in 4/11 patient series, 
indicating that at least ~36% of patients carried more than one unrelated strain of C. albicans. 
We removed non-clonal samples from further consideration, and all subsequent analyses 
focused on samples from the 10 patients with at least two clonal isolates. 
Despite these clonal relationships, the distance between isolates indicated significant genetic 
diversity within each patient series (Figure 2B), typically with each isolate differing by 
several thousand SNPs from its ‘progenitor’ isolate (Figure 2 - source data 1 and 2). These 
data could reflect two evolutionary scenarios: accumulation of de novo mutations followed by 
selection (Figure 1B), or largely pre-existing variation with selection acting to vary the 
frequency of different genotypes in the population (Figure 1C). The large number of SNPs 
detected suggests that isolates from later time points in a series are not simply direct 
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descendants of the earlier isolate; however, since mutation and mitotic recombination rates 
can be elevated under stressful conditions (e.g. drug treatment (Forche et al., 2011; Galhardo 
et al., 2007)), we cannot rule out the possibility that some of the variation may be due to de 
novo events. Formally distinguishing between these two models is not possible with the data 
at hand. However, the observation that different isolates collected on the same day from 
patient 14 (2440 and 2501) and patient 16 (3107 and 3119) differed by 9,668 and 18,291 
SNPs, respectively (Figure 2 - source data 1 and 2), and had very different fluconazole MIC 
levels (Table 1) and different fitness phenotypes (Figure 6, 7, and 8) supporting the role of 
standing diversity. Thus, we conclude that a population of related but divergent genotypes of 
the same lineage exists within a given patient. We next sought to identify potentially adaptive 
genetic changes by focusing on large-scale events (LOH and aneuploidies) as well as single 
nucleotide polymorphisms.  
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Figure 2 - figure supplement: SNP heterozygosity profiles for each strain. The 
heterozygosity profiles shows, in chromosomal order (top), each variant locus that exists in at 
least one strain in the series (white is a heterozygous SNP, blue is homozygous for the 
SC5314 allele, red is a homozygous SNP relative to SC5314). (A) Patient 1; (B) Patient 7; 
(C) Patient 9; (D) Patient 14; (E) Patient 15; (F) Patient 16; (G) Patient 30; (H) Patient 42; 
(I) Patient 43; (J) Patient 59. Only Patient 9 (C), Patient 16 (F), Patient 42 (H), and Patient 64 
(not shown**) contain un-related isolates. ** Patient 64 contained an isolate (4380) whose 
genome aligned poorly to the C. albicans reference, but aligned well to C. dubliniensis.  
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Genetic alterations absent from the progenitor, persistent within a patient, and 
recurrent across patients are likely adaptive 
Given the high number of SNPs, LOH events and aneuploidies, we next devised a strategy to 
identify those changes that are likely to play an adaptive role in drug resistance and host 
adaptation. Focusing on genetic alterations absent from the (drug sensitive) progenitor but 
present in later isolates, we defined alterations as persistent if present within the same patient 
at all subsequent time points after the isolate in which they are first identified. We reasoned 
that such persistent changes will include those variants that were driven to sufficiently high 
frequency by selection to ensure repeated sampling (Figure 1B and 1C, yellow lightning 
bolt), whereas non-persistent (transient) ones do not (Figure 1B and 1C, pink lightning bolt). 
We consider the special case of a genetic change detected only in the endpoint strain as 
‘persistent’ as well, since several of the time courses consist of only two or three isolates. We 
apply the persistence filter to better identify potentially adaptive aneuploidies, LOH events, 
and SNPs.  
The large number of SNPs detected required additional filtering; therefore, to further restrict 
our analysis to potentially adaptive SNPs, we first excluded all background mutations, 
defined as any SNP relative to the reference present in all isolates from a series.  Next, we 
focused on nonsynonymous polymorphisms in coding regions and employed two different 
strategies to identify potentially adaptive changes. First, to identify potential drivers of 
adaptation, we focused on non-synonymous SNPs that were homozygous for a genotype not 
found in the progenitor strain that persisted in the subsequent isolates (e.g. G/T > A/A) 
consistent with positive selection.  In the second strategy, polymorphic genes were 
considered recurrent across patients when persistent, nonsynonymous polymorphisms 
appeared within the same open reading frame (ORF) in different patient series (Figure 1, 
Figure 5 - source data 1). We considered only those that were not included in LOH regions, 
as these regions artificially inflate the estimates of persistence and recurrence. Recurrence 
allows us to better handle polymorphisms from the endpoint isolate in a series for which 
‘persistence’ does not provide a meaningful filter. Thus, polymorphisms only in the terminal 
isolate in one patient will only be further considered if polymorphisms also recurred in the 
same ORF in a series from two other patients. For example, filtering for both persistence and 
recurrence across at least three series brought the number of polymorphisms for patient 1 
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from 13,562 polymorphisms to 23 recurrent genes (Figure 2 - source data 1 and 2, Figure 5 
- source data 1).  
 
LOH events are commonly associated with increased resistance  
LOH events were detected in the vast majority (9/10) of the series, and were often persistent, 
recurrent and associated with increased drug resistance (Figure 3 and 4, Figure 3 and 4 - 
source data 1). For example, two of three LOH events in Patient 1 were persistent and 
associated with an increase in MIC and both of these events were recurrent, such that LOH 
events in these genomic regions coincided with increases in MIC in other patients. Highly 
recurrent LOH events occurred on the right arm of chromosome 3 (in Patients 1, 9, 14, 16, 
30, and 59; Figure 3A,B, Figure 4B,C, Figure 3 and 4- source data 1) and on the left arm 
of chromosome 5 (in Patients 1, 14, 15, and 43; Figure 3A, Figure 4C,H, Figure 3 and 4 - 
source data 1). These regions include key genes implicated in drug resistance: on 
Chromosome 3, genes encoding the Cdr1 and Cdr2 efflux pumps and the Mrr1 transcription 
factor that regulates the Mdr1 major facilitator superfamily efflux pump (Schubert et al., 
2011), and on Chromosome 5 genes encoding the drug target Erg11, and Tac1, a transcription 
factor that positively regulates expression of CDR1 and CDR2 (Coste et al., 2006). The extent 
of persistence and recurrence of these two LOH events is statistically significant under a 
naïve binary model (p<0.009 for the Chr3R LOH; p<0.009 for the Chr5L LOH). The 
recurrence of LOH events that coincide with changes in MIC suggests that they have been 
positively selected to rise in frequency relative to the progenitor strain. Notably, some of the 
recurrent LOH events may have been difficult to detect previously on SNP arrays (Forche et 
al., 2008; Forche et al., 2004; Forche et al., 2005), due to the relative paucity of SNPs in 
those regions in the reference strain, SC5413, itself a clinical isolate.  
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Figure 3 LOH events were often persistent while aneuploidies were often transient 
For each time series shown are the genomes of all isolates (rows) from a patient, ordered 
from the first isolate (progenitor, top) to the last (evolved, bottom). Boxes on right indicate 
the MIC of the respective strain (black: high, white: low; gray scale at bottom). Persistent 
LOHs: blue, transient LOHs: pink; trisomies (all transient): green. The sequence coverage 
along each chromosome is indicated by black tickmarks. (A) Patient 1 has four LOH events, 
each coinciding with an increase in MIC (gray scale boxes, right). One LOH is transient 
(isolate 2, chromosome R, pink), and three are persistent (isolate 3, chromosome 3; isolate 
13, chromosome 5; and isolate 16, chromosome 5, blue). The ploidy changes (isolates 6, 8, 
13) are all transient. (B) Patient 7 has one LOH event (isolate 2307, chromosome 3, blue) 
which coincides with an increase in MIC.  
 
Driver mutations (e.g. G/T > A/A) in these regions are suggestive of a point mutation 
followed by an LOH of the mutant allele that confers an advantage. There were 131 such 
mutations in 86 ORFs from 18 LOH regions from the 10 clonal patient series (Table 1 and 
Figure 5 Figure 5 - source data 3). 
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Figure 4 Persistent and transient LOH and aneuploidies. For each time series shown are 
the genomes of all isolates (rows), ordered from the first isolate (progenitor, top) to the last 
(evolved, bottom). Boxes on right indicate the MIC of the respective strain (black: high, 
white: low, grey scale at bottom). Persistent LOHs: light blue, transient LOHs: pink; 
trisomies (all transient): green. The coverage along each chromosome is indicated by black 
tickmarks. (A) Patient 9; (B) Patient 14; (C) Patient 15; (D) Patient 16; (E) Patient 30; (F) 
Patient 42; (G) Patient 43; (H) Patient 59. Several LOHs are recurrent (right arm of 
chromosome 3, left arm of chromosome 5, and chromosome 1). We also observe i5L in 
patients 16, isolate 3120 (D) and patient 30, isolate 5106 (E), but neither coincides with an 
increase in MIC. 
 
Some of the SNPs were in genes that encode key players in drug resistance and were 
associated with large LOH events. For example, a nonsynonymous homozygous change in 
the fluconazole drug target ERG11 was associated with the formation of the persistent LOH 
on the left arm of chromosome 5 in Patient 1 (Figure 3A), consistent with previous reports 
(White, 1997c) as was TAC1 in Patient 42. In another example, the persistent and recurrent 
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LOH on the right arm of chromosome 3 in Patients 9 and 16 was associated with the 
appearance of a homozygous mutation in MRR1 (Schubert et al., 2011), a regulator of MDR1 
expression. Other mutations were in genes not previously related to fluconazole resistance, 
including cell adhesion (ALS3,5 and 7, and HYR3,(Hoyer et al., 1998) (Sheppard et al., 2004) 
(Hoyer et al., 2008) , filamentous growth (FGR14, FGR28 and EFH1, (Connolly et al., 2013; 
Uhl et al., 2003) and biofilm formation (BCR1 and YAK1, (Goyard et al., 2008; Nobile et al., 
2012; Nobile and Mitchell, 2005b; Noble et al., 2010b). 
 
Figure 5 Co-occurrence of nonsynonymous substitutions across isolates reveals 
functional clusters. For each of the recurrently mutated 240 genes (genes in which 
nonsynonymous persistent SNPs appear in more than 3 patients and are not within an LOH 
region), we constructed a patient-by-gene binary vector (shown as cluster membership 
matrices, right, green: gene is persistently mutated in patient per definition above). We 
clustered the resulting patient by gene matrix using NMF clustering to reveal 5 coherent 
clusters (correlation matrix of the clusters left; red: positive correlation; blue: negative 
correlation; white: no correlation). Functional enrichment of clusters was revealed using gene 
ontology, and genes matching the enriched cluster function are bolded. We have overlaid 
recurrent driver mutations (e.g. G/T > A/A) (n = 17) occurring outside of LOH regions 
(yellow circle, green box) and inside LOH regions (yellow circle, white box). 
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Aneuploidies are not predictive of MIC, but may facilitate the appearance of drug 
resistance  
Aneuploidies, either whole chromosome or segmental, were evident in at least one isolate 
from 80% (8/10) of the clonal patient series, with the most prevalent aneuploidies involving 
Chromosome 5 (6 of 8 patients with at least one aneuploid isolate). In contrast to the 
persistent nature of LOH events, persistent aneuploidies were more rare, and were not 
consistently associated with adaptive increases in MIC levels (Figure 3 and 4).  
While we cannot definitively infer an ordering of events from our singly sampled isolates, we 
hypothesize that aneuploidy contributes to the evolution of LOH by increasing the likelihood 
of its occurrence. For example, in four of the six patients with a Chromosome 5 LOH, the 
LOH event is preceded by or is concomitant with Chromosome 5 trisomy. Thus, the 
additional copy may increase the likelihood of an LOH event on that chromosome. In three of 
these cases, ERG11, located on the region of Chromosome 5 with LOH, was mutated. 
Additionally, isolates in two of the seven patients with a Chromosome 3 LOH were trisomic 
for this chromosome. 
 
Persistent SNPs in 240 recurrently polymorphic genes identify targets likely associated 
with and drug resistance and host adaptation. 
We identified persistent, nonsynonymous coding SNPs within 1,471 genes that fell outside 
LOH tracts. Among these we identified 338 driver polymorphisms in 168 genes (Figure 5- 
source data 2). These again include ERG11 in patient 9, 14, 30, and 59 and TAC1 in patients 
1, 7, 14, 15, 30 and 43 (Figure 5). Applying the recurrence filter (i.e., persistent 
nonsynonymous SNPs that appeared in the same ORFs in 3 or more patient series to the list 
of 1,471 genes), we identified 240 polymorphic genes that are more likely to have contributed 
to adaptation (Figure 5 -source data 1). This number of genes is more likely than expected 
by chance (p<0.0001, by simulation). Though the coding sequence for these 240 recurrent 
genes is longer than average, and thus a larger target for mutation, ( 2.21  1.53kb vs. 1.83  
1.29kb for non-recurrent persistent genes, p < 3.68*10
-5
, t-test), our simulation accounts for 
gene length, suggesting we see significantly more recurrence than expected by chance alone. 
Notably, we identified 17 persistent recurrently polymorphic genes that were also drivers (8 
of which were also homozygosed in an LOH tract) (Figure 5, Figure 5 – source data 1, 2, 
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and 3). Finally, polymorphisms in 166 of the 240 genes appeared together with and increase 
in MIC and are thus stronger candidates for making a significant functional contribution to 
resistance (Figure 5- figure supplement 1, Figure 5 – source data 4, p<0.00001, by 
simulation).  
The set of 240 recurrently mutated genes was enriched for fungal-type cell wall and cell 
surface genes, including several members in each of three cell wall gene families important 
for biofilm formation and virulence: the Hyr/Iff proteins (HYR1,3 and IFF8,6); the Als 
adhesins (ALS1-4,7,9); the PGA-30-like proteins (7 genes) (Figure 5- source data 1(Hoyer 
et al., 2008). All three gene families have previously shown to be specifically enriched in 
pathogenic Candida species (Butler et al., 2009). There are also seven members of the FGR 
gene family, involved in filamentous growth that is specifically expanded in C. albicans 
(Figure 5- source data 1, (Butler et al., 2009).   
The most recurrently mutated gene outside of an LOH region was Axl1 (persistently mutated 
in eight series), followed by ten genes mutated in seven series. Notably, persistent SNPs in 
ERG11, which encodes the drug target, appeared in Patients 9, 14, 30 and 59) in addition to 
mutations in the LOH events in Patients 1, 15, and 43 (Figure 5 – source data 1). Thus, 
ERG11 was affected in 70% (7/10) of the patient series. More generally, 171 of the 240 genes 
were also mutated in an LOH tract in at least one additional patient (15/171 in 3 or more 
additional patients and 34/171 in 2 additional patients). Likewise Hyr3 was persistently 
mutated in nine of the patients, three of which occurred in LOH tracts, including one in which 
a new allele was homozygosed (Figure 5, Figure 5 – source data 1, 2, and 3).  
Next, we partitioned the 240 recurrently mutated genes into 5 ‘co-occurrence clusters’ based 
on the correlation in their mutation occurrence patterns (Figure 5, Figure 5 – source data 1). 
These correlations are significantly higher than expected in a null model (KS test, P< 2.2
x
10
-
126
, Wilcoxon Rank Sum test, P<0.0196, permutation test). The characterized genes in most 
of the clusters have coherent functions. Cluster 1 is enriched for cell wall and cell surface 
genes, Cluster 2 for cell cycle and stress genes, Cluster 3 for genes involved in drug response 
and Cluster 5 for carbohydrate binding (Figure 5, Figure 5 – source data 1).  Most of the 
genes in these clusters are not well characterized and represent new candidates involved drug 
resistance and adaptation to the host environment.  
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Changes in virulence phenotypes in evolved drug-resistant isolates  
To explore the possibility that some of the mutations reflect adaptation to other factors 
besides drug, we next measured four additional phenotypes (Methods). Filamentation, 
adhesion and competitive fitness were measured in competition assays in standard tissue 
culture medium with and without drug in vitro; and virulence was measured in a nematode 
model of infection (Jain et al., 2013a).  
We found substantial variation in many of these phenotypes between isolates in the same 
series (Figure 6, 7 and 8), supporting the notion that the isolates are samples from a broad 
range of genetic variants within clonal (single infection) populations. In general, increased 
fitness in vitro (in the absence of drug) correlated with an increase in traits associated with 
virulence (adhesion, filamentation and virulence in nematode). For example, the later isolates 
in the series from patients 30 and 43 had increased fitness and higher virulence by all three 
measures (Figure 6A, B). Similarly, a decrease in fitness in isolate 13 of patient 1 was 
accompanied by a decrease in virulence (Figure 6C). A notable exception was patient 59, 
where fitness in vitro decreased while virulence phenotypes increased (Figure 6D). 
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Figure 6 Filamentation, adhesion and virulence increase concurrently with fitness. For 
each pair of consecutive isolates (green preceding blue), shown are the fitness (far left, Y 
axis, Methods), adhesion (left, Y axis, Methods), filamentation (middle, Methods) and 
virulence in a worm model of infection (right). For virulence, shown are Kaplan-Meier plots 
of survival rates for each isolate, where significant changes in virulence were observed 
between the two isolates (P < 0.001, log-rank test). (A) Patient 30 isolates 5106 and 5108; 
(B) patient 43 isolates 1649 and 3034; (C) Patient 1 isolates 12 and 13; (D) patient 59 isolates 
3917 and 4617. 
Initially in a series, drug resistance (MIC) and in vitro fitness (in the absence of drug) were 
anti-correlated, suggesting that these are competing selective pressures. When MIC increases 
first appeared, they were usually accompanied by a decrease in fitness in the absence of drug 
(Patient 1, isolates 2-4, 13, 15 and 16, Patients 9, 14, 15 16, and 59, Figure 7). Of course, 
consistent with the elevated MIC, these isolates exhibited increased relative fitness in the 
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presence of the drug (Figure 8). This is also consistent with a recent study in C. albicans 
showing that resistance conferred by gain-of-function mutations in the transcription factors 
Mrr1, Tac1 and Upc2 are associated with reduced fitness under non-selective conditions in 
vitro as well as in vivo during colonization of a mammalian host (Sasse et al., 2012).  
 
Figure 7. Emergence of increased drug resistance often coincides with reduction in 
fitness in absence of drug. (A) For each patient (panel) shown is the fitness (Methods) of 
each strain (Y axis, mean ± STDV), ordered from the progenitor to evolved isolates (left to 
right, X axis). The MIC of each strain is shown in the grey boxes on top (white: low; black: 
high, color bar at bottom). Isolates with aneuploidies are marked by asterisks. (B) Shown is 
the fitness (Methods) for each double deletion mutant strain and corresponding wild type 
strain (Y axis, mean ± STDV). The wild type strain (SN50) is on the far left and locus names 
are given for the mutant isolates (X axis). Double asterisks denote the MIC of the one mutant 
strain that differs from that of SN50.  
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Furthermore, consistent with selection of strains with compensatory variations, isolates from 
later time points often were more fit than those from earlier time points (measured in vitro, in 
the absence of drug) without further changes in MIC (e.g., patient 1, isolates 5-7, isolate 14, 
Figure 7). This is consistent with previous studies in bacteria (Bjorkman and Andersson, 
2000) and in a single documented case in C. glabrata (Singh-Babak et al., 2012), suggesting 
that compensatory mutations arise to offset the major fitness cost of mutations conferring 
drug resistance.  
 
Figure 8 The difference in fitness in the presence or absence of Fluconazole. Shown is the 
mean difference in fitness in the absence and presence of drug (Y axis, error bars are +/- 
STDV; n > 3) for isolates (X axis) that showed a decrease in fitness (Figure 6A) in the 
absence of drug concomitant with an increase in MIC (asterisks), and flanking isolates in 
patient 1 and 59 (ordered from the progenitor (P) to evolved isolates (left to right, X axis). 
The difference in fitness is calculated as the difference in selection coefficient (s, Y axis) 
between matching competition experiments in RPMI and those in RPMI with one half the 
MIC for Fluconazole (Table 1) for each isolate tested (X axis). Negative values indicate that 
the strain had higher fitness in the presence of fluconazole versus assays without fluconazole. 
In this context it appears that aneuploidies (Figure 7, asterisks), while largely transient, may 
be an important intermediate giving rise to more stable adaptive genotypes in some cases 
(Yona et al., 2012). For example, in Patient 1 isolate 13, an increase in MIC and a trisomy of 
5 of 8 chromosomes accompanies a large decrease in fitness (in the absence of drug) relative 
to the preceding isolate 12 (Figure 7) but increased fitness in the presence of drug (Figure 
8). Isolate 14 has a similar MIC phenotype to isolate 13, but is euploid (Figure 3) and is 
much more fit (Figure 7). Consistent with the generally negative effect of aneuploidy on 
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fitness (Tang and Amon, 2013), absence of the extra chromosomes resulted in improved 
overall fitness. 
Candidate mutated genes associated with drug resistance or virulence 
Overall, the analysis of clinical isolates identified a range of new candidate genes that may 
affect drug resistance, fitness and/or virulence. To test the contribution of some of the 
recurrently identified genes to specific C. albicans phenotypes, we analyzed 23 of these 
persistent and recurrently mutated genes using available homozygous deletion mutants from a 
deletion strain collection (Noble et al., 2010b).  We tested all those loci recurrently mutated 
in our data for which a deletion mutant was available.  
We measured the MIC of fluconazole and in vitro fitness of each of 23 deletion isolates. One 
gene (orf19.4658) caused a 2-fold decrease in MIC, whereas the other 22 mutants tested did 
not have a significant effect on MIC. Deletion mutants are loss of function mutations, 
whereas the previously identified mechanisms of fluconazole resistance are “gain of 
function”, resulting in increases in the amount or activity level of Erg11 (Asai et al., 1999; 
Oliver et al., 2007) or the efflux of drug transporters (Coste et al., 2006; Dunkel et al., 2008).  
Therefore, it is possible that the recurrent nonsynonymous coding SNPs in the other loci we 
identified in the clinical isolates confer resistance. Alternatively, these loci may not be 
involved in fluconazole resistance per se but have a more general role in adaptation to the 
complex host environment.  Consistent with a role in host adaptation, the majority of the 
deletion mutants affected in vitro fitness in a culture medium purported to approximate in 
vivo conditions (Figure 7, Methods).  Three were more fit (Figure 7), including CCN1, that 
encodes a G1 cyclin required for hyphal growth maintenance (Loeb et al., 1999) and 
orf19.4471, an ortholog of S. cerevisiae VPS64, which is required for cytoplasm to vacuole 
targeting of proteins (Bonangelino et al., 2002), is involved in recycling pheromone receptors 
(Kemp and Sprague, 2003), and is identified as an ‘aneuploidy-tolerating mutant’ (Torres et 
al., 2010). Among the least fit were cell wall protein genes (HYR1, HYR3 and PIR1 (de 
Groot et al., 2004). 
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6.5 Discussion 
 
Here, we sequenced and analyzed the genomes of C. albicans serial clinical isolates by 
comparing ‘consecutive’ isolates from one patient to reach novel insights into the evolution 
of drug resistance within the human host. This approach allowed us to distinguish (and 
remove from further analysis) isolates that were non-clonal and to estimate that at least ~45% 
of the patients carried at least one unrelated strain of C. albicans. We used the clonal isolates 
to identify persistent SNPs, and the different series to identify those persistent SNPs that 
recurred within the same ORFs, thereby focusing the analysis on a small set of loci where the 
identified variants are more likely to be adaptive, and excluding the substantial background of 
likely neutral variation that hitchhike along with the others that are selective beneficial 
mutations.  
Our study identified a surprisingly large amount of genetic diversity in each series, especially 
in light of the report of only 26 SNPs detected in a single clinical series of Candida glabrata 
isolates that spanned a 10 month period (Singh-Babak et al., 2012). Several reasons may 
account for this difference. First, fluconazole, the antifungal drug used to treat the patients in 
our series, is fungistatic, such that many cells exposed to the drug arrest their growth but do 
not die. Thus, the range of diversity in the initial population is not entirely lost. In contrast, 
the C. glabrata study involved exposure to caspofungin, an echinocandin fungicidal drug. 
Therefore, most cells likely died upon drug exposure and only the rare survivors went on to 
seed the remaining population. Accordingly, the C. glabrata isolates may have been 
subjected to selection that would have removed much of the initial diversity in the 
population, whereas in the C. albicans series diversity persisted and selection acted mostly to 
change the relative proportions of different genotypes. Second, C. albicans is a heterozygous 
diploid, while C. glabrata is haploid, and thus by its very nature, homozygous. Mutations can 
be more readily assimilated in a diploid than in a haploid organism, since deleterious 
mutations are potentially buffered by a functional version (Thompson et al., 2006). 
Furthermore, because C. albicans genomes are initially much more diverse (with tens of 
thousands of heterozygous SNPs in a given isolate), LOH is a high frequency mechanism 
available to reveal mutations more readily. Third, C. albicans lab isolates undergo a stress-
induced elevation of mutation and mitotic recombination rates (Forche et al., 2011; Ponder et 
al., 2005; Rosenberg, 2011) and exposure to a mammalian host clearly results in elevated 
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frequencies of LOH and aneuploidy (Forche et al., 2009). Thus, we hypothesize that C. 
albicans isolates within the human host also undergo elevated levels of LOH, and possibly of 
mutation to generate a wider range of diversity. Additionally, they may not only tolerate 
genome and proteome diversity (Santos et al., 2004; Selmecki et al., 2010b), but also 
generate large-scale genetic variation as a means of adaptation (Chang et al., 2013; Gresham 
et al., 2008; Pavelka et al., 2010; Yona et al., 2012). 
LOH of several genes important for fluconazole resistance have been reported previously 
(ERG11) (Oliver et al., 2007), TAC1 (Coste et al., 2006) and MRR1 (Schubert et al., 2011), 
however, the degree to which LOH is important in clinical infections was not known. In the 
10 patients studied here, LOH was commonly observed (9/10) and was associated with 
changes in MIC. As we detected LOH of mutations in ERG11 in 3 patients, it would be of 
interest to know if the LOH in these known genes was sufficient to increase MIC, or if other 
genes within the homozygous region make important contributions. 
Aneuploidies appeared frequently within the drug resistant isolates, which is consistent with 
previous reports (Selmecki et al., 2006). Unlike LOH events, aneuploidies were often 
transient, and thus not uniquely correlated to increases in drug resistance. Perhaps these 
aneuploidies provide a mechanism akin to genetic assimilation (‘phenotype precedes 
genotype’), in which cells are provided with a phenotypic mechanism that facilitates survival 
until a more stable and/or less costly mechanism is attained. In this case, the mechanism 
would be genetic but unstable—the acquisition of one or more extra chromosomes. 
Nevertheless, aneuploidies may cause increased frequencies of LOH events through whole 
chromosome loss, as well as by increasing the likelihood of recombination events. A transient 
role for aneuploidy is consistent with recent findings from in vitro evolution studies in S. 
cerevisiae (Yona et al., 2012) in which a transient aneuploidy was responsible for fitness at 
elevated temperature, but was eventually replaced by a more stable mutation.  
In addition, a substantial number of persistent and recurrent SNPs, and clusters of co-
occurring SNPs, implicate a broad range of pathways and functions that likely provide some 
growth advantage in the presence of the complex selective pressures found in the host. In 
particular there was strong enrichment for cell wall gene families purported to be critical 
determinants of the transition from commensalism to pathogenesis (Gow and Hube, 2012).  
The genes in several of these families (e.g. Als1, 7 and Hyr/Iff genes) frequently contain 
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intragenic tandem repeats. Variation in intragenic repeat number modulates phenotypic 
diversity in adhesion and biofilm formation (Verstrepen et al., 2005).  This functional 
diversity of cell surface antigens has been proposed, in fungi and other pathogens, to allow 
rapid adaptation to the environment and evasion of the host immune system (Gemayel et al., 
2010).  Indeed, many of the isolates evolved additional phenotypes, including in vitro fitness, 
filamentation, adhesion and in vivo virulence, and the data presented here points to candidate 
genes that underlie some of these evolved traits. For example, the evolved isolate (4617) in 
patient 59 had a dramatic increase in filamentation relative to the progenitor that was 
concomitant with the appearance of persistent SNPs in genes associated with filamentous 
growth: CHO1, MNN2 and 5 different FGR (filamentous growth regulator) genes (Uhl et al., 
2003).. 
The evolution of drug resistance in C. albicans has many parallels with somatic evolution of 
cancer cells undergoing chemotherapy or treated with specific inhibitors. These include 
variation on a background of clonal descent, lack of sexual recombination, acquisition of 
drug resistance, lack of diploid fidelity in successive mitotic divisions, and increased 
mutation and mitotic recombination rates (under stress). Indeed, several recent studies have 
shown a similar spectrum of genetic alterations during the somatic evolution of cancers in 
patients undergoing chemotherapy (Landau et al., 2013; Podlaha et al., 2012) or treated with 
specific inhibitors (Ding et al., 2012) to those observed here.  
Finally, our data and analyses provide a rich and novel resource for Candida researchers and 
a host of candidate genes for further functional studies. While our analysis focused on 
recurrent SNPs in ORFs, we nonetheless cataloged the many genetic alterations found in 
intergenic regions (Figure 2 - source data 1), some of which could affect gene regulation. It 
will be especially interesting to analyze the similarities and differences in additional C. 
albicans genome sequences that are likely to become available in the near future. Our results 
suggest there may be complex population dynamics during the transition from commensal to 
pathogen, and across the course of treatment. As sequencing capacity continues to grow, it 
will be especially interesting to more fully sample this population level diversity during 
longitudinal collection to better understand these dynamics.  In particular, it will be 
interesting to determine the degree to which specific mutations recur in different isolates 
prior to and after the acquisition of drug resistance. 
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6.6 Materials and Methods 
 
Isolates 
Isolates were isolated from HIV-infected patients with oropharyngeal candidiasis, as 
previously described (Perea et al., 2001a; White, 1997b). The patients were not on azole 
antifungal treatment at time of enrollment; subsequent samples were collected during 
recurrence of infection. The isolates and are detailed in Table 1. 
 
Drug susceptibility  
Minimal inhibitory concentrations (MIC) were determined for each strain using fluconazole 
E-test strips (0.016–256 μg/ml, bioMérieux, Durham, NC) on RPMI 1640-agar plates 
(Remel). Overnight YPD cultures were diluted in sterile 0.85% NaCl to an OD600 of 0.01 
and 250 uL was plated using beads. After a 30-minute pre-incubation, 2-3 E-test strips were 
applied and plates were incubated at 35ºC for 48 hours. The susceptibility endpoint was read 
at the first growth-inhibition ellipse, and the median value is reported here. 
 
Illumina sequencing 
Genomic DNA was prepared from different clinical time courses via a Qiagen Maxiprep kit 
and sequenced using 101base paired-end Illumina sequencing (Mardis, 2008b). Library 
preparation included an 8 base barcode (Grabherr et al., 2011) ;43 samples from 11 patients 
were sequenced. All reads were mapped to the SC5314 reference genome (Candida Genome 
Database, gff downloaded on January 4, 2010) using the BWA alignment tool (version 0.5.9) 
(Li and Durbin, 2009). To minimize false positive SNP calls near insertion/deletion (indel) 
events, poorly aligning regions were identified and realigned using the GATK 
RealignerTargetCreator and IndelRealigner (GATK version 1.4-14, (version 1.4-14) 
(McKenna et al., 2010). Coverage for each strain is reported in Table 1. Coverage was 
defined as the total number of bases with BWA mapping quality greater than 10 divided by 
the total number of sites in the nuclear genome. Isolate 4380 aligned poorly to the SC5314 
genome; however, this sequence aligned at high identity to the C. dubliniensis, and was 
therefore removed from further analysis. Reads are deposited for access to the NCBI SRA 
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under project accession number SRP028114. 
 
SNP calling  
SNP were identified using Unified Genotyper (GATK version 1.4.14) (McKenna et al., 
2010), using read alignments to the SC5314 reference sequence. Unreliable SNPs were 
identified using the GATK Variant Filtration module, with the version 3 best practice 
recommended annotation filters (QD < 2.0, MQ < 40.0, FS > 60.0, HaplotypeScore > 13.0, 
MQRankSum < -12.5, ReadPosRankSum < -8.0) except that the HaplotypeScore was also 
filtered if greater than two standard deviations above the mean of all HaplotypeScore values. 
The combined list of SNP positions across all strains was used to evaluate those matching the 
reference allele; by emitting all sites using Unified Genotyper, high quality reference matches 
were identified as positions with quality of 30 or greater, with positions with extremes of read 
depth (top or bottom 0.5% quantile) eliminated.  A matrix of all strains by all positions was 
created from the SNP calls, with reference calls added where identified. Non-clonal isolates 
(see below) were removed from further analysis. 
 
Sequenom iPLEX genotyping assay  
Loci chosen for validation were selected because they were: (1) persistent within their time 
courses; and (2) at least 150 bp away another SNP in either direction. 578 targets from 9 time 
courses were interrogated. This allowed us to compare our sequencing and genotyping 
predictions for 2499 cases (genetic locus X strain combination); 2270 predictions were 
confirmed as correct by Sequenom genotyping and 229 were incorrect (Table 2). Based on 
the 2499 cases at which comparison was possible, the SNP calling accuracy was determined 
to be 90.8%. 
 
Determination of relatedness to determine clonality 
We investigated the phylogenetic relationship of all strains using SNP calls to determine 
relatedness between strains; positions with missing data in 10% or more of strains were 
eliminated, resulting in a total of 201,793 parsimony informative positions.  A distance based 
tree was estimated using maximum parsimony with PAUP* (4.0) (Swofford, 2002); a step 
matrix was used to estimate the distance between homozygous and heterozygous positions, 
  
196 
 
 
where each of the homozygotes are two steps apart from each other and one step from the 
heterozygote.  SNP positions were resampled using 1,000 bootstrap replicates, and the 
phylogeny re-estimated to test the branch support. We define isolates with a branch distance 
of greater than 20,000 as non-clonal. 
 
Copy-number determination 
For each strain, we calculated a per-locus depth-of-coverage using GATK(McKenna et al., 
2010), with a minimal mapping quality of 10. The number of reads aligning to each 5 kb 
window across the nuclear genome was calculated and then normalized to the genome 
median. Each bin was then multiplied to the ploidy for the majority of the genome as 
determined by a FACS assay (below). We then applied a sliding window across each bin, 
defining a potential CNV if 70% of 10 consecutive bins had a normalized count > 2.5x. 
Regional amplifications are identified if > 15% of the chromosome is identified as having a 
CNV. Boundaries were confirmed by visual inspection in the Integrative Genome Viewer 
(Robinson et al., 2011a).  
 
High-resolution ploidy analysis by flow cytometry 
C. albicans cultures were grown to log phase. 200μl of culture was centrifuged in a round 
bottom microtiter plate and pellets were resuspended in 20μl of 50mM Tris pH8 / 50mM 
EDTA (50/50 TE). 180μl of 95% ethanol was added and suspensions were stored overnight 
at 4°C. Cells were centrifuged and pellets washed twice with 200μl of 50/50 TE, then 
resuspended in 50μl of RNAse A at 1mg/ml in 50/50TE and incubated 1 hour at 37°C. Cells 
were centrifuged and pellets resuspended in 50μl of Proteinase K at 5mg/ml in 50/50 TE for 
30 minutes at 37°C. Cells were washed in 50/50 TE and pellets resuspended in 50μl of a 1:85 
dilution SYBR Green I (Invitrogen, Carlsbad, CA) in 50/50 TE and incubated overnight in 
the dark at 4°C. Cells were centrifuged and pellets were resuspended in 700μl 50/50 TE and 
read on a FACScaliber flow cytometer (BD Biosciences, San Jose, CA). Flow data was fitted 
with a multi-Gaussian cell cycle model to produce estimates for whole genome ploidy. 
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LOH determination 
For each time course, we assembled the high quality SNPs (post-filtering, above) from multi-
sample calling into the columns of a matrix, ordered by genome position, with the isolates in 
rows, ordered temporally. The genetic state of each locus in each sample was coded to 
distinguish loci homozygous for the haploid reference (-1), heterozygous SNPs (0), and 
homozygous SNPs for the non-reference state (1). We then applied a sliding window method 
across each chromosome, only looking at sites in which a SNP call was made in at least one 
isolate. An LOH event was defined as occurring if (1) at least one isolate had a 
heterozygosity content > 40%, and (2) at least one other isolate had a heterozygosity content 
< 5%. Window sizes were of length 500. Boundaries were trimmed such that if a window 
terminated in a heterozygous site in the isolate for which the LOH occurred, it was trimmed 
back until it was homozygous. If two 500+ windows were within 7 KB of each, the region 
was assessed to determine if the event was actually one event and merged if the heterozygous 
sites in the inter-window space had homozygosed. If two isolates had LOHs that overlapped 
but did not have precisely identical boundaries, the LOH regions were combined such that the 
LOH interval for both isolates was the same. All LOH regions were confirmed by visual 
inspection and are listed in Figures 3 and 4-source data 1.  
 
Classification of SNPs 
For each time course, each SNP was classified for its position in the genome (Figure 2- 
source data 1). If the SNP fell within an ORF, the reference and altered amino acids were 
reported. If the SNP fell outside of an ORF, the distance to the closest flanking ORFs was 
reported, as well as the SNP’s orientation with respect to these ORFs. SNP genotypes that are 
common to all isolates (including the ‘progenitor’) were classified as background mutations. 
Genotypes not present in the progenitor or evolved strain, but that occur in one or more 
intermediate strain, are classified as transient. Finally, genotypes that occur after the 
progenitor, and persist through the terminally evolved time point, are classified as persistent. 
To determine if the number of persistent non-synonymous SNPs (nsSNPs) occurring in 
conjunction with changes in MIC was greater than expected, we developed a simple model to 
simulate the occurrence of nsSNPs outside of LOH regions at each time point.  For each time 
point (i), a random variable Xi ~ Pois(λi) was assigned, where λi represents the Poisson 
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parameter for each time point: 
λi = m/T * ti 
m = 1471, the number of ORFs with persistent nsSNP 
T = 23, the number of time points 
ti = the length of time (days) for time point (i) divided  
by the mean length of time   
The number of persistent nsSNP containing ORFs for each of the 14 time points associated 
with a change in MIC was summed, and this was repeated 100,000 times to build a 
probability distribution, where p(observing x mutated ORFs) was determined by dividing the 
number of successes for each bin by the number of trials.  
To determine the probability of observing x recurrent, persistently mutated ORFs outside of 
LOH regions, we developed an additional stochastic simulation model. For each patient series 
(i), at each non-LOH ORF (j), a random variable, Xij ~ B(n, pij) was assigned, where n 
represents the number of trials, 1, and p represents the probability of a SNP occurring in that 
ORF:  
p = mi / Mi * hj  
mi = number of ORFs with persistent nsSNPs found  
outside of LOH events for patient series (i) 
Mi = number of ORFs outside of LOH events for patient series (i)  
hj = log normalized ORF length divided by mean log  
normalized ORF length for ORF (j).   
 
This was repeated 10,000 times to build the a distribution, and p(observing x recurrent 
nsSNPs) was determined by dividing the number of successes in each bin the cumulative 
number of trials.  
 
Analysis of co-occurring mutations 
For co-occurrence analysis we focused only SNPs that (1) had persistent nonsynonymous 
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coding SNPs that did not occur in LOH regions and (2) recurred in three or more time 
courses. We generated for each such gene a binary patient vector, and we used NMF (Brunet 
et al., 2004) clustering to identify the optimal number of clusters, based on local maximas. 
This was accomplished using the “NMFConsensus” module (version 5) in GenePattern. To 
determine the most appropriate number of clusters, k was selected such that it was the 
smallest value for which the cophenetic correlation begins decreasing.  We then tested each 
of the co-occurrence gene clusters for functional enrichment (below). To determine if the 
degree of co-occurrence would have arisen by chance, we ran 1,000 iterations of one million 
edge-pair swaps from the original binary matrix, calculating a Pearson correlation matrix for 
each of the 1,000 iterations. We compared the distribution of Pearson correlations on the real 
and permuted vectors using a two-sample Kolmogorov-Smirnov (KS) test and Wilcoxon 
Rank Sum test.  
 
Functional enrichment  
We calculated the overlap of each co-occurring cluster with Gene Ontology gene sets using 
the Gene Ontology toolset from the Candida Genome Database. Bonferroni adjusted P-values 
as well as the False Discovery Rate are reported (Figures 5 – source data 1). 
 
Competition assay to assess fitness  
We measured the relative fitness of the progenitor and evolved lines in RPMI medium, 
competing them against a reference strain, expressing ENO1::YFP. Isolates stored at -80ºC 
were revived on rich media petri plates and then grown overnight in 3 ml cultures of minimal 
media in a roller drum at 35 ºC. An aliquot of cells in each culture was removed, sonicated in 
a Branson 450 sonifier, and the concentration of cells was determined using a Cellometer 
M10 (Nexelocom). The reference strain and experimental competitors were added to fresh 
RPMI medium in a 1:1 ratio and a final cell concentration of 1 x 10
7
 cells/ml. The cultures 
were grown for 24 hours in a roller drum at 35 ºC. Cells were then counted as above, and 3 x 
10
6 
cells were transferred to fresh RPMI medium grown for 24 hours in a roller drum at 35 ºC 
(transfer cycle 1). This procedure was repeated (transfer cycle 2). This protocol represents 5–
10 generations of growth, depending on the strain genotype. The ratio of the two competitors 
was quantified at the initial and final time points by flow cytometry (Accuri). Three to six 
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independent replicates for each fitness measurement were performed. The selective 
advantage, s, or disadvantage of the evolved population was calculated as previously 
described (Thompson et al., 2006), where E and R are the numbers of evolved and reference 
cells in the final (f) and initial (i) populations, and T is the number of generations that 
reference cells have proliferated during the competition. 
 
Competition assay to assess fitness with and without fluconazole 
Fitness assays were performed as described above except that the reference strain used was a 
derivative of the drug resistant isolate 4639 from patient 59 (Table 1) expressing ENO1::YFP 
and competition experiments were performed in RPMI (cell culture medium, Gibco) and in 
RPMI with one half the MIC for fluconazole (Table 1) initiated from replicate 1:1 mixtures 
of the same population of cells for each isolate tested.  
 
C. elegans survival assay 
A C. elegans survival assay was performed as previously described(Jain et al., 2009b). 
Briefly, E. coli OP50 and the different C. albicans clinical isolates were grown overnight 
respectively in LB at 37°C and YPD at 30°C. E. coli was then centrifuged and resuspended to 
a final concentration of 200 mg/ml, while C. albicans isolates were diluted with sterile water 
to OD600=3. Small petri dishes (3.5 cm) containing NGM agar were spotted with a mixture of 
10 ml streptomycin (stock solution 50 mg/ml), 2.5 ml of E. coli, 0.5 ml of C. albicans and 7 
ml of sterile water. The plates were incubated overnight at 25°C and 20 young synchronized 
N2 C. elegans adults were transferred on the spotted plates. Synchronous populations of adult 
worms were obtained by plating eggs on NGM plates seeded with E. coli OP50 at 20°C for 2-
3 days. In this time frame, the eggs hatch and the larvae reach young adulthood. The survival 
assay was carried at 20°C and worms were scored daily by gentle prodding with a platinum 
wire; dead worms were discarded while live ones were transferred to seeded plates grown 
overnight at 25°C. Worms accidentally killed while transferring or found dead on the edges 
of the plates were censored. Statistical analysis was performed using SPSS software; survival 
curves were obtained using the Kaplan-Meier method and p-values by using the log-rank test. 
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Filamentation assay  
Overnight cultures grown in YPD at 30°C were normalized to OD600=1 with sterile water and 
spotted on Spider agar media (1% mannitol, 1% Difco nutrient broth, 0.2% K2HPO4). Plates 
were incubated at 37 °C and colonies photographed 3, 7 and 10 days post spotting. As a 
negative control for filamentation cph1/cph1 efg1/efg1(Lo et al., 1997) double mutant strain 
was used.  
 
In vitro adhesion assay  
The In vitro adhesion assay was performed as previously described for S. cerevisiae 
(Reynolds and Fink, 2001). Briefly, cultures were grown in Synthetic Complete (SC) media + 
0.15% glucose at 30°C overnight. Cells were then centrifuged at maximal speed and 
resuspended to OD600=0.5 in fresh media. 200 ml of each culture were dispensed into 8 wells 
of a flat bottom 96-well plate and incubated at 37°C for 4 hours. The content of the plate was 
then decanted and 50 ml of crystal violet added to each well. After 45 minutes of incubation 
at room temperature, the content of the plate was decanted and the plate was rinsed ten times 
in DI water by alternate submerging and decanting. 200 ml of 75% methanol was added to 
each well and absorbance was measured after 30 minutes at OD590. An edt1/edt1 knockout 
mutant (Zakikhany et al., 2007) was used as a negative control for adhesion. 
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7 Conclusions and future directions  
 
 
Overall this thesis shed light on the complex mechanisms that lead C. albicans to its 
virulence. By using an in vivo model system previously developed in the lab, we identified 
four virulence factors that have been poorly characterized in the literature and that are 
important for inducing pathogenicity in C. elegans. Between these four novel virulence 
factors we focused on ZCF15, a transcription factor never found in prokaryotes or other 
eukaryotes and that can therefore be used as a target for potential therapeutic intervention.  
We showed here that ZCF15 plays a major role in the pathogen’s ability to resist toxic 
reactive oxygen species generated by the host. ZCF15 deletion leads to a reduced virulence in 
nematodes and murine macrophages unless we crippled the ability of the host to produce 
reactive oxygen species. Moreover, ZCF15 deletion leads to a reduced virulence even in the 
significant more complex environment of the mouse blood stream reiterating its important 
role in virulence. 
In addition to ZCF15 we functionally characterized in this thesis ZCF29, a gene in the same 
family of transcription factors that has been shown by others to have a role in virulence and 
ROS resistance. By using genome scale approaches like RNA-Seq and Chip-Seq we showed 
that ZCF15 plays a major role in controlling carbon metabolism and in inducing ROS 
detoxification processes when C. albicans is exposed to ROS. On the other hand, ZCF29 
plays an important role in regulating N-metabolism and is required for down regulating 
ribosome biogenesis upon ROS exposure. 
Although this thesis pinpointed the genes and biological processes that ZCF15 and ZCF29 
are regulating, more experiments are required to fully dissect the metabolic pathways that are 
controlled by ZCF15 and ZCF29. For example, in order to discriminate if any of the genes 
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found differentially expressed in zcf15/zcf15 and zcf29/zcf29 are directly or indirectly 
controlled by ZCF15 and ZCF29 we can obtain deletion strains in these genes and 
phenotypically characterized them. Knockouts that have phenotypes that recapitulate the once 
observed in zcf15/zcf15 and zcf29/zcf29 are likely working in the same pathway and further 
epistasis experiments can indicate their order in the pathway. Moreover, because TF are 
known to cooperate with other TF in the process of binding DNA, a yeast two hybrid screen 
can be used to discover potential binding partners that can subsequently be validated by co-
immunoprecipitation experiments.   
Because ZCF15 and ZCF29 are so fundamental for C. albicans biology and they are not 
conserved in humans, they can also be considered for potential drug targeting. Once their 
DNA binding partners are fully characterized it is possible to design peptide mimetics that 
recognized these sites and prevent their binding. Overall, this thesis identified novel C. 
albicans virulence determinants that can be used by the larger community for further 
biological studies or even drug targeting. 
 
 
  
  
214 
 
 
8 Appendix  
 
8.1 Potential vaccine approach against C. albicans Saps  
 
Saps are a family of 10 secreted aspartyl proteases that have been long recognized as an 
important C. albicans virulence factors (Fallon et al., 1997). These hydrolytic enzymes are 
believed to be secreted during the infection in order to degrade host tissues and allow C. 
albicans penetration to deeper epithelial layers (Naglik et al., 2003a). Saps have a highly 
conserved aspartate residue that plays a major role in the catalysis and Figure 0.1 depict more 
in detail their mechanisms of action. Saps are translated in the endoplasmic reticulum as 
preproteins. As shown in Figure 0.1 A, Kex2, a subtilisin-like protease cleaves the 
preproteins in the Golgi generating mature Saps that are subsequently secreted to the 
extracellular space (Newport and Agabian, 1997). In the extracellular space Saps have 
different optimum pHs of activities with Sap1-3 at pH 3-7 and Sap 4-6 at pH 3-7 (Figure 0.1 
A) indicating that their individual roles in infection might varies depending on the local tissue 
acidities (Parnanen et al., 2010).  
Upon secretion, Saps cooperate with C. albicans Als (agglutinin-like sequences) 
glycoproteins and facilitate pathogen’s adhesion and tissue invasion (Figure 0.1 B). In 
particular it has been recently theorized that the apical domain of Als protrude from the C. 
albicans cells wall and bind the C-terminus domain of host cell surface proteins (Salgado et 
al., 2011). Saps cooperates to the Als binding by partially hydrolyzing host cell proteins and 
consequently exposing more free C-terminus domains that are available for Als binding 
(Figure 0.1 B).  
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Figure 0.1 C. albicans Saps secretion and hypothesized mechanism of action. 
A) Saps are translated in the endoplasmic reticulum as preprotein, cleaved by Kex2 in the 
Golgi and subsequently secreted in the extracellular space by a complex system of 
vesicles. Figure adapted from Naglik et al., 2003 
B) Saps and Als proteins facilitate pathogen’s adhesion and penetration to deeper human 
tissues. Als N-termini protrude out of the C. albicans cell wall (N1-N2) and bind free C-
terminus ends of host cell proteins (red). The subsequent secretion of Saps leads to 
hydrolysis of host cell proteins and facilitate the binding of other Als proteins to human 
tissue. Figure adapted from Salagado et al., 2011     
 
During our large scale reverse genetic study described in chapter 3 we showed that 
homozygous deletion of C. albicans sap8 was significantly less capable of inducing Dar in 
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nematodes. In this chapter we expanded our study from just SAP8 to all other Saps and 
evaluated the contribution of individual genes in this family to the C. albicans’ ability to 
induce Dar in nematodes. We showed here that either the pharmacological or genetic 
inhibition of Saps reduces the C. albicans ability to induce Dar and that the deletion of 
multiple Saps has an additive effect on the phenotype. Encouraged by these results we 
propose a possible vaccine alternative that, in contrast with what is currently under 
development (Sandini et al., 2011), doesn’t target just one Sap but potentially the entire 
family.    
In order to expand our study on the role of Saps in inducing the Dar phenotype we obtained 
homozygous knockout mutants in each of the Saps from sap1-/- to saps-/- as well as two 
double mutants (sap1-/- sap2-/- and sap2-/- sap3-/-) and one triple mutants (sap1-/- sap2-/- 
sap3-/-). All of these strains were a kind donation of Joachim Morschhauser from the 
University of Wuzburg and they are described in (Lermann and Morschhauser, 2008). As 
shown in Figure 0.2 the deletion of each of the Saps tested reduces the C. albicans ability to 
induce the Dar phenotype and the deletion of multiple saps makes the effect even more 
pronounced. In addition when we added to our assay 200mM of pepstatin A, a proteinase 
inhibitor previously shown to be very potent against Saps (Schaller et al., 2003), we observed 
a statistically significant reduction in the C. albicans ability to induce Dar. Taken together, 
our data mirrors what has been shown by others in mammalian system of infections and (a) 
reiterates the importance of Saps for C. albicans virulence (b) validates our approach of 
studying infection in nematodes.     
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Figure 0.2 biochemical or genetic inactivation of Saps reduces the pathogen’s ability to 
induce Dar.  
Single, double and triple C. albicans homozygous knockout mutants have a reduced ability in 
inducing Dar in nematodes (grey and blue bars). The addition of pepstatin A (a specific Saps 
inhibitor) reduces C. albicans wildype ability to induce the Dar phenotype in nematodes (red 
bars). 
Saps are small, secreted enzymes that have limited homology with human proteins. The 
combination of these three features makes them ideal candidates for potential drug targeting 
or for epitope-based vaccine approaches (Cassone, 2013). Indeed, a recombinant truncated 
version of Sap2 has been expressed in E. coli and shown to be effective in protecting mice 
from C. albicans infection when injected either prophylactically or post infection (De 
Bernardis et al., 2012). A vaccine approach using a recombinant Sap2 delivered through 
influenza-like virosome have recently entered phase I clinical trial (NCT010671310). 
The results from these studies are encouraging however injecting a truncated version of Sap2 
is expected to trigger an immunological response that raises antibody specifically for Sap2. 
Here, we propose an alternative approach in which multiples Saps can potentially be targeted 
simultaneously. We aligned the amino acid sequences of all secreted Saps with the three 
human closest homologs (cathepsin B, pepsin A and renin) using the algorithm clustalW 
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(Larkin et al., 2007). We identified 5 regions that are conserved within all C. albicans Saps 
and noticed that domain 4 (Figure 0.3 top) is highly conserved within C. albicans Saps and 
simultaneously highly divergent to human homologs. This region represents a stretch of 35 
amino acids with the following consensus sequence 
EATGTPYDNVPVTLKKQGIIAKNAYSLYLNSPEAS. When we looked for the location of 
this sequence on the available Sap2p crystal structure (Cutfield et al., 1995) we found that it 
lies on a highly exposed region of the protein that is ideal for potential antibody binding 
(Figure 0.3 top left corner, yellow loop).  
 
Figure 0.3 Sequence alignment showing the five C. albicans Saps conserved domains. 
The five conserved domains are reported in yellow. Domains 3 and 5 contain the two 
catalytic subunits (highlighted in red) while domain 4 is the domain proposed for potential 
epitope based vaccine development. Top left corner represents the 3-D structure of Sap2 in 
which domain 4 has been highlighted in yellow.     
  
We believe that the 35 amino acids long consensus sequence can be recombinantly expressed 
and potentially used for some preliminary pre-clinical testing in mice. The first tests would 
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involve toxicological and immunological studies to determine if the sequence can be safely 
administrated and if it does trigger an immunological response.  
Overall our data shows that Saps are important for triggering the Dar response in nematodes 
and that the deletion of multiple Saps has an additive effect. We therefore proposed an 
potential alternative vaccine approach in which multiple Saps can be targeted simultaneously. 
In order to follow up on this idea further immunological and toxicological studies are 
required. For example it would be critical to evaluate the immunogenicity of this epitope-
based approach and its ability to prevent infection in mouse models of infections.   
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8.2 H2O2 responsive and transcription factor dependent genes: enriched biological 
functions   
 
In chapter 4.3.4.2 we described that ribosome biogenesis was the most statistically significant 
enriched biological function between the genes found to be H2O2 responsive and ZCF29 
dependent. Here we report the other enriched biological functions for completion.  In Figure 
4.17 we defined a cluster of genes called “1, less downregulated in zcf29/zcf29”. In addion to 
ribosome biogenesis this cluster has enriched biological function highly related to ribosome 
biogenesis like rRNA metabolic process, ribosome small subunit biogenesis, cleavage 
involved in rRNA processing as well as others like nitrogen compound metabolic process 
(Figure 8.1) 
 
Figure 8.1: Biological functions enriched in genes H2O2 downregulated and ZCF29 
dependent  
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In Figure 4.17 we defined a cluster of genes called “4, less upregulated in zcf29/zcf29”.  
Biological functions enriched in this group of genes are reported in Figure 8.2. Enriched 
biological functions include oxidation-reduction process but to a statistically lower degree 
compared to the biological functions we found in Figure 8.1. In Figure 8.1 we found 
“ribosome biogenesis” to be the most statistically significant biological function with pvalue 
= 1.38 x 10
-18
 compared to “oxidation-reduction process” that was enriched with pvalue = 3.1 
x 10
-4 
in Figure 8.2.  
 
Figure 8.2: Biological functions enriched in genes H2O2 upregulated and ZCF29 
dependent 
 
In Figure 4.20 we defined a cluster of genes called “1, less downregulated in zcf15/zcf15” 
and biological functions enriched in this group of genes is reported in Figure 8.3. As we 
articulated in paragraph 4.3.5 carbon metabolism was the most statistically enriched 
biological function.  
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Figure 8.3: Biological functions enriched in genes H2O2 downregulated and ZCF15 
dependent  
 
In Figure 4.20 we defined a cluster of genes called “4, less upregulated in zcf15/zcf15“and 
biological functions enriched in this cluster is reported in Figure 8.4.  
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Figure 8.4: Biological functions enriched in genes H2O2 upregulated and ZCF15 
dependent  
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